{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-23T04:46:12.316914",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "3a85659e-3311-44a0-9af8-34df9a7aa1d7",
    "instanceType": "Study",
    "versions": [
      {
        "id": "4fc9911c-4cdd-4493-8fef-5b00adba4b35",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "53f815de-d2aa-4196-b7bc-5cf86661b341",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "65681ff7-3e55-4c20-9319-963899bfc7e2",
              "standardCode": {
                "id": "3370c6c2-14f7-4779-ba68-a0cac44dbbaa",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Non-Randomized"
            },
            "arms": [
              {
                "id": "69cceaa6-27e9-44c7-89dd-009684da73e0",
                "name": "Arm A: Prophylaxis",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Participants currently on a prophylaxis treatment regimen with FVIII receive BIVV001 at a dose of 50 IU/kg IV once weekly (QW) for 52 weeks.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "e170d4e3-d129-4ade-bff7-65cc79f89002",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "ae2741e5-89e4-4b0f-99aa-e194c8da3e24",
                "name": "Arm B: On-Demand to Prophylaxis",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Participants currently on an on-demand treatment regimen receive BIVV001 50 IU/kg IV on demand for 26 weeks, then switch to 50 IU/kg IV once weekly (QW) prophylaxis for 26 weeks.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "ade84947-3fa5-4b4e-aee5-a0fb0216795f",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "41dc7ee7-979e-4304-b558-3588c8746511",
                "name": "Sequential PK Subgroup",
                "instanceType": "StudyCohort",
                "characteristic": "16 participants from Arm A at selected sites undergoing extensive PK sampling at Baseline and Week 26"
              },
              {
                "id": "644d2637-9c0c-4ff4-bc3e-87703af77d6e",
                "name": "Surgery Subset",
                "instanceType": "StudyCohort",
                "characteristic": "Participants from any arm who undergo major surgery during the study"
              }
            ],
            "studyCells": [
              {
                "id": "dc4af46c-7e8b-4cb2-a800-5c6322156cc7",
                "armId": "69cceaa6-27e9-44c7-89dd-009684da73e0",
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "elementIds": [
                  "edaf1bde-379f-40ee-b08c-82cd9f5fcc4a"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "3376d0f4-cbaa-43cb-b8f1-8b849ceeb3e4",
                "armId": "69cceaa6-27e9-44c7-89dd-009684da73e0",
                "epochId": "cef7bcfe-ebd5-4843-b81b-ac5befc4c7df",
                "elementIds": [
                  "06a3061f-ea41-4bbc-8107-bf9ec8da5bc9"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "fc6fc75e-4d04-4c0f-8489-b28dab846acd",
                "armId": "69cceaa6-27e9-44c7-89dd-009684da73e0",
                "epochId": "ba6b8294-c645-485f-83e5-1baad468a52a",
                "elementIds": [
                  "ba779421-40c5-4e97-ae09-60773e1587d0"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "15d7b5dd-93f6-429f-ab8a-1ce40b14206d",
                "armId": "69cceaa6-27e9-44c7-89dd-009684da73e0",
                "epochId": "5b559c18-06f1-4d54-8b41-7357e1561044",
                "elementIds": [
                  "5f781586-9703-4c9c-9910-169ef3cfe95d"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "6f1e28d0-b342-428e-a496-42f05e0e45ae",
                "armId": "69cceaa6-27e9-44c7-89dd-009684da73e0",
                "epochId": "75a5f120-5a60-4b55-93ee-15e4a81e4189",
                "elementIds": [
                  "22b591e0-0c8e-4b86-a622-1675da4b914c"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "b355fb05-d16a-4f28-bec1-13be1aade201",
                "armId": "69cceaa6-27e9-44c7-89dd-009684da73e0",
                "epochId": "a139d7f0-3d19-463e-892c-f70d434b2b97",
                "elementIds": [
                  "7d7ba28c-bef3-48ef-a272-5c316b8d9119"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "a0070f7c-ead5-41df-900c-a3fe790d91c4",
                "armId": "ae2741e5-89e4-4b0f-99aa-e194c8da3e24",
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "elementIds": [
                  "627441f8-c7e8-4af8-b491-af742166e21c"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "1ad37e3a-ef46-4767-85f3-df728b466d67",
                "armId": "ae2741e5-89e4-4b0f-99aa-e194c8da3e24",
                "epochId": "cef7bcfe-ebd5-4843-b81b-ac5befc4c7df",
                "elementIds": [
                  "a6d0e72b-df86-4434-8cf2-024c1902804e"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "4c1fa769-057a-4e6f-892b-ff9b8059e906",
                "armId": "ae2741e5-89e4-4b0f-99aa-e194c8da3e24",
                "epochId": "ba6b8294-c645-485f-83e5-1baad468a52a",
                "elementIds": [
                  "fde35f34-8824-4953-aae9-309d8c6bd8a6"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "8c61fc74-211e-48c4-a206-2704bbac1d9a",
                "armId": "ae2741e5-89e4-4b0f-99aa-e194c8da3e24",
                "epochId": "5b559c18-06f1-4d54-8b41-7357e1561044",
                "elementIds": [
                  "bdb0b85b-1074-4d3a-8396-fae55d625896"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "61209439-60f7-4523-bb8c-52f0b083b0f2",
                "armId": "ae2741e5-89e4-4b0f-99aa-e194c8da3e24",
                "epochId": "75a5f120-5a60-4b55-93ee-15e4a81e4189",
                "elementIds": [
                  "2be3c3dd-25ff-439c-8ac0-769c01c7c69e"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "85f0b525-8cd6-47c7-b590-355486820fea",
                "armId": "ae2741e5-89e4-4b0f-99aa-e194c8da3e24",
                "epochId": "a139d7f0-3d19-463e-892c-f70d434b2b97",
                "elementIds": [
                  "57b0322d-d150-47f6-9eb7-a2bb7af88daf"
                ],
                "instanceType": "StudyCell"
              }
            ],
            "studyElements": [
              {
                "id": "edaf1bde-379f-40ee-b08c-82cd9f5fcc4a",
                "name": "Arm A: Prophylaxis - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A: Prophylaxis during Screening"
              },
              {
                "id": "06a3061f-ea41-4bbc-8107-bf9ec8da5bc9",
                "name": "Arm A: Prophylaxis - Baseline",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A: Prophylaxis during Baseline"
              },
              {
                "id": "ba779421-40c5-4e97-ae09-60773e1587d0",
                "name": "Arm A: Prophylaxis - Arm A Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A: Prophylaxis during Arm A Treatment Period"
              },
              {
                "id": "5f781586-9703-4c9c-9910-169ef3cfe95d",
                "name": "Arm A: Prophylaxis - Arm B Period 1",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A: Prophylaxis during Arm B Period 1"
              },
              {
                "id": "22b591e0-0c8e-4b86-a622-1675da4b914c",
                "name": "Arm A: Prophylaxis - Arm B Period 2",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A: Prophylaxis during Arm B Period 2"
              },
              {
                "id": "7d7ba28c-bef3-48ef-a272-5c316b8d9119",
                "name": "Arm A: Prophylaxis - Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A: Prophylaxis during Safety Follow-up"
              },
              {
                "id": "627441f8-c7e8-4af8-b491-af742166e21c",
                "name": "Arm B: On-Demand to Prophylaxis - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B: On-Demand to Prophylaxis during Screening"
              },
              {
                "id": "a6d0e72b-df86-4434-8cf2-024c1902804e",
                "name": "Arm B: On-Demand to Prophylaxis - Baseline",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B: On-Demand to Prophylaxis during Baseline"
              },
              {
                "id": "fde35f34-8824-4953-aae9-309d8c6bd8a6",
                "name": "Arm B: On-Demand to Prophylaxis - Arm A Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B: On-Demand to Prophylaxis during Arm A Treatment Period"
              },
              {
                "id": "bdb0b85b-1074-4d3a-8396-fae55d625896",
                "name": "Arm B: On-Demand to Prophylaxis - Arm B Period 1",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B: On-Demand to Prophylaxis during Arm B Period 1"
              },
              {
                "id": "2be3c3dd-25ff-439c-8ac0-769c01c7c69e",
                "name": "Arm B: On-Demand to Prophylaxis - Arm B Period 2",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B: On-Demand to Prophylaxis during Arm B Period 2"
              },
              {
                "id": "57b0322d-d150-47f6-9eb7-a2bb7af88daf",
                "name": "Arm B: On-Demand to Prophylaxis - Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B: On-Demand to Prophylaxis during Safety Follow-up"
              }
            ],
            "maskingRoles": [
              {
                "id": "3473be0f-9c28-4e8b-bbea-cb39c5b1cfe3",
                "text": "This is an Open Label study with no masking",
                "isMasked": false,
                "instanceType": "Masking"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "e4bd1192-78ac-4c51-a9c9-51cd790a7234",
                "identifier": "I 01",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ae040abb-f723-4df3-b63c-a52328e016dc",
                "instanceType": "EligibilityCriterion",
                "name": "Age requirement",
                "nextId": "e60f4f12-b7a6-49e9-a4ed-e638a85b68f1"
              },
              {
                "id": "e60f4f12-b7a6-49e9-a4ed-e638a85b68f1",
                "identifier": "I 02",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7ab41c21-431e-409d-ac58-04d5745ede79",
                "instanceType": "EligibilityCriterion",
                "name": "Severe hemophilia A diagnosis",
                "previousId": "e4bd1192-78ac-4c51-a9c9-51cd790a7234",
                "nextId": "af00bbd2-4550-44f6-b446-10ba1afee58e"
              },
              {
                "id": "af00bbd2-4550-44f6-b446-10ba1afee58e",
                "identifier": "I 03",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "385e0c6c-a841-49cd-9dd1-25cfd67249ed",
                "instanceType": "EligibilityCriterion",
                "name": "Previous treatment history",
                "previousId": "e60f4f12-b7a6-49e9-a4ed-e638a85b68f1",
                "nextId": "9bbaba4a-1bb1-4c4b-9ac5-40c43917d604"
              },
              {
                "id": "9bbaba4a-1bb1-4c4b-9ac5-40c43917d604",
                "identifier": "I 04",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "95e96023-be13-4c16-b6b1-f7e686694d2f",
                "instanceType": "EligibilityCriterion",
                "name": "Current treatment regimen",
                "previousId": "af00bbd2-4550-44f6-b446-10ba1afee58e",
                "nextId": "88d278c3-32de-4b7f-b890-78d1547540e7"
              },
              {
                "id": "88d278c3-32de-4b7f-b890-78d1547540e7",
                "identifier": "I 05",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "01a54295-587a-4933-9dc1-f7e01b08bab2",
                "instanceType": "EligibilityCriterion",
                "name": "Platelet count",
                "previousId": "9bbaba4a-1bb1-4c4b-9ac5-40c43917d604",
                "nextId": "65587f36-3ab2-4985-9522-47a9534a9ad2"
              },
              {
                "id": "65587f36-3ab2-4985-9522-47a9534a9ad2",
                "identifier": "I 06",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ea140f0a-d3fa-41cd-8d2f-ef5408c4b808",
                "instanceType": "EligibilityCriterion",
                "name": "HIV status requirements",
                "previousId": "88d278c3-32de-4b7f-b890-78d1547540e7",
                "nextId": "6b9a5216-ad13-46da-a329-e40ec2000cdf"
              },
              {
                "id": "6b9a5216-ad13-46da-a329-e40ec2000cdf",
                "identifier": "I 07",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "24c0f3dc-f1c4-4462-acad-fd1f3014729d",
                "instanceType": "EligibilityCriterion",
                "name": "ePD training and use",
                "previousId": "65587f36-3ab2-4985-9522-47a9534a9ad2",
                "nextId": "ba5e2ea0-307e-4de4-b919-933b6dc6733c"
              },
              {
                "id": "ba5e2ea0-307e-4de4-b919-933b6dc6733c",
                "identifier": "I 08",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "38bbc066-24a5-4b6d-bdff-0558bc34e187",
                "instanceType": "EligibilityCriterion",
                "name": "Sex and contraception",
                "previousId": "6b9a5216-ad13-46da-a329-e40ec2000cdf",
                "nextId": "6a8114b2-5f38-46b0-8161-11966b00a2b1"
              },
              {
                "id": "6a8114b2-5f38-46b0-8161-11966b00a2b1",
                "identifier": "I 09",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "17789054-b13c-4145-af0f-dfcbd8ae5c7e",
                "instanceType": "EligibilityCriterion",
                "name": "Informed consent",
                "previousId": "ba5e2ea0-307e-4de4-b919-933b6dc6733c",
                "nextId": "65334bb6-35b8-4b71-a479-ae57808917ef"
              },
              {
                "id": "65334bb6-35b8-4b71-a479-ae57808917ef",
                "identifier": "I 10",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a9cea678-7979-4e7d-80ef-7dd3c9079a99",
                "instanceType": "EligibilityCriterion",
                "name": "Legal authorization",
                "previousId": "6a8114b2-5f38-46b0-8161-11966b00a2b1"
              },
              {
                "id": "a82b15ed-5af7-4342-bb00-a8c9b8889571",
                "identifier": "E 01",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "bbeb4179-a5ef-4bbe-a7a9-ed7f03eaec68",
                "instanceType": "EligibilityCriterion",
                "name": "Liver disease exclusion",
                "nextId": "a13aa462-ad31-49fe-b0e2-def661c056b3"
              },
              {
                "id": "a13aa462-ad31-49fe-b0e2-def661c056b3",
                "identifier": "E 02",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "381e171b-4005-4be0-a5ad-cf1ea38dee43",
                "instanceType": "EligibilityCriterion",
                "name": "Active infection exclusion",
                "previousId": "a82b15ed-5af7-4342-bb00-a8c9b8889571",
                "nextId": "e805035b-a0c9-43d6-9994-3b29f6a551a9"
              },
              {
                "id": "e805035b-a0c9-43d6-9994-3b29f6a551a9",
                "identifier": "E 03",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "303bcccb-a043-433b-9f7a-1b4c7b45529b",
                "instanceType": "EligibilityCriterion",
                "name": "Other coagulation disorders",
                "previousId": "a13aa462-ad31-49fe-b0e2-def661c056b3",
                "nextId": "b31ebafa-b2c6-433c-98a8-9c12a04f997b"
              },
              {
                "id": "b31ebafa-b2c6-433c-98a8-9c12a04f997b",
                "identifier": "E 04",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2749e41d-faea-459e-8242-28a3a3e3f84b",
                "instanceType": "EligibilityCriterion",
                "name": "Hypersensitivity history",
                "previousId": "e805035b-a0c9-43d6-9994-3b29f6a551a9",
                "nextId": "ef999539-b8b2-44b8-a882-4d8477aa375c"
              },
              {
                "id": "ef999539-b8b2-44b8-a882-4d8477aa375c",
                "identifier": "E 05",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "33d920ad-5041-4e11-9e49-7e0c211a978f",
                "instanceType": "EligibilityCriterion",
                "name": "Historical inhibitor test",
                "previousId": "b31ebafa-b2c6-433c-98a8-9c12a04f997b",
                "nextId": "b4408f75-d48f-4019-8ef1-86d778ca13cc"
              },
              {
                "id": "b4408f75-d48f-4019-8ef1-86d778ca13cc",
                "identifier": "E 06",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "84696e18-2503-4863-828d-66c1be05cbd6",
                "instanceType": "EligibilityCriterion",
                "name": "Screening inhibitor result",
                "previousId": "ef999539-b8b2-44b8-a882-4d8477aa375c",
                "nextId": "9003d616-1e85-4c8c-bde2-3bf67a0aed2f"
              },
              {
                "id": "9003d616-1e85-4c8c-bde2-3bf67a0aed2f",
                "identifier": "E 07",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6e59124c-34d2-466e-a874-bf2bbd77bc3b",
                "instanceType": "EligibilityCriterion",
                "name": "Renal function",
                "previousId": "b4408f75-d48f-4019-8ef1-86d778ca13cc",
                "nextId": "c243dcab-dee4-4ec6-a372-8f233b51a803"
              },
              {
                "id": "c243dcab-dee4-4ec6-a372-8f233b51a803",
                "identifier": "E 08",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2af382af-aed7-42b0-8950-29c93164505b",
                "instanceType": "EligibilityCriterion",
                "name": "Liver enzymes",
                "previousId": "9003d616-1e85-4c8c-bde2-3bf67a0aed2f",
                "nextId": "b389e1dd-68f3-4f7b-9a97-ed9fa5e59f1b"
              },
              {
                "id": "b389e1dd-68f3-4f7b-9a97-ed9fa5e59f1b",
                "identifier": "E 09",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "497a56c8-53d3-4c15-8533-56963768e2ae",
                "instanceType": "EligibilityCriterion",
                "name": "Bilirubin levels",
                "previousId": "c243dcab-dee4-4ec6-a372-8f233b51a803",
                "nextId": "9f8732e5-b402-4099-ad1b-000d821d7c46"
              },
              {
                "id": "9f8732e5-b402-4099-ad1b-000d821d7c46",
                "identifier": "E 10",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "69a4425d-b027-405b-ae5a-c5fac0070909",
                "instanceType": "EligibilityCriterion",
                "name": "Recent vaccination",
                "previousId": "b389e1dd-68f3-4f7b-9a97-ed9fa5e59f1b",
                "nextId": "8c4593c8-fc88-4ddd-b1ad-c43ea825f825"
              },
              {
                "id": "8c4593c8-fc88-4ddd-b1ad-c43ea825f825",
                "identifier": "E 11",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a3311dbf-0b70-4136-8f2d-009061e403e9",
                "instanceType": "EligibilityCriterion",
                "name": "Anti-platelet therapy",
                "previousId": "9f8732e5-b402-4099-ad1b-000d821d7c46",
                "nextId": "5628e669-603b-4cb6-8cfd-cad33c1abaad"
              },
              {
                "id": "5628e669-603b-4cb6-8cfd-cad33c1abaad",
                "identifier": "E 12",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "059ccc70-ef6b-4762-8f48-f0786221c41f",
                "instanceType": "EligibilityCriterion",
                "name": "NSAID use",
                "previousId": "8c4593c8-fc88-4ddd-b1ad-c43ea825f825",
                "nextId": "c54aa7c1-f5ab-4c64-b96a-41a561292d26"
              },
              {
                "id": "c54aa7c1-f5ab-4c64-b96a-41a561292d26",
                "identifier": "E 13",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "96115527-73ce-4152-aa92-1528f269c795",
                "instanceType": "EligibilityCriterion",
                "name": "Immunosuppressive drugs",
                "previousId": "5628e669-603b-4cb6-8cfd-cad33c1abaad",
                "nextId": "c275287b-7639-4764-89cd-c01fe73ec918"
              },
              {
                "id": "c275287b-7639-4764-89cd-c01fe73ec918",
                "identifier": "E 14",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "32751b56-7ad1-4bd9-99af-7a597ac07e18",
                "instanceType": "EligibilityCriterion",
                "name": "Recent emicizumab use",
                "previousId": "c54aa7c1-f5ab-4c64-b96a-41a561292d26",
                "nextId": "b9d12d8b-6487-4186-99d6-c942c465aa8d"
              },
              {
                "id": "b9d12d8b-6487-4186-99d6-c942c465aa8d",
                "identifier": "E 15",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "5f86b516-cb9c-4195-8c3c-f467aadb71b8",
                "instanceType": "EligibilityCriterion",
                "name": "Previous enrollment",
                "previousId": "c275287b-7639-4764-89cd-c01fe73ec918",
                "nextId": "19065286-d1f1-4d68-b617-e1e2303de8a5"
              },
              {
                "id": "19065286-d1f1-4d68-b617-e1e2303de8a5",
                "identifier": "E 16",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f87dd868-c552-47e4-b2df-cb44e38280d3",
                "instanceType": "EligibilityCriterion",
                "name": "Investigational product use",
                "previousId": "b9d12d8b-6487-4186-99d6-c942c465aa8d",
                "nextId": "741eaab5-cd2c-4715-902e-26af166dd48f"
              },
              {
                "id": "741eaab5-cd2c-4715-902e-26af166dd48f",
                "identifier": "E 17",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fa6caa5a-bf81-4e7d-afa2-33b09b790ee8",
                "instanceType": "EligibilityCriterion",
                "name": "Recent major surgery",
                "previousId": "19065286-d1f1-4d68-b617-e1e2303de8a5",
                "nextId": "b6aee513-3473-43bc-9ab7-5f83a4fa824d"
              },
              {
                "id": "b6aee513-3473-43bc-9ab7-5f83a4fa824d",
                "identifier": "E 18",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9c089551-721c-4e8a-8e86-ad144120d7fe",
                "instanceType": "EligibilityCriterion",
                "name": "Institutionalization",
                "previousId": "741eaab5-cd2c-4715-902e-26af166dd48f",
                "nextId": "fa73e2c9-dc15-4166-a305-80b33aa42b76"
              },
              {
                "id": "fa73e2c9-dc15-4166-a305-80b33aa42b76",
                "identifier": "E 19",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "89654928-f13c-4c9a-a4a5-bfb4ac957a4f",
                "instanceType": "EligibilityCriterion",
                "name": "Country-specific regulations",
                "previousId": "b6aee513-3473-43bc-9ab7-5f83a4fa824d",
                "nextId": "421e0526-adac-4a25-ab77-958bb46711cf"
              },
              {
                "id": "421e0526-adac-4a25-ab77-958bb46711cf",
                "identifier": "E 20",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2328606c-4dff-456e-8f58-ee8edb69de6a",
                "instanceType": "EligibilityCriterion",
                "name": "Investigator judgment",
                "previousId": "fa73e2c9-dc15-4166-a305-80b33aa42b76",
                "nextId": "40195c15-d66b-4af1-b375-9c86695ae597"
              },
              {
                "id": "40195c15-d66b-4af1-b375-9c86695ae597",
                "identifier": "E 21",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8b48dede-38f5-4622-b399-53dc4a1d64fb",
                "instanceType": "EligibilityCriterion",
                "name": "Sponsor/Investigator dependency",
                "previousId": "421e0526-adac-4a25-ab77-958bb46711cf"
              }
            ],
            "population": {
              "id": "a6c02097-2779-415e-a9d4-f2a5564789da",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "e4bd1192-78ac-4c51-a9c9-51cd790a7234",
                "e60f4f12-b7a6-49e9-a4ed-e638a85b68f1",
                "af00bbd2-4550-44f6-b446-10ba1afee58e",
                "9bbaba4a-1bb1-4c4b-9ac5-40c43917d604",
                "88d278c3-32de-4b7f-b890-78d1547540e7",
                "65587f36-3ab2-4985-9522-47a9534a9ad2",
                "6b9a5216-ad13-46da-a329-e40ec2000cdf",
                "ba5e2ea0-307e-4de4-b919-933b6dc6733c",
                "6a8114b2-5f38-46b0-8161-11966b00a2b1",
                "65334bb6-35b8-4b71-a479-ae57808917ef",
                "a82b15ed-5af7-4342-bb00-a8c9b8889571",
                "a13aa462-ad31-49fe-b0e2-def661c056b3",
                "e805035b-a0c9-43d6-9994-3b29f6a551a9",
                "b31ebafa-b2c6-433c-98a8-9c12a04f997b",
                "ef999539-b8b2-44b8-a882-4d8477aa375c",
                "b4408f75-d48f-4019-8ef1-86d778ca13cc",
                "9003d616-1e85-4c8c-bde2-3bf67a0aed2f",
                "c243dcab-dee4-4ec6-a372-8f233b51a803",
                "b389e1dd-68f3-4f7b-9a97-ed9fa5e59f1b",
                "9f8732e5-b402-4099-ad1b-000d821d7c46",
                "8c4593c8-fc88-4ddd-b1ad-c43ea825f825",
                "5628e669-603b-4cb6-8cfd-cad33c1abaad",
                "c54aa7c1-f5ab-4c64-b96a-41a561292d26",
                "c275287b-7639-4764-89cd-c01fe73ec918",
                "b9d12d8b-6487-4186-99d6-c942c465aa8d",
                "19065286-d1f1-4d68-b617-e1e2303de8a5",
                "741eaab5-cd2c-4715-902e-26af166dd48f",
                "b6aee513-3473-43bc-9ab7-5f83a4fa824d",
                "fa73e2c9-dc15-4166-a305-80b33aa42b76",
                "421e0526-adac-4a25-ab77-958bb46711cf",
                "40195c15-d66b-4af1-b375-9c86695ae597"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "64de7fdd-f80e-4d50-8e85-ee8b904d9129",
                "name": "Primary Efficacy Objective",
                "text": "To evaluate the efficacy of BIVV001 weekly prophylaxis as estimated by the mean ABR and one-sided 97.5% CI in Arm A.",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "019f4561-6557-4439-8540-3efb2db37b0d"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "749df980-4bc6-4655-a4b6-0dbd0ddf2b33",
                "name": "Key Secondary Efficacy Objective",
                "text": "To perform an intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "170ab6c8-8297-47bc-bbd9-75fb2098ca0d"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "97bf3e8b-e1d7-4971-9399-063e059b07e5",
                "name": "Secondary Patient Reported Outcomes Objective",
                "text": "To evaluate the effect of BIVV001 on physical health, pain intensity, and joint health",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "2534c9cc-5f27-43d1-8e23-de869740b7a3",
                  "c9ec0d7f-8e43-4c8e-9eae-0325e796b610",
                  "db7e46a1-fc4b-4b0f-ba68-773160fa843b"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "47a1bc6a-fbe2-4f13-b382-5dc0fcd4c1c8",
                "name": "Safety Objective",
                "text": "To assess the safety and immunogenicity of IV BIVV001",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "9a46aa27-2779-4a1e-a1b1-325d411e020b",
                  "5a0595b0-c8f2-4aee-a8b8-d176aa3be12c"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "ea9857cd-78eb-4e6b-8e4e-388053b26b17",
                "name": "Pharmacokinetics Objective",
                "text": "To assess the pharmacokinetics of IV BIVV001",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "4d4d9f47-c63a-401b-bdeb-c60182e28d48"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "fc2b2382-7c7a-4588-b544-59d721dea4d4",
                "name": "Exploratory Objective",
                "text": "To evaluate participants’ expectations of treatment and perception of treatment impact",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "d078e20d-5194-4b5a-89bb-2dd83d900288"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "019f4561-6557-4439-8540-3efb2db37b0d",
                "name": "Primary Efficacy Endpoint",
                "text": "Annualized Bleeding Rate (ABR) in Arm A",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "170ab6c8-8297-47bc-bbd9-75fb2098ca0d",
                "name": "Key Secondary Efficacy Endpoint",
                "text": "Intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "2534c9cc-5f27-43d1-8e23-de869740b7a3",
                "name": "Haem-A-QoL Physical Health Score",
                "text": "Change from baseline to Week 52 in Haem-A-QoL (≥17 years old) Physical Health score",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              },
              {
                "id": "c9ec0d7f-8e43-4c8e-9eae-0325e796b610",
                "name": "PROMIS Pain Intensity 3a",
                "text": "Change from baseline to Week 52 in PROMIS Pain Intensity 3a",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "db7e46a1-fc4b-4b0f-ba68-773160fa843b",
                "name": "HJHS Total Score",
                "text": "Change from baseline to Week 52 in Hemophilia Joint Health Score (HJHS) total score",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "9a46aa27-2779-4a1e-a1b1-325d411e020b",
                "name": "Safety Endpoints",
                "text": "Incidence and severity of AEs, clinically significant changes in laboratory parameters, vital signs, and physical examination findings",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "5a0595b0-c8f2-4aee-a8b8-d176aa3be12c",
                "name": "Immunogenicity Endpoint",
                "text": "Incidence of inhibitor development",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "4d4d9f47-c63a-401b-bdeb-c60182e28d48",
                "name": "PK Parameters",
                "text": "PK parameters summarized for both the one-stage aPTT clotting assay and two-stage chromogenic assay",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "d078e20d-5194-4b5a-89bb-2dd83d900288",
                "name": "Exit Interview Endpoint",
                "text": "Participants’ expectations of treatment and perception of treatment impact assessed via exit interview",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              }
            ],
            "estimands": [
              {
                "id": "f13a7ee5-ec42-4bcc-af00-2052098ae60f",
                "name": "Primary Efficacy Estimand - ABR in Arm A",
                "populationSummary": "Previously treated patients (PTPs) ≥12 years of age with severe hemophilia A (ITT/Full Analysis Set) Summary measure: Mean ABR estimated via Negative-Binomial regression with one-sided 97.5% CI.",
                "analysisPopulationId": "87df6cdb-7712-410b-afcb-7208a390ae34",
                "variableOfInterestId": "019f4561-6557-4439-8540-3efb2db37b0d",
                "interventionIds": [
                  "3e241492-10cb-43b0-ade2-666ddcf6592e"
                ],
                "intercurrentEvents": [
                  {
                    "id": "8597422c-e188-4364-92f5-7c95907b0973",
                    "name": "Treatment discontinuation",
                    "text": "Participant permanently discontinues study treatment before 52 weeks",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "822dd606-f920-41c2-9952-737c57a3ebe5",
                    "name": "Use of non-study FVIII products",
                    "text": "Use of FVIII products other than BIVV001 (except in life-threatening emergencies)",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "BIVV001 50 IU/kg IV once weekly (QW)",
                "analysisPopulation": "Previously treated patients (PTPs) ≥12 years of age with severe hemophilia A (ITT/Full Analysis Set)",
                "variableOfInterest": "Annualized Bleeding Rate (ABR)",
                "summaryMeasure": "Mean ABR estimated via Negative-Binomial regression with one-sided 97.5% CI"
              },
              {
                "id": "47e6b510-1b4d-4dac-acf9-e2dcb298b8b6",
                "name": "Key Secondary Efficacy Estimand - Intra-patient ABR Comparison",
                "populationSummary": "Participants in Arm A with ≥6 months study duration and ≥6 months historical prophylaxis data Summary measure: Median difference in ABR (Non-inferiority margin of 4).",
                "analysisPopulationId": "43ca2bbd-6a5b-4e30-a51e-53a056474046",
                "variableOfInterestId": "170ab6c8-8297-47bc-bbd9-75fb2098ca0d",
                "interventionIds": [
                  "08738674-1bf7-457c-8357-7d7d4cf8a2e9"
                ],
                "intercurrentEvents": [
                  {
                    "id": "1b4c6fa6-9a88-433b-acb0-8ade148dfac4",
                    "name": "Study withdrawal",
                    "text": "Participant withdraws from study before completing 6 months of BIVV001 treatment",
                    "strategy": "Hypothetical",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "BIVV001 50 IU/kg IV QW vs. Historical FVIII Prophylaxis",
                "analysisPopulation": "Participants in Arm A with ≥6 months study duration and ≥6 months historical prophylaxis data",
                "variableOfInterest": "Intra-patient difference in ABR",
                "summaryMeasure": "Median difference in ABR (Non-inferiority margin of 4)"
              },
              {
                "id": "bbbc8855-3985-49d9-b8ff-0fbbe994a2f2",
                "name": "Secondary Efficacy Estimand - Physical Health Score",
                "populationSummary": "Adult patients (≥17 years old) in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
                "analysisPopulationId": "d1bc6ac6-953a-479e-aae9-af99bc148529",
                "variableOfInterestId": "2534c9cc-5f27-43d1-8e23-de869740b7a3",
                "interventionIds": [
                  "c019e9f7-5851-4eee-be14-4d318c6f4e4a"
                ],
                "intercurrentEvents": [
                  {
                    "id": "20c54e6e-2521-4693-9990-a82bc72a2b24",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "BIVV001 50 IU/kg IV QW",
                "analysisPopulation": "Adult patients (≥17 years old) in Arm A",
                "variableOfInterest": "Change from baseline to Week 52 in Haem-A-QoL Physical Health score",
                "summaryMeasure": "Adjusted mean change from baseline using MMRM"
              },
              {
                "id": "bef0c8d6-2029-4333-af46-9b2c4b250f46",
                "name": "Secondary Efficacy Estimand - Pain Intensity",
                "populationSummary": "Participants in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
                "analysisPopulationId": "a8aa2ce8-e598-4115-b259-1b5f8f0a06dc",
                "variableOfInterestId": "c9ec0d7f-8e43-4c8e-9eae-0325e796b610",
                "interventionIds": [
                  "cb3e534b-1431-4c52-9560-a2a7962cdcf7"
                ],
                "intercurrentEvents": [
                  {
                    "id": "9263b99c-962f-48c0-b179-7dd8a3138266",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "BIVV001 50 IU/kg IV QW",
                "analysisPopulation": "Participants in Arm A",
                "variableOfInterest": "Change from baseline to Week 52 in PROMIS Pain Intensity 3a",
                "summaryMeasure": "Adjusted mean change from baseline using MMRM"
              },
              {
                "id": "9275780d-1245-4198-827a-701297617f22",
                "name": "Secondary Efficacy Estimand - Joint Health",
                "populationSummary": "Participants in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
                "analysisPopulationId": "a798271c-98c9-4738-9058-804f95e4d492",
                "variableOfInterestId": "db7e46a1-fc4b-4b0f-ba68-773160fa843b",
                "interventionIds": [
                  "cf089a9e-7896-4124-8872-34ca315b6bde"
                ],
                "intercurrentEvents": [
                  {
                    "id": "832d5b82-976d-4c72-bd1f-26b83d071ce8",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "BIVV001 50 IU/kg IV QW",
                "analysisPopulation": "Participants in Arm A",
                "variableOfInterest": "Change from baseline to Week 52 in HJHS total score",
                "summaryMeasure": "Adjusted mean change from baseline using MMRM"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "67ca25e7-534b-4174-a551-cffcca8e2818",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "e6f81b3c-e754-4689-a756-a12c0c642a76",
                "instances": [
                  {
                    "id": "e6f81b3c-e754-4689-a756-a12c0c642a76",
                    "activityIds": [
                      "610f1bad-97a5-4257-bda6-d470c96c4344"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "64acf26c-7e0a-4313-84a0-c2343c1bc7b7",
                    "activityIds": [
                      "cea776ef-376b-4390-abcc-b413758a6bdb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "4845cf5f-2ef2-460a-91ce-cd6fb9d77b81",
                    "activityIds": [
                      "cea776ef-376b-4390-abcc-b413758a6bdb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "ed71a833-a147-4a0f-80cf-ca198aec8848",
                    "activityIds": [
                      "72466392-e800-419c-8311-b41b2c6f711c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "5d6a95cd-e172-4a76-a858-652c1822ba3a",
                    "activityIds": [
                      "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "05e35ff7-55e9-418b-a9c0-40a9d08dec61",
                    "activityIds": [
                      "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "215512ab-0f16-49dc-943e-cf9315878275",
                    "activityIds": [
                      "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "bae799ae-06b4-4e49-906c-08e9db4e09ab",
                    "activityIds": [
                      "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "03b426af-7ad7-4c32-810d-c3101344faa8",
                    "activityIds": [
                      "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "95109208-ccd7-4f6e-b232-886aad67f524",
                    "activityIds": [
                      "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "7e64258c-b47f-4653-8c62-b8112eac7f52",
                    "activityIds": [
                      "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "b96607c2-fa56-47cc-8402-a0c49b25cc7a",
                    "activityIds": [
                      "237043a1-edaf-43f1-afec-2bef91a0b934"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "2583668a-6cca-4dc5-a24e-25f445e0cd38",
                    "activityIds": [
                      "d302fc6f-6360-48fc-badd-4e32c5d4c140"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "3d3131b7-14b0-483c-b921-d236bdbc27bf",
                    "activityIds": [
                      "0249edfe-fb3a-4154-aa84-fdf09a49d9a2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "3554c795-764c-4df4-aeaf-e42c3a00449c",
                    "activityIds": [
                      "5f7ce80e-4941-4b7f-a1ac-87252b1c9f28"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "f83a473d-6a62-4bb2-ab6c-f55cd6c7af9e",
                    "activityIds": [
                      "be883257-ec2f-472b-b90a-5edd6de1e881"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "3b98adbf-6110-4c53-9668-7864f9315f18",
                    "activityIds": [
                      "be883257-ec2f-472b-b90a-5edd6de1e881"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "977580f5-fb4c-48b8-a8b9-8e05a858c3c8",
                    "activityIds": [
                      "be883257-ec2f-472b-b90a-5edd6de1e881"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "f807cea6-2d74-4f5e-96d2-be3af17054c8",
                    "activityIds": [
                      "be883257-ec2f-472b-b90a-5edd6de1e881"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "acd6064c-1ce6-447e-9581-c7630b4e7765",
                    "activityIds": [
                      "be883257-ec2f-472b-b90a-5edd6de1e881"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "7b7dc4f2-0496-4791-896a-79dac3c27bd6",
                    "activityIds": [
                      "be883257-ec2f-472b-b90a-5edd6de1e881"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_8",
                    "encounterId": "a9e3b166-f778-4723-89a5-604c54ebb179",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "db06a82a-8497-421d-93de-7e7348be47dc",
                    "activityIds": [
                      "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "15df965c-d79b-469b-999f-6f724dbf85f4",
                    "activityIds": [
                      "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "bb9f0752-6da6-46c3-a4fe-fb3b9cde07dc",
                    "activityIds": [
                      "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "25837db3-5f2c-455e-a480-7ab69c229e9d",
                    "activityIds": [
                      "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "3f3345cf-39bd-458c-a080-052408ac585c",
                    "activityIds": [
                      "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "15304608-b6ca-4727-8593-0da62658ce60",
                    "activityIds": [
                      "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_8",
                    "encounterId": "a9e3b166-f778-4723-89a5-604c54ebb179",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "012ea815-bad5-4348-b6a3-0497da3d22d2",
                    "activityIds": [
                      "22364548-d56c-414b-a7c4-2af9e39fdc64"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "5a8f023f-2c7a-48a4-b193-3ada04442d28",
                    "activityIds": [
                      "22364548-d56c-414b-a7c4-2af9e39fdc64"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "88e558aa-c1d1-4315-a271-1c479d305c8c",
                    "activityIds": [
                      "22364548-d56c-414b-a7c4-2af9e39fdc64"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "987ec939-45b9-4842-acdb-2b3c747dcd06",
                    "activityIds": [
                      "22364548-d56c-414b-a7c4-2af9e39fdc64"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "e4a6aa38-efb2-4697-91de-777cb6fb0eaa",
                    "activityIds": [
                      "22364548-d56c-414b-a7c4-2af9e39fdc64"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "b6c6cffa-ea11-4d4e-ae08-b855a0a9b399",
                    "activityIds": [
                      "22364548-d56c-414b-a7c4-2af9e39fdc64"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_8",
                    "encounterId": "a9e3b166-f778-4723-89a5-604c54ebb179",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "677ebf8c-0573-4857-a8d8-45344aa35d0e",
                    "activityIds": [
                      "b473ec84-1bfe-44c6-983c-ccff73d621dc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "72e70676-dbb2-468d-ae93-c2142d7118b9",
                    "activityIds": [
                      "b473ec84-1bfe-44c6-983c-ccff73d621dc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "04500622-683c-44c4-bd19-045531aa802e",
                    "activityIds": [
                      "b473ec84-1bfe-44c6-983c-ccff73d621dc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "d0c93743-8abe-4393-b549-fa303f3f685e",
                    "activityIds": [
                      "b473ec84-1bfe-44c6-983c-ccff73d621dc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "feda6c93-c361-4094-b2fe-64cf00ee25a7",
                    "activityIds": [
                      "b473ec84-1bfe-44c6-983c-ccff73d621dc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "b5becce2-9a72-4fde-bf39-d426de310d69",
                    "activityIds": [
                      "b473ec84-1bfe-44c6-983c-ccff73d621dc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "5336f1d2-39a6-4c22-976f-d29f4a8397f6",
                    "activityIds": [
                      "1bfbd19b-b16f-4a48-b148-b10eac1d4c64"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "d354b7ac-daf3-4bb5-8c13-5a2f68fe75cf",
                    "activityIds": [
                      "e62aaa1e-820e-421d-a2b4-cd1f723b120c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "1fca7bb8-a2a7-4633-a654-f04e272c1bc5",
                    "activityIds": [
                      "36a0e78e-4296-4387-8247-7aaebde9bd33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "da71fc59-6f7c-4bd0-ad76-9e04801eaead",
                    "activityIds": [
                      "36a0e78e-4296-4387-8247-7aaebde9bd33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "b2c82ac5-46d0-451c-bd0d-3ea7123e7a8d",
                    "activityIds": [
                      "36a0e78e-4296-4387-8247-7aaebde9bd33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "2df78130-fce1-44ea-bcb2-77e63baac25a",
                    "activityIds": [
                      "36a0e78e-4296-4387-8247-7aaebde9bd33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "4c7bdf86-74c7-4291-879b-086e842c9f6c",
                    "activityIds": [
                      "36a0e78e-4296-4387-8247-7aaebde9bd33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "372f9038-0ccd-4398-bf9b-1f98e5fa832b",
                    "activityIds": [
                      "36a0e78e-4296-4387-8247-7aaebde9bd33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "d8aa6bf8-f836-4b50-b3e6-570193401f35",
                    "activityIds": [
                      "36a0e78e-4296-4387-8247-7aaebde9bd33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "b1628edb-b7cc-44a6-8127-4be8d90982e5",
                    "activityIds": [
                      "5327b400-a0cc-4e3a-b89c-a29a26a75167"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "e53606cb-e26c-4cc6-90a9-7d4702aa55e9",
                    "activityIds": [
                      "5327b400-a0cc-4e3a-b89c-a29a26a75167"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "e9559bde-88ea-443c-8ee9-47bd0010b367",
                    "activityIds": [
                      "5327b400-a0cc-4e3a-b89c-a29a26a75167"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "783c2616-8ca8-48b8-9807-2c0b53cc9472",
                    "activityIds": [
                      "2ec5a524-1a97-4ff0-81e7-ba65e0852c55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "aab69a98-d2ab-4e9c-b306-f765bbd5f423",
                    "activityIds": [
                      "2ec5a524-1a97-4ff0-81e7-ba65e0852c55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "a4ccaa98-80eb-498b-8512-3bc71709bd44",
                    "activityIds": [
                      "2ec5a524-1a97-4ff0-81e7-ba65e0852c55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "6faed330-2119-41b2-9db9-0fe5a0e27b53",
                    "activityIds": [
                      "2ec5a524-1a97-4ff0-81e7-ba65e0852c55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "66f4b177-6bf7-433d-9d1a-d74f22e9fcde",
                    "activityIds": [
                      "2ec5a524-1a97-4ff0-81e7-ba65e0852c55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "afc3f019-0702-4549-aa40-074ebc71b04c",
                    "activityIds": [
                      "2ec5a524-1a97-4ff0-81e7-ba65e0852c55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "10152472-50dd-4d5b-a201-6ffc510215ef",
                    "activityIds": [
                      "2ec5a524-1a97-4ff0-81e7-ba65e0852c55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "7d4b15c2-a02c-4c7d-8ab7-004fa3bb073a",
                    "activityIds": [
                      "c5840ccd-ebc1-4016-ae91-ea38b952e412"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "be96c9fa-5243-49e1-a32a-391db136552b",
                    "activityIds": [
                      "c5840ccd-ebc1-4016-ae91-ea38b952e412"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c72838f9-e6d6-4433-9ef7-988d58d1eca4",
                    "activityIds": [
                      "c5840ccd-ebc1-4016-ae91-ea38b952e412"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "6032ab41-e319-484a-be28-caa9774abf17",
                    "activityIds": [
                      "c5840ccd-ebc1-4016-ae91-ea38b952e412"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "dc4df9de-be4e-443e-9a90-cbb13128764f",
                    "activityIds": [
                      "c5840ccd-ebc1-4016-ae91-ea38b952e412"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "0333fc6a-f1fa-4203-916f-866f4d924b19",
                    "activityIds": [
                      "c5840ccd-ebc1-4016-ae91-ea38b952e412"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "ab32cf82-f388-43d0-935b-801a818676b7",
                    "activityIds": [
                      "c5840ccd-ebc1-4016-ae91-ea38b952e412"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "70a97fc2-445c-48a3-a48d-9c89d7fecc58",
                    "activityIds": [
                      "9ecb19e2-4a31-4255-998e-a30389df2b4c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "6a0e9329-cb8a-45a1-b5ed-c72181a101ae",
                    "activityIds": [
                      "9ecb19e2-4a31-4255-998e-a30389df2b4c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "75f54e20-05d0-45ca-a1a6-80b001d260d8",
                    "activityIds": [
                      "9ecb19e2-4a31-4255-998e-a30389df2b4c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "b1ed49cd-7921-4606-8156-0354df546f5d",
                    "activityIds": [
                      "9ecb19e2-4a31-4255-998e-a30389df2b4c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "acf42f1a-2b60-428d-8702-5e28b0e0afb7",
                    "activityIds": [
                      "9ecb19e2-4a31-4255-998e-a30389df2b4c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c06e6f5e-fb7a-4915-ac1f-40ad71d476bc",
                    "activityIds": [
                      "9ecb19e2-4a31-4255-998e-a30389df2b4c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "17db278a-e58a-4751-b194-58bc7c1cc396",
                    "activityIds": [
                      "9ecb19e2-4a31-4255-998e-a30389df2b4c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "da397123-4459-40cc-8d3c-1c7e593bca96",
                    "activityIds": [
                      "012a558b-ef32-4cd4-8494-1edbe44163e8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "aea7ba72-6982-4d06-9350-a6b0c73eb981",
                    "activityIds": [
                      "012a558b-ef32-4cd4-8494-1edbe44163e8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "96adb4b4-06e6-41c9-8f62-efe849d87fcd",
                    "activityIds": [
                      "012a558b-ef32-4cd4-8494-1edbe44163e8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c44edee0-7d38-455b-bd0a-3e718374eb8f",
                    "activityIds": [
                      "012a558b-ef32-4cd4-8494-1edbe44163e8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "efe9f292-61b5-459d-92f0-0b21a46e19f0",
                    "activityIds": [
                      "012a558b-ef32-4cd4-8494-1edbe44163e8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "f948ef7a-d178-482a-9460-420b51957df5",
                    "activityIds": [
                      "012a558b-ef32-4cd4-8494-1edbe44163e8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "43a06a10-53e7-4770-9896-7386c691242a",
                    "activityIds": [
                      "012a558b-ef32-4cd4-8494-1edbe44163e8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "faad1041-9dd2-4aa3-9fbc-cd1e8533e7aa",
                    "activityIds": [
                      "44076f02-54fb-48cd-940f-243b01db52a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "24bcf44b-8877-4b69-8b11-388edcfe57ed",
                    "activityIds": [
                      "44076f02-54fb-48cd-940f-243b01db52a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c7615d44-6eb5-4f9d-9a2d-708244acc4e2",
                    "activityIds": [
                      "44076f02-54fb-48cd-940f-243b01db52a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "7ea76dae-6f5b-4c67-ab99-14eba1484db8",
                    "activityIds": [
                      "55b85ae5-79c2-49f8-b354-ead564f0b857"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "d7905fec-2edd-4de2-a18b-5e363f2aec4d",
                    "activityIds": [
                      "d7ecac8b-a972-4f88-8cba-08dc5281627a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "8ede4f70-abcb-45a9-a09d-8c91683f1321",
                    "activityIds": [
                      "d7ecac8b-a972-4f88-8cba-08dc5281627a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "75631b22-f8dd-428c-9931-0ed77d68457e",
                    "activityIds": [
                      "d7ecac8b-a972-4f88-8cba-08dc5281627a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "42094644-75ff-4f0a-a782-d63bf88a1fa6",
                    "activityIds": [
                      "d7ecac8b-a972-4f88-8cba-08dc5281627a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "996d1790-7a43-4702-9baa-04c1e7bd0578",
                    "activityIds": [
                      "d7ecac8b-a972-4f88-8cba-08dc5281627a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "5a6b496d-41c9-4789-81fe-5c0358bac9d4",
                    "activityIds": [
                      "0a2f244e-2e64-415d-b599-46e7dfffd3ee"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_24@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "4e41770c-b966-41d6-a362-a6bab8ea6004",
                    "activityIds": [
                      "0a2f244e-2e64-415d-b599-46e7dfffd3ee"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_24@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "3c525631-23cc-402a-af0f-ea3c1d1e6703",
                    "activityIds": [
                      "563785e3-c9ea-445a-8860-bb8b0d268c69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "cfe26ef5-b26e-411e-a78b-862fb66eca9b",
                    "activityIds": [
                      "563785e3-c9ea-445a-8860-bb8b0d268c69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "a18d31f8-39e9-4cc8-9176-e81f3fcbd06c",
                    "activityIds": [
                      "563785e3-c9ea-445a-8860-bb8b0d268c69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "7b544464-68be-467c-864f-1595206c7af6",
                    "activityIds": [
                      "563785e3-c9ea-445a-8860-bb8b0d268c69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "6b324e44-a5db-4620-8cbf-4121feb5d131",
                    "activityIds": [
                      "563785e3-c9ea-445a-8860-bb8b0d268c69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "70d54121-f87b-4dc4-bbd4-772518c75e9a",
                    "activityIds": [
                      "563785e3-c9ea-445a-8860-bb8b0d268c69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "f09d72c9-7cec-418a-a785-36480c0d8e69",
                    "activityIds": [
                      "563785e3-c9ea-445a-8860-bb8b0d268c69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "1bc9a46f-894d-40a7-a725-0c92b22d8e8d",
                    "activityIds": [
                      "e45433b5-90e1-4471-8cc1-71a4ac578f37"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_26@enc_1",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "312aec59-830a-4a57-96b0-0e80185991ff",
                    "activityIds": [
                      "e45433b5-90e1-4471-8cc1-71a4ac578f37"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_26@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "9566b712-85be-4f69-b78a-1de4fc43e7d5",
                    "activityIds": [
                      "5dbb1b6d-2881-45c5-947a-f5abbba99712"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_27@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "92508b45-b98e-48b3-9fbd-770738394454",
                    "activityIds": [
                      "58702b84-7ba4-4b73-99eb-72c9f9acc0af"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "e050320c-142a-4a11-a9b2-04bf442c3e6b",
                    "activityIds": [
                      "58702b84-7ba4-4b73-99eb-72c9f9acc0af"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "0dda0161-f249-47d7-a3d6-81a230149ce2",
                    "activityIds": [
                      "6ecfdea3-c015-4f87-962e-3c0c3a3dae4f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c7a22b2a-33f7-4412-bea6-2b69a8a24c75",
                    "activityIds": [
                      "6ecfdea3-c015-4f87-962e-3c0c3a3dae4f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "47c50291-3360-4df3-bfbb-2dccb31c5a16",
                    "activityIds": [
                      "6ecfdea3-c015-4f87-962e-3c0c3a3dae4f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "bc9f71e2-4132-418c-866d-e17f6e3c74a8",
                    "activityIds": [
                      "6ecfdea3-c015-4f87-962e-3c0c3a3dae4f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "d6674631-b35a-4461-a377-7c1b7c2f56a6",
                    "activityIds": [
                      "6ecfdea3-c015-4f87-962e-3c0c3a3dae4f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c2f68ee4-739d-40ba-9c0a-6e10f7285b48",
                    "activityIds": [
                      "44658d7b-7486-402d-a992-56d8c8a672bc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_30@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "bc423d4c-c836-4c7d-9387-9b1a9195c9a6",
                    "activityIds": [
                      "44658d7b-7486-402d-a992-56d8c8a672bc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_30@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "fd3a38ac-ca1b-47d1-92ab-d0858f96a8a5",
                    "activityIds": [
                      "44658d7b-7486-402d-a992-56d8c8a672bc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_30@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "62c46219-6371-47c1-b6c2-745a8967a672",
                    "activityIds": [
                      "6fe03ca8-9487-40eb-a53e-e6aeaa7946f3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_31@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "84b2f2c5-a5bd-41fd-ba48-eaee53f6224a",
                    "activityIds": [
                      "6fe03ca8-9487-40eb-a53e-e6aeaa7946f3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_31@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "6072331f-377a-47cf-99aa-5af0fe8de36d",
                    "activityIds": [
                      "6fe03ca8-9487-40eb-a53e-e6aeaa7946f3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_31@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "a5f5f8a8-3ad8-4284-b5a5-a6b706a4537d",
                    "activityIds": [
                      "557e3f44-797c-47af-95f5-734e3683b90e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_32@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "a954d183-136e-4146-9716-67a7493f7664",
                    "activityIds": [
                      "557e3f44-797c-47af-95f5-734e3683b90e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_32@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c8d38f5f-681b-40b3-85e1-49db82a88ae9",
                    "activityIds": [
                      "557e3f44-797c-47af-95f5-734e3683b90e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_32@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "6f90a4cd-7574-439a-a505-ee9b20e2410e",
                    "activityIds": [
                      "0033d0c4-cd3f-4da1-b6bb-636787467d57"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_33@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "8059f8d2-2f17-4a43-8e20-4c8eaf182679",
                    "activityIds": [
                      "0033d0c4-cd3f-4da1-b6bb-636787467d57"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_33@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "0508656f-5282-4e39-9e4c-b184c6389624",
                    "activityIds": [
                      "0033d0c4-cd3f-4da1-b6bb-636787467d57"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_33@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "c390e6b3-9f05-42a2-88fa-fb86f8997e44",
                    "activityIds": [
                      "0a754a18-a635-44d5-b363-eadf29293321"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_34@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "6765c918-f2ec-480f-9217-e74e2a17ffe8",
                    "activityIds": [
                      "0a754a18-a635-44d5-b363-eadf29293321"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_34@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "86f82cab-6106-43a3-9a3f-655c12a64a81",
                    "activityIds": [
                      "0a754a18-a635-44d5-b363-eadf29293321"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_34@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "a98963df-be95-4262-8a8b-e521c107a502",
                    "activityIds": [
                      "32fa8fa9-ba0e-445c-92dd-0d9f5c124053"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_35@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "3fe63c0a-4018-4b2f-ad32-e65a818f8557",
                    "activityIds": [
                      "32fa8fa9-ba0e-445c-92dd-0d9f5c124053"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_35@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "45d14bb3-2d2f-43f3-8c27-39afbc3392c7",
                    "activityIds": [
                      "4e5d5d05-d882-49cd-aee7-b819d64cc583"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_36@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "f3fb47e2-17b6-44fa-8e5c-65cd241b239a",
                    "activityIds": [
                      "4e5d5d05-d882-49cd-aee7-b819d64cc583"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_36@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "f6f45d78-2839-464e-815f-900fe416c75b",
                    "activityIds": [
                      "4e5d5d05-d882-49cd-aee7-b819d64cc583"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_36@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "eddaed90-99bf-4889-8f4a-a562d1b7200f",
                    "activityIds": [
                      "c18a6c0b-6c48-4750-a9fd-d6a78655fc81"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_37@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "d3eaeddc-a514-49aa-b43c-6fd0056d6c7c",
                    "activityIds": [
                      "9aeca392-dd20-4cc8-a891-e8a78660dc62"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_38@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "19949d62-d079-4559-adb3-882d7fd0a8e7",
                    "activityIds": [
                      "9aeca392-dd20-4cc8-a891-e8a78660dc62"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_38@enc_3",
                    "encounterId": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "aabcc5b4-5fe1-4500-b7a7-add78f34ba06",
                    "activityIds": [
                      "9aeca392-dd20-4cc8-a891-e8a78660dc62"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_38@enc_4",
                    "encounterId": "24b23484-3b93-4b55-804d-ab685681e86e",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "99accfd0-eedc-4cd1-926d-ece262cebf34",
                    "activityIds": [
                      "9aeca392-dd20-4cc8-a891-e8a78660dc62"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_38@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "047627a8-9cb3-489a-ac8b-39ebeafd7719",
                    "activityIds": [
                      "9aeca392-dd20-4cc8-a891-e8a78660dc62"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_38@enc_6",
                    "encounterId": "07806163-4b22-4820-b2e9-13578147926d",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "09f1327d-af36-490f-9ed4-698c8872140e",
                    "activityIds": [
                      "9aeca392-dd20-4cc8-a891-e8a78660dc62"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_38@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "e19b3424-2b62-49f1-8940-7523e4a6aa0e",
                    "activityIds": [
                      "9aeca392-dd20-4cc8-a891-e8a78660dc62"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_38@enc_8",
                    "encounterId": "a9e3b166-f778-4723-89a5-604c54ebb179",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "50b7b0c4-a856-4ba1-bd9c-3ffc538a8648",
                    "activityIds": [
                      "44b0638b-c2f2-43db-86df-41de0df940fc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_39@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "7bcbfdf1-5a04-482b-8294-7032bb26ab8a",
                    "activityIds": [
                      "04dbfd5c-fd90-4875-bb5e-37ba111401b7"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_40@enc_2",
                    "encounterId": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "978a09fc-8b44-4bf0-9b74-223b0311776e",
                    "activityIds": [
                      "04dbfd5c-fd90-4875-bb5e-37ba111401b7"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_40@enc_5",
                    "encounterId": "15613da3-250f-4e12-8c11-2d28c6118d19",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "603937b9-d745-4f7d-b36e-5229744509cb",
                    "activityIds": [
                      "04dbfd5c-fd90-4875-bb5e-37ba111401b7"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_40@enc_7",
                    "encounterId": "522edf7d-389d-4d4f-b615-f8fd80205885",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "53114f50-64b6-4654-8e80-a84c0f71c612",
                    "name": "InformedConsent",
                    "description": "Event anchor: InformedConsent",
                    "activityIds": [
                      "610f1bad-97a5-4257-bda6-d470c96c4344"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "65c9c5c0-76d3-4bfa-af14-3ccbbfe3f961",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "c59266e1-fe7c-4455-a5f1-4e5ea916c810",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 10
                      }
                    ],
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                    "scheduledDay": 1
                  },
                  {
                    "id": "74a1a394-878e-4f37-b048-813600813419",
                    "name": "Screening",
                    "description": "Visit anchor: Screening",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "65c9c5c0-76d3-4bfa-af14-3ccbbfe3f961",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      },
                      {
                        "id": "c59266e1-fe7c-4455-a5f1-4e5ea916c810",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 20
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "7fa81a3b-5071-464d-b0ee-39b2dfe1bc95",
                    "name": "Baseline",
                    "description": "Visit anchor: Baseline",
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "65c9c5c0-76d3-4bfa-af14-3ccbbfe3f961",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      },
                      {
                        "id": "c59266e1-fe7c-4455-a5f1-4e5ea916c810",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 50
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "e811562d-fe24-4b8e-8056-d90fecbb5d17",
                    "name": "FirstDose",
                    "description": "Event anchor: FirstDose",
                    "activityIds": [
                      "e45433b5-90e1-4471-8cc1-71a4ac578f37"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "65c9c5c0-76d3-4bfa-af14-3ccbbfe3f961",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "c59266e1-fe7c-4455-a5f1-4e5ea916c810",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 60
                      }
                    ],
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                    "scheduledDay": 1
                  },
                  {
                    "id": "ef1ca940-6883-46e9-b2cd-0133c19b81e5",
                    "name": "Anchor: Standard Visit Window",
                    "activityIds": [],
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "d4d52e77-eb62-4c58-857b-6b3aab760729",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      },
                      {
                        "id": "8ab4ff42-ddfa-40b6-8f48-fb59c2748537",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      }
                    ],
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  },
                  {
                    "id": "e6aa3d0b-1edb-4a23-9b3f-ef860bd6646a",
                    "name": "Anchor: Safety Follow-up Call",
                    "activityIds": [],
                    "encounterId": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "b33e018c-4412-4868-a2d5-52bcab4e67cd",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      },
                      {
                        "id": "4107bc06-5ddd-4b86-a3be-c09854206d12",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      }
                    ],
                    "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4"
                  }
                ],
                "timings": [
                  {
                    "id": "53647a43-ff60-480f-a28b-279f792306ec",
                    "name": "Screening Window",
                    "type": {
                      "id": "c07ec88f-2616-42d9-9bdc-cb4457467602",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P8W",
                    "valueLabel": "8 weeks",
                    "relativeToFrom": {
                      "id": "e089652f-03e9-4981-bdfa-895a3b69a459",
                      "code": "C71159",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Baseline",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "74a1a394-878e-4f37-b048-813600813419",
                    "instanceType": "Timing",
                    "windowLower": "-P56W",
                    "windowUpper": "P0W"
                  },
                  {
                    "id": "a1448af4-cd39-48ed-ab4b-093f10090e1f",
                    "name": "Screening Inhibitor Test Washout",
                    "type": {
                      "id": "5a5ed698-70cd-4c0a-9335-e90d52d65151",
                      "code": "C71149",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Before",
                      "instanceType": "Code"
                    },
                    "value": "PT48H",
                    "valueLabel": "48 hours",
                    "relativeToFrom": {
                      "id": "d4774c5a-e801-4fff-9b0a-75e7a8b0b49a",
                      "code": "C71158",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Screening",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "74a1a394-878e-4f37-b048-813600813419",
                    "instanceType": "Timing",
                    "windowLower": "-PT48H",
                    "windowUpper": "PT0H"
                  },
                  {
                    "id": "5c9f7fb2-bdbb-4bb4-ae3f-ea26ba3bd335",
                    "name": "Baseline Washout Conventional FVIII",
                    "type": {
                      "id": "36f7b8b6-abbd-4955-bd68-cd87aa88016c",
                      "code": "C71149",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Before",
                      "instanceType": "Code"
                    },
                    "value": "PT96H",
                    "valueLabel": "96 hours",
                    "relativeToFrom": {
                      "id": "326c9818-0e2a-4853-afc3-dd654769ec61",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "7fa81a3b-5071-464d-b0ee-39b2dfe1bc95",
                    "instanceType": "Timing",
                    "windowLower": "-PT96H",
                    "windowUpper": "PT0H"
                  },
                  {
                    "id": "d6be92c3-a4df-446e-86fc-190b23c61d18",
                    "name": "Baseline Washout EHL FVIII",
                    "type": {
                      "id": "682a7384-0a88-4368-a4c0-c17bc41d96f3",
                      "code": "C71149",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Before",
                      "instanceType": "Code"
                    },
                    "value": "PT120H",
                    "valueLabel": "120 hours",
                    "relativeToFrom": {
                      "id": "e4a545f9-7d6f-4a55-929b-fda4e6349cb0",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "7fa81a3b-5071-464d-b0ee-39b2dfe1bc95",
                    "instanceType": "Timing",
                    "windowLower": "-PT120H",
                    "windowUpper": "PT0H"
                  },
                  {
                    "id": "a11a4b6f-9154-4f12-b649-3eca66f7695a",
                    "name": "Standard Visit Window",
                    "type": {
                      "id": "13b4fccb-988d-4409-9937-c98136c6e2bf",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "b395df42-3c53-4c78-a6cf-390e63ef7f15",
                      "code": "C71157",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Previous Visit",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "ef1ca940-6883-46e9-b2cd-0133c19b81e5",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P7D"
                  },
                  {
                    "id": "402c84a5-12bd-4c2a-8d93-86d3424bdfd1",
                    "name": "Safety Follow-up Call",
                    "type": {
                      "id": "96b4cc8f-b826-4f15-ae83-9155099d757a",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P14D",
                    "valueLabel": "Day 14",
                    "relativeToFrom": {
                      "id": "54d5f7b0-d8c9-49f8-8a38-5784fe337f4b",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "e6aa3d0b-1edb-4a23-9b3f-ef860bd6646a",
                    "instanceType": "Timing",
                    "windowLower": "P14D",
                    "windowUpper": "P21D"
                  },
                  {
                    "id": "280b3702-c4df-4042-b95b-32f03960156c",
                    "name": "Minor Dental Surgery Blood Draw",
                    "type": {
                      "id": "62a35220-776a-477d-812e-b7a7f211d4e5",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P3D",
                    "valueLabel": "Day 3",
                    "relativeToFrom": {
                      "id": "363b963f-9227-4861-95b1-50b1bb9841f8",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "f6515aa4-2cdb-453c-9b5c-5e83978d3d78",
                    "instanceType": "Timing",
                    "windowLower": "-P3D",
                    "windowUpper": "P0D"
                  }
                ],
                "exits": [
                  {
                    "id": "1b535d50-5eb8-4334-9e15-45f73220ce4f",
                    "name": "Pregnancy Exit",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Female participant becomes pregnant"
                  },
                  {
                    "id": "8c405e7d-db5a-4208-b347-a1b89c70aad9",
                    "name": "Study Completion",
                    "exitType": "Completion",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Completion of Week 52 visit and safety follow-up"
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "38b1bc55-12ed-4ada-aa72-9fbd770bfaf1",
                "name": "Baseline BIVV001 Day 1",
                "instanceType": "Encounter",
                "type": {
                  "id": "6f29bba1-2353-4efa-8c1e-1d0fa990985b",
                  "code": "C142615",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "4b322956-9593-4323-9dc8-219c97dd52cc",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "5612719e-7b18-4d13-b963-757d79f948b5",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "b42d1fef-e89b-47d7-9648-70b33cbb482d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "4c03ee38-6e0a-4a3f-acb8-b09ad1e91a37",
                "name": "Screening (Week -8 to Day 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "2da73db8-517e-47c8-b626-3c180a0366b8",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "d39d999c-dec9-4d20-8d15-58d92580364c",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "de1c43fb-8cb3-4f9a-88d9-81f8fd55e39a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "19791520-3b33-4475-8acd-997d4f9289df",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "a35bbeb1-3b01-440e-8d26-3220a3496541",
                "name": "Week 4 ±7 days",
                "instanceType": "Encounter",
                "type": {
                  "id": "4ffa70c4-9c1d-4fc4-b9a6-4c22a1c9f81c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "8e5c8a41-06a8-425c-95f7-97d93ae3247a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ebce9ab0-822a-45f6-a610-0a9e624e7d57",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "6e3eb7b4-22f7-40ef-b029-f3473568081f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 4
                  }
                ]
              },
              {
                "id": "24b23484-3b93-4b55-804d-ab685681e86e",
                "name": "Week 13 ±7 days",
                "instanceType": "Encounter",
                "type": {
                  "id": "a3ad615b-0dba-4ed8-89f0-97a29c8ca04b",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "5ceb87ee-9fd1-40b4-b1af-4f4d0a5019fc",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "947fe421-13b6-482d-b04a-5d49c00954fe",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "eba3c0df-cd91-4956-9e2b-079e546fef08",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 13
                  }
                ]
              },
              {
                "id": "15613da3-250f-4e12-8c11-2d28c6118d19",
                "name": "Week 26 ±7 days",
                "instanceType": "Encounter",
                "type": {
                  "id": "03dfa303-f70a-4acf-acbd-ccaf955ff915",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "a7c86b3d-16f6-4a44-917a-08e224aad8de",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "dd931674-58da-4e8d-a97f-84f3c4c89866",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "df09eb9a-7fdc-48d0-ad4c-c4165e85362d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 26
                  }
                ]
              },
              {
                "id": "07806163-4b22-4820-b2e9-13578147926d",
                "name": "Week 39 ±7 days",
                "instanceType": "Encounter",
                "type": {
                  "id": "ef0f1315-6bbd-41fc-b5dd-4723fae0dda9",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "7319e85c-5299-4bd8-ac0d-23b8c3e8bd0e",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b9a2a1ff-0276-4453-bb16-9da7d9e75fda",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "6193fab3-af4c-401a-bbb5-8ffd67d516d6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 39
                  }
                ]
              },
              {
                "id": "522edf7d-389d-4d4f-b615-f8fd80205885",
                "name": "Week 52/ EOS/ET ±7 days",
                "instanceType": "Encounter",
                "type": {
                  "id": "66e0c04c-e436-4e2b-bd52-f4a408cf7778",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "End of Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "16bd7bee-fe31-4010-b7dd-1b5c79831357",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "90877901-21fe-41b4-bb2f-9a7ebd13401f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "177b6cbc-072c-48f5-b45d-c4ef02f314ef",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 52
                  }
                ]
              },
              {
                "id": "7c6adeba-33e0-49ef-b5ef-a759433426d9",
                "name": "Safety follow-up call or visit",
                "instanceType": "Encounter",
                "type": {
                  "id": "b725052e-ddda-45bf-b06f-d02407be3a31",
                  "code": "C98777",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "b9363925-06fa-4db4-bd50-67246893bf07",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "0dbb54d2-cd62-421d-a328-3bcedec04071",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "phone"
                  }
                ]
              },
              {
                "id": "a9e3b166-f778-4723-89a5-604c54ebb179",
                "name": "Unscheduled visit",
                "instanceType": "Encounter",
                "type": {
                  "id": "83480af5-dc4f-428d-8799-7e9ca004546f",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Unscheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "extensionAttributes": [
                  {
                    "id": "42dda4b3-93c1-4475-a52d-6e6dec402bd8",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "04fdc1e3-805a-4779-bb68-508c3d3679bb",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              }
            ],
            "activities": [
              {
                "id": "5dbb1b6d-2881-45c5-947a-f5abbba99712",
                "name": "Abbreviated pharmacokinetic Sampling",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "763ee12b-42b0-4022-88d9-a0ff77f4d2b0",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a8df37aa-9069-4f2c-8159-3ba1b2d8f9fa",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "48a92e69-c159-40d8-92e2-6ad25b2149ce",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "012a558b-ef32-4cd4-8494-1edbe44163e8",
                "name": "Anti-rFVIIIFc-VWF-XTEN Antibody (ADA)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a4e3c953-e08c-41a3-9147-2c449c53cd55",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "caf9488e-9ede-498d-a2ba-b40bc56a19f0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "212ce96b-8256-4cd5-b642-a966bde5872d",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "cea776ef-376b-4390-abcc-b413758a6bdb",
                "name": "Assessment of eligibility",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a49df0a7-05f0-43e1-bc79-101be4ec6e38",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ce29872f-bb77-45d0-a10b-f9f589ee9a62",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "7f663ffd-5c2f-40ca-9070-4640ebb5f271",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "e62aaa1e-820e-421d-a2b4-cd1f723b120c",
                "name": "CD4 count, viral load",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ef175bc4-eac2-4302-97de-97a96fc70e34",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f663087b-de4c-432a-afeb-27f07abd773f",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "cc684b0d-b61b-4856-950e-e09eb4b84b6c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "2ec5a524-1a97-4ff0-81e7-ba65e0852c55",
                "name": "Clinical chemistry",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "610230d8-fb43-41c1-a00d-66d845284f70",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a05b804f-7886-4520-9a56-31e29831fa15",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "34c128e6-1d07-49d3-9066-b31507017975",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "5327b400-a0cc-4e3a-b89c-a29a26a75167",
                "name": "Coagulation parameters",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "61fa2d9a-6f98-4b62-9053-cc2715ae5461",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6e04090e-413a-40e0-9925-21260d58891a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "26f587a6-9880-4634-b7b6-54762420c4a3",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "72466392-e800-419c-8311-b41b2c6f711c",
                "name": "Demographics",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "8625803f-ffe0-47e3-bb3d-86dc8139f26c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "88e2652a-5975-41d1-b0be-83bcee4ca798",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "92c22940-0a60-4008-920d-c38cf218726b",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4e5d5d05-d882-49cd-aee7-b819d64cc583",
                "name": "EQ-5D-5L",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "bc140c42-84eb-4d61-b2ee-c2a3d65ba914",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b0414722-d374-4731-bd44-c0d0da91be19",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "e9bd5b5c-ad73-49e5-859e-115a7a98b2ac",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "6019b58e-9d7e-4cb7-82fe-14f711496a24",
                "name": "Electrocardiogram",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "6019b58e-9d7e-4cb7-82fe-14f711496a24",
                    "name": "Electrocardiogram",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "57d08622-d51e-4b61-a931-b65fc891c3c9",
                      "code": "C25391",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Diagnostic Procedure",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "ECG",
                    "description": "Diagnostic imaging of heart electrical activity"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "be860419-c2e2-417e-ba4a-0c2054b28c1f",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "30ea228e-3885-4b32-adee-d2809302e2df",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "c27c6a50-42cc-4ccc-a677-27d4db8a4dae",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "e45433b5-90e1-4471-8cc1-71a4ac578f37",
                "name": "Electronic patient diary (ePD) training / administration/ review",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d29ba8f2-f0ad-4208-925c-71acdd2894e4",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "2471ce1f-774b-4d63-91c6-029c18eef057",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "assessment"
                  },
                  {
                    "id": "6b4396c4-e88f-4484-ac15-a048891feaac",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "44b0638b-c2f2-43db-86df-41de0df940fc",
                "name": "Exit interview",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3f9a093c-fe43-4c00-9db7-0f8ebb4441d8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "2546fcc5-10fb-4014-abac-a882ac295518",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "433b1937-a6a3-4a17-98a9-e6063b303f19",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0249edfe-fb3a-4154-aa84-fdf09a49d9a2",
                "name": "FVIII activity (1-stage aPTT assay)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "106bc9e0-5902-4855-8c7e-1e582d7d7066",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "75ab00d4-7a7f-4605-834f-254c3bf3e9db",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "079e6a50-e276-4ab2-a0b0-06adfc2ea1a1",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "6ecfdea3-c015-4f87-962e-3c0c3a3dae4f",
                "name": "FVIII peak and trough sampling",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c414dd5b-3847-46a5-ba2f-0aa4bb4d9788",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "75487fb4-53bf-4631-a3ec-d11e66d30954",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "5744a3cb-ceb0-4398-ba08-fa229442e574",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "5f7ce80e-4941-4b7f-a1ac-87252b1c9f28",
                "name": "Genotype",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "edf2886c-45a5-4011-a58e-50553d87ed25",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "68435a78-7174-4f70-a3b6-b52d14c2df6c",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "7e491c8a-a7eb-4c38-8ac0-b4b9ba29f597",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "557e3f44-797c-47af-95f5-734e3683b90e",
                "name": "HAL (≥18 years old) or pedHAL (<18 years old)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "373ebff8-e103-4bea-9c24-76e151b27aa5",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "15d618bb-f20e-47e5-899e-61dc328b8b89",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "78a7b8f2-c18b-4e28-a0b3-3a78e3cddf64",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "1bfbd19b-b16f-4a48-b148-b10eac1d4c64",
                "name": "HIV, HBV, and HCV status",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "5ae3bf74-1819-4ac2-91c9-280c834d1048",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "7db45a1f-d91f-4c3d-8f3e-650312f616fb",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "cf924c93-1386-417d-afc8-2271c7deff19",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "44076f02-54fb-48cd-940f-243b01db52a5",
                "name": "HJHS joint assessments",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1ce6f44a-76db-4eae-9bd8-6be2d29216e9",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c1b2d805-e78f-4f88-a777-ada4103b7e9e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "2aa29249-bdbc-447c-89a0-1e071a8ffa4a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "6fe03ca8-9487-40eb-a53e-e6aeaa7946f3",
                "name": "Haem-A-QoL (≥17 years old) or Haemo QoL (<17 years old)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ff69bda5-fe78-4bb4-a985-bf7df784ce35",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a6e50cd7-9d53-4c8a-94ae-d18acd3d4ed6",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "1ae5d0a6-4b90-4acd-9a8d-f817800c2676",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "04dbfd5c-fd90-4875-bb5e-37ba111401b7",
                "name": "Healthcare Resource Utilization",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "737d01d1-cf87-4999-b77d-24c7dacbbf6d",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "586ace89-6cff-486a-adfd-81a5c78007b6",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "ad55f95d-2adc-46de-a422-48b15d78bfde",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "237043a1-edaf-43f1-afec-2bef91a0b934",
                "name": "Height",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "cac166f7-a5fa-4637-9a2b-9479f7cd18be",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "de189f6b-d218-4ccb-acbe-17d1b73492bf",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "646c672c-42d1-482e-9c8e-f8f5e7c78ed1",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "36a0e78e-4296-4387-8247-7aaebde9bd33",
                "name": "Hematology",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "6908d941-54ff-4038-9aaf-e87b41beb25c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "45eed840-3a78-4404-add8-82b6b3b2ccb8",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "f01c504f-5b82-449c-8585-3966869ccfc2",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "be883257-ec2f-472b-b90a-5edd6de1e881",
                "name": "In-clinic BIVV001 dosing",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "80233522-6f6f-478e-9fc4-64850c6fe2f9",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c9abf390-6025-4c6b-b592-4cff4c471ba2",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "f1ea58f7-cf65-4c9b-969e-82a121beae76",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "610f1bad-97a5-4257-bda6-d470c96c4344",
                "name": "Informed consent",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "4c067e54-86d8-4c18-a62e-d55f71b9eab4",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "22ce82c0-d63d-4697-af95-40e0e3aa37ed",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  },
                  {
                    "id": "48801da7-96ac-4c11-918f-62f8dcb9b349",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a1768e96-f62b-48f2-8029-16891bb48bd9",
                "name": "Intravenous Injection",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "a1768e96-f62b-48f2-8029-16891bb48bd9",
                    "name": "Intravenous Injection",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "c3419514-bd3e-41f0-80ac-2e1abd6ce609",
                      "code": "96374",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Therapeutic, prophylactic, or diagnostic injection; intravenous push",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Slow Push IV Injection",
                    "description": "Administration of BIVV001 via slow push IV injection over 8 ±2 minutes"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b3e5921f-89ca-4f49-8f82-9b129fdd60c6",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "56a1a84e-8654-4378-bd37-5d2caf118eb9",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "4ba70b71-28c1-43af-9a57-25e99cac4270",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "55b85ae5-79c2-49f8-b354-ead564f0b857",
                "name": "Investigator's target joint assessment",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "f95384de-9af8-440b-a2dd-7f83bc08c3cb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8ccf04c7-408d-48fb-8c73-d83c441611fa",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "82bfb588-0d0d-4858-895f-83024a6c0161",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "1a2e2dbf-db94-4b9b-b0dd-4254a8f586f9",
                "name": "Joint Health Assessment",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "1a2e2dbf-db94-4b9b-b0dd-4254a8f586f9",
                    "name": "Joint Health Assessment",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "13dca10f-fa9a-40b3-baee-da318279e45b",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Assessment",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "HJHS",
                    "description": "Examination of joints per the Hemophilia Joint Health Score"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c82c53ca-b690-46d1-97a7-f8041f2de59e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "fee65200-c962-4051-a92f-fcfb83fd4158",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "f6be7a73-8eb0-426d-bd98-fc1eed629bf3",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d302fc6f-6360-48fc-badd-4e32c5d4c140",
                "name": "Medical, surgical, and hemophilia history",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "edda462c-76b4-43a9-8ef3-d77dabe601d8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "43a14154-1dd8-49d4-85b8-26cdf4eb8bf9",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "dc4938a2-fc76-4778-a26a-6dd8ee635bbb",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ef1e4cc6-9f5c-4d19-9017-f7b0408552c3",
                "name": "Nijmegen-modified Bethesda Assay",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c830ebf2-aa70-42a3-9413-0a3b54e16846",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "307e8f2b-f923-42be-879c-03be31f9bac5",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "6c8558db-226b-4635-8598-7a8bf4ebc1ca",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "9ecb19e2-4a31-4255-998e-a30389df2b4c",
                "name": "Nijmegen-modified Bethesda assay (inhibitor assay)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1cce97f7-fd5c-4c62-8379-4d0a530c757f",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c53b42ff-14c7-493c-8bf2-d243a22ae7e1",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "f061fe28-5f37-4e25-950a-62e7a30d190c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "44658d7b-7486-402d-a992-56d8c8a672bc",
                "name": "PROMIS Assessments",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "103bb6ae-efa0-47d8-bf4b-da1b003f6e92",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4e5c5045-b735-4070-9335-7935f4670817",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "66d500b6-1ace-4a1d-83ce-e977abecc57a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "32fa8fa9-ba0e-445c-92dd-0d9f5c124053",
                "name": "Patient Global Impression of Change",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c0c67537-cb35-4449-b686-388b133abf1f",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f7439cb8-39bf-46ec-a58d-dad96b9b2212",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "d7839777-7dab-4f98-a9a4-ecc6815b7c15",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0a754a18-a635-44d5-b363-eadf29293321",
                "name": "Patient Global Impression of Severity (activity and joint)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "799c6fa6-bd73-4023-8b73-2516f62220aa",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "dfe382d2-c0a8-434b-ae80-16d8578f55fa",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "652d33b7-6afe-405c-ab9a-347780db80eb",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "9aeca392-dd20-4cc8-a891-e8a78660dc62",
                "name": "Physical Activity Monitor (ActiGraph Activity Monitor)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "07a9a37d-a555-4476-9c46-2a92c0a4adbf",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d7773e3f-3d29-42ed-a3f7-88736daad79b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "56103ca5-1ab2-4cfe-b760-7c126699ebec",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f2c0cea5-f3df-4a91-9103-1f05104352f1",
                "name": "Physical Examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b9d91240-6181-43dc-b007-c931ef8f5567",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "38517ac7-b580-4845-86a4-3fd994322af0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "7ab59694-5f31-42eb-a735-bebc3cfe9171",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f",
                "name": "Physical exam",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3814da57-0137-4c43-80e0-6d77e37bb2a9",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "9210abf5-2514-4a16-8a04-abaec9674820",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "688c847b-fd70-4665-9342-f80724e09f79",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d7ecac8b-a972-4f88-8cba-08dc5281627a",
                "name": "Physician's global assessment of response to treatment (PGA)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d1b6b441-5777-4002-8cd6-b90aada48d2c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "7d12e7f9-4346-4938-8596-a8d34eed3187",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "4745a9ed-53ac-4295-8bb4-16e41efac51d",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "b473ec84-1bfe-44c6-983c-ccff73d621dc",
                "name": "Pregnancy testing",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "f2678407-736c-44b7-8ef3-7c5d52deb3ce",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4b4f414a-5544-403e-8c3c-00c4bf6ff2d4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "d114eb0f-bd58-4ae8-8ae3-d51880313fc9",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "58702b84-7ba4-4b73-99eb-72c9f9acc0af",
                "name": "Sequential pharmacokinetic sampling",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1baddd3a-e77a-4d5f-ab20-aff5fab8f192",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "0d818edc-4b91-4c78-aef3-9111784da5a4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "8179478e-9b32-4ec8-8bd8-08a64f645e8a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "563785e3-c9ea-445a-8860-bb8b0d268c69",
                "name": "Serum and plasma samples (optional)",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "134006c0-2ee3-4a7f-b889-26964103c93c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4d9da64f-d70a-4e75-9b13-c3755b70d27e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "bfaea4f5-3561-455e-9588-c0aaaf10d920",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0033d0c4-cd3f-4da1-b6bb-636787467d57",
                "name": "TSQM-9",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "40acfd8a-73f8-4ac4-844d-883e99c7b507",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c795c24a-45ee-42ac-8897-1106489f1f83",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "7f9fa58b-66e5-4e9e-b725-39e39a35d8cf",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c18a6c0b-6c48-4750-a9fd-d6a78655fc81",
                "name": "Treatment Preference Survey",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d89b52a3-8ffb-4d19-8399-5d8040127d77",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "87540420-c435-4c31-9f66-4ba861dc6c25",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "assessment"
                  },
                  {
                    "id": "b81bb6d2-82dc-47d6-8e38-0988aefa7069",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f4670981-67c5-40d3-98ea-bd54e4ac3f93",
                "name": "Ultrasound Imaging",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "f4670981-67c5-40d3-98ea-bd54e4ac3f93",
                    "name": "Ultrasound Imaging",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "803fb00c-3374-4d0f-ae04-51d98f857b14",
                      "code": "C17369",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Imaging Technique",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Joint Ultrasound",
                    "description": "Anatomical structural joint-health assessment via JADE or HEAD-US protocols"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "039dfd83-7ef6-4776-876f-819dc6304c48",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "e0cf5ac3-67c4-4e3e-abd2-e3ce205c9528",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "e0021baa-d7c1-4f85-b7f2-c159a49a022e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0a2f244e-2e64-415d-b599-46e7dfffd3ee",
                "name": "Ultrasound joint assessments",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "552aab6c-460b-4e18-9dbd-12a3e1ff9178",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b5c2d7b1-37b9-46bb-aa91-5341ed2bb233",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "8fec6a2a-e236-44c6-b37f-584504f2761f",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c30348b2-1c0f-4790-8bd7-6771facc9f61",
                "name": "Venipuncture",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "c30348b2-1c0f-4790-8bd7-6771facc9f61",
                    "name": "Venipuncture",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "4be90d3e-df75-4d13-8616-75c59febf2a7",
                      "code": "36415",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Collection of venous blood by venipuncture",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Blood Draw",
                    "description": "Collection of blood samples for FVIII activity, laboratory safety panels, and PK sampling"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "7b5bd483-b34b-4683-bd60-e33cc33b5195",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "ddefbbc0-dc84-4530-8856-16b9bc5f7380",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "0e09fcf7-7636-4f44-9911-4dd23b6a45ee",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d544f99e-13a1-49e7-a131-4a06854d7278",
                "name": "Vital Signs Monitoring",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "646bb90d-5e99-45f5-badf-04a5a72e3266",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "c95a1890-323b-4ad3-adf4-7e71247bff49",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "df8e9bad-8f14-40df-9e50-46e7b41a5b7e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "22364548-d56c-414b-a7c4-2af9e39fdc64",
                "name": "Vital signs",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "6bf7e109-eaf6-4a6e-9ab2-b291950c90fd",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "82d4dfb2-4790-4534-8fbf-210a3ddd4674",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "f6ddaf77-fa76-4e6f-9452-0be8bb2b8fb1",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376",
                "name": "Weight",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "62a12fc0-04af-4248-9c5d-c07567a631e1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3db7bc50-a4bc-4b36-a774-ae9cd7194cc8",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "11136f6d-1ffb-4d83-ad7c-3a1f7b9c4f2e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c5840ccd-ebc1-4016-ae91-ea38b952e412",
                "name": "von Willebrand Comprehensive Panel",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "609d84c2-967a-4906-90db-55cc81458d86",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d557a1ad-067f-4aa1-9da7-dd840c5a50c0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "46de2f9b-be01-4f78-a094-6fb8c086cf91",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "ee6af7d4-82f5-436e-9ab8-fa9826c837e4",
                "name": "Study Period | Screening/Lead-in",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "ff69491c-0549-422e-8ff2-a4d4ae0a634c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "29ea12c2-a2ab-4e7e-8815-65be82b6cfbc",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "61ca0952-b71d-4a4b-9d90-4d04155a45f0",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "48d42220-b37a-403d-b7a1-dbab4192978c",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "1"
                  }
                ]
              }
            ],
            "activityGroups": [
              {
                "id": "1a97b24f-d9cd-49aa-893b-90d9db187982",
                "name": "General Assessments",
                "description": null,
                "childIds": [
                  "610f1bad-97a5-4257-bda6-d470c96c4344",
                  "cea776ef-376b-4390-abcc-b413758a6bdb",
                  "72466392-e800-419c-8311-b41b2c6f711c",
                  "327cffc5-0b80-4a2c-8dc0-b6f2ccac3376",
                  "237043a1-edaf-43f1-afec-2bef91a0b934",
                  "d302fc6f-6360-48fc-badd-4e32c5d4c140",
                  "0249edfe-fb3a-4154-aa84-fdf09a49d9a2",
                  "5f7ce80e-4941-4b7f-a1ac-87252b1c9f28",
                  "be883257-ec2f-472b-b90a-5edd6de1e881"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Informed consent",
                  "Assessment of eligibility",
                  "Demographics",
                  "Weight",
                  "Height",
                  "Medical, surgical, and hemophilia history",
                  "FVIII activity (1-stage aPTT assay)",
                  "Genotype",
                  "In-clinic BIVV001 dosing"
                ]
              },
              {
                "id": "b26ced41-f6d8-40e7-bf36-3d80ba3a019b",
                "name": "Safety",
                "description": null,
                "childIds": [
                  "e10e5c6d-0d13-40c0-8c40-f2eeee70c95f",
                  "22364548-d56c-414b-a7c4-2af9e39fdc64",
                  "b473ec84-1bfe-44c6-983c-ccff73d621dc",
                  "1bfbd19b-b16f-4a48-b148-b10eac1d4c64",
                  "e62aaa1e-820e-421d-a2b4-cd1f723b120c",
                  "36a0e78e-4296-4387-8247-7aaebde9bd33",
                  "5327b400-a0cc-4e3a-b89c-a29a26a75167",
                  "2ec5a524-1a97-4ff0-81e7-ba65e0852c55",
                  "c5840ccd-ebc1-4016-ae91-ea38b952e412",
                  "9ecb19e2-4a31-4255-998e-a30389df2b4c",
                  "012a558b-ef32-4cd4-8494-1edbe44163e8"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Physical exam",
                  "Vital signs",
                  "Pregnancy testing",
                  "HIV, HBV, and HCV status",
                  "CD4 count, viral load",
                  "Hematology",
                  "Coagulation parameters",
                  "Clinical chemistry",
                  "von Willebrand Comprehensive Panel",
                  "Nijmegen-modified Bethesda assay (inhibitor assay)",
                  "Anti-rFVIIIFc-VWF-XTEN Antibody (ADA)",
                  "Adverse event/serious adverse event recording",
                  "Prior and concomitant medications and concomitant therapies and procedures",
                  "Monthly telephone call"
                ]
              },
              {
                "id": "8835b38c-dadc-415f-9502-65e3a75a802c",
                "name": "Efficacy",
                "description": null,
                "childIds": [
                  "44076f02-54fb-48cd-940f-243b01db52a5",
                  "55b85ae5-79c2-49f8-b354-ead564f0b857",
                  "d7ecac8b-a972-4f88-8cba-08dc5281627a",
                  "0a2f244e-2e64-415d-b599-46e7dfffd3ee",
                  "563785e3-c9ea-445a-8860-bb8b0d268c69",
                  "e45433b5-90e1-4471-8cc1-71a4ac578f37"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "HJHS joint assessments",
                  "Investigator's target joint assessment",
                  "Physician's global assessment of response to treatment (PGA)",
                  "Investigator's assessment of participant's response to treatment of bleeding episodes treated at the study site",
                  "Ultrasound joint assessments",
                  "Serum and plasma samples (optional)",
                  "Electronic patient diary (ePD) training / administration/ review",
                  "Participant's completion of ePD including at-home dosing, bleeding episodes, and assessment of response to treatment of bleeding episodes"
                ]
              },
              {
                "id": "63608c43-c46d-44fc-90a2-e3f6a8ced22f",
                "name": "Pharmacokinetics",
                "description": null,
                "childIds": [
                  "5dbb1b6d-2881-45c5-947a-f5abbba99712",
                  "58702b84-7ba4-4b73-99eb-72c9f9acc0af",
                  "6ecfdea3-c015-4f87-962e-3c0c3a3dae4f"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Abbreviated pharmacokinetic Sampling",
                  "Sequential pharmacokinetic sampling",
                  "FVIII peak and trough sampling"
                ]
              },
              {
                "id": "1e047fbc-9611-4639-9099-ff31bb947b83",
                "name": "Participant-Reported Outcomes",
                "description": null,
                "childIds": [
                  "44658d7b-7486-402d-a992-56d8c8a672bc",
                  "6fe03ca8-9487-40eb-a53e-e6aeaa7946f3",
                  "557e3f44-797c-47af-95f5-734e3683b90e",
                  "0033d0c4-cd3f-4da1-b6bb-636787467d57",
                  "0a754a18-a635-44d5-b363-eadf29293321",
                  "32fa8fa9-ba0e-445c-92dd-0d9f5c124053",
                  "4e5d5d05-d882-49cd-aee7-b819d64cc583",
                  "c18a6c0b-6c48-4750-a9fd-d6a78655fc81",
                  "9aeca392-dd20-4cc8-a891-e8a78660dc62",
                  "44b0638b-c2f2-43db-86df-41de0df940fc",
                  "04dbfd5c-fd90-4875-bb5e-37ba111401b7"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "PROMIS Assessments",
                  "Haem-A-QoL (≥17 years old) or Haemo QoL (<17 years old)",
                  "HAL (≥18 years old) or pedHAL (<18 years old)",
                  "TSQM-9",
                  "Patient Global Impression of Severity (activity and joint)",
                  "Patient Global Impression of Change",
                  "EQ-5D-5L",
                  "Treatment Preference Survey",
                  "Physical Activity Monitor (ActiGraph Activity Monitor)",
                  "Exit interview",
                  "Healthcare Resource Utilization"
                ]
              }
            ],
            "notes": [
              {
                "id": "ed7b375b-3c81-4258-8e54-3802fe5720dd",
                "text": "a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening Period is up to 8 weeks before Baseline. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "6adf56da-76db-45a0-be13-3e601578ae94",
                "text": "b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period before the Baseline Visit for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "99a7f201-f37b-4d42-bb97-9f2817db49ec",
                "text": "c. Participants should schedule their study visits to be 7 ±1 day after the previous prophylactic dose of BIVV001.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "adf5b7c1-2725-4314-ab83-76f66be44e32",
                "text": "d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in the Sequential PK arm should schedule their Week 26 study visit to be 7 (+2) days after the previous prophylactic dose of BIVV001.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "cf90e45b-a743-4376-ba38-e242a500fe6e",
                "text": "e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or at the discretion of the Investigator. If a participant has an unscheduled visit, the Investigator will record data as appropriate based on the purpose of the visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "1c134d49-d4b0-4eeb-86fd-21903ca05456",
                "text": "f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant enrolls in the open-label extension study. For France specific pregnancy testing at the safety follow-up visit refer to Section 10.11.1.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7dc1de06-ad4a-400e-806b-30e21e02d614",
                "text": "g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior to any study-related procedures, including washout of current FVIII therapy specifically for entry into the study, or the country's local regulations. Participant assent must also be obtained where applicable (according to the study site's geographic region).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "ca78cc36-b971-4fd1-8c2d-76becf28e3aa",
                "text": "h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted by local regulations. Race and ethnicity will be collected for reasons described in Section 10.1.4.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2d7765c3-2501-4bca-9484-de65e039391a",
                "text": "i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not previously documented. For Repeat Screening Visit, update with any changes since original Screening Visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "51de4ecc-1e92-49bc-8567-d32c37c8d700",
                "text": "j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committees) will be governed by a separate informed consent. HLA genotype will not be needed if previously documented.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9722f6b0-148b-401a-8a01-8f578d6db1be",
                "text": "k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period prior to BIVV001 Day 1 dose administration for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor. Washout prior to all other scheduled inhibitor tests must be at least 7±1 days. Inhibitor and ADA samples will be collected prior to BIVV001 dosing. Separate samples for anti-rFVIIIFc-VWF-XTEN antibody (ADA) testing will be collected at the same timepoint when any samples are collected for inhibitor testing (including samples for suspected inhibitor and confirmatory inhibitor tests). All inhibitor assays, including the assay for the Screening Visit and any confirmatory assays, will be performed by the central laboratory using the Nijmegen-modified Bethesda assay. If a Nijmegen-modified Bethesda assay result returns as ≥0.6 BU/mL, a separate sample must be collected and tested for confirmation of inhibitor development within 2 to 4 weeks of the original sample. Testing for potential ADA formation will be performed at a central laboratory using a validated rFVIIIFc-VWF-XTEN-specific ADA assay. Confirmed positive samples will be further characterized for antibodies specific to FVIII, Fc, D'D3, or XTEN.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "01edafb3-5311-494f-8f12-6893f17c7959",
                "text": "l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participants in Arm B will have BIVV001 doses at visits Day 1, Weeks 26, 39, and 52. During the Scheduled study visits, BIVV001 will be delivered via a slow push IV injection of 8 ±2 minutes, at a rate of administration determined by the participant's comfort level. For all BIVV001 injections performed at home BIVV001 will be delivered via a slow push IV injection at a rate of administration determined by the participant's comfort level according to the vial and injection rate recommendations (Table 7). Injection start and stop time will be recorded in the eCRF. Other doses may be self/caregiver administered at home (or in clinic) (Table 3)",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "068990fa-9e47-4267-8d2b-e293012e9ade",
                "text": "m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (°C). Vital signs should be taken after the participant has been resting supine for 5 minutes. Vital signs will be measured pre-injection and 30 (±15 minutes) from the start of injection at clinic visits. Vital signs should also be taken at any unscheduled visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7ef53327-a831-4c21-89c7-4fefe50b6662",
                "text": "n. Applicable to female participants only. A serum pregnancy test should be performed at screening. For all other time points, the choice of the pregnancy test (urine or serum) is at the discretion of the Investigator. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from further participation if the serum pregnancy result is positive.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "6977afef-8814-4951-a56f-50b76dc442c8",
                "text": "o. For participants who have been historically negative, viral testing will be performed at a central laboratory. Human immunodeficiency virus (HIV) tests will include HIV-1 antibodies, HIV-2 antibodies and HIV-1 p24 antigen. Hepatitis B virus (HBV) tests will include HBV surface antigen, anti-HBV surface antibody and anti-HBV core antibody. Hepatitis C virus (HCV) tests will include anti-HCV antibodies.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "79ea1fc2-5c97-4848-894e-a5b812303396",
                "text": "p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be performed at the central laboratory if results are not available from within 26 weeks prior to screening.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9b5f79e6-a1f1-4769-aadb-178f05b99c5b",
                "text": "q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differential, platelet count, hemoglobin (Hgb), and hematocrit (Hct). Blood samples for hematology analysis will be collected prior to BIVV001 dosing.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9c34971a-3124-44d3-8a9f-bef9bad3ae37",
                "text": "r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin, blood urea nitrogen (BUN), creatinine, glucose, total protein, sodium, potassium, and chloride. Blood samples for clinical chemistry analysis will be collected prior to BIVV001 dosing.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c38be2c8-a1e4-4b4b-8a55-2ecdb76509d9",
                "text": "s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] ristocetin cofactor activity and VWF antigen). Blood samples for analysis of Von Willebrand comprehensive panel will be collected prior to any BIVV001 dosing.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a2376181-17eb-4c90-ba2f-0ca6a46949e0",
                "text": "t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed consent form (ICF) through the Safety Follow-Up Call or Visit will be recorded on the case report form (CRF). Pain medication related to Hemophilia and administered within 2 weeks prior to the visit will be recorded on the CRF.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9e91c65a-b45e-4f6c-997d-5e47ec209fd6",
                "text": "u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies and procedures from signing of ICF through the Safety Follow-Up Call or Visit will be recorded on the CRF.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "e69b455e-1886-4b4e-aada-7f62f8338bb1",
                "text": "v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month for the site staff to check on each participant's status. During the monthly telephone call, the participant's parent/caregiver will also be reminded about the requirement for timely ePD data entry, and assessments of \"spontaneous\" and \"traumatic\" bleeding episodes will be noted.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "fd5385c6-6de7-4fa0-ad10-1eeaa86c41b2",
                "text": "w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS). At baseline, the Investigator will assess the presence of any target joints according to ISTH criteria.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "df481daa-8a94-45a2-87db-7d8af616b102",
                "text": "x. For bleeding episodes treated at the study sites, the Investigator will contact the participant approximately 72 hours from the time the BIVV001 injection was administered to treat the bleeding episode and record the participant's assessment of response to BIVV001 treatment on the eCRF using a 4-point bleeding response scale. For bleeding episodes that are treated at home, participants will record response to bleeding episodes in the ePD.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "b7063a26-48c8-4dca-b1c8-a546b2768f96",
                "text": "y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity and Damage Examination (JADE) protocol and/or Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) in a subpopulation of participants from Arm A at selected sites. The Ultrasound can be performed at the Baseline visit or up to 2 weeks after the Baseline Visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c3bd94f4-f394-4fd6-8110-0a88c34f18a8",
                "text": "z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laboratory (if required) for future research, eg., immunology assays, further coagulation assays, or clarification of clinical or laboratory AE, etc. This is optional and participants will sign an additional consent for this research.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9b8e7801-eeb8-4a85-a6fc-cb9e87f12a4a",
                "text": "aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of response to bleeding episodes using a 4-point bleeding response scale. The participant should record response approximately 72 hours from the time the first BIVV001 injection was administered to treat the bleeding episode, unless treatment of the bleed was administered in the clinic. In that case, the investigator will report the participant's response to treatment via the eCRF.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c3dd0cc3-738c-4d1f-8e46-b6e596f7efb7",
                "text": "bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated PK sampling after the first dose of BIVV001 (Baseline). See abbreviated PK sampling details in Table 2.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "b092e143-155e-4878-a48f-d428bcbe1aa2",
                "text": "cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Baseline and again at Week 26. See sequential PK sampling details as described in Table 3.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "16b4fa11-45a7-4bf2-a4f1-44cfbe320ad2",
                "text": "dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 min ± 3 min post injection. This trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ADA) samples taken predose (Table 2).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "42e6f471-029f-4779-89b9-2f2d1a852ca6",
                "text": "ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference ≥18 years old or PROMIS Pediatric-SF Pain Interference <18 years old), and Physical Function (PROMIS-SF Physical Function ≥18 years old or PROMIS Pediatric-SF Physical Activity <18 years old). See Section 8.1.2.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "ddcf44a1-0907-49d1-8b0e-5509f1b0bcfb",
                "text": "ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patient perception of activity and a single question on patient perception of joint health. See Section 8.1.2.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "08bc6fec-5e5b-458f-8989-a7116a700e0c",
                "text": "gg. Treatment preference survey will consist of 2 questions on patient preference and a single question on Patient Global Impression of Change (PGIC). See Section 8.1.2.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "023fc595-9595-4b14-a245-99b8a7d0713b",
                "text": "hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical grade accelerometer (ActiGraph Activity Monitor) worn on the nondominant wrist. Device will be worn daily for 8 consecutive days after the scheduled visits at Screening, Baseline, Weeks 4, 13, 26, 39, and for 8 consecutive days before the Week 52 visit. Refer to Section 8.1.4",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "48f0570d-eb9e-4782-8e28-39344b01f3a1",
                "text": "ii. Coagulation parameters include activated partial thromboplastin time (aPTT)",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "d28e622f-e972-4bfd-851d-553303a71b6f",
                "text": "jj. Please refer to Section 10.11.2 for Italy specific requirement",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "97c15d66-5014-4c70-be66-d0d6ed110fe1",
                "text": "kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7deee9f3-7876-4e3a-8089-704c1bc20894",
                "text": "ll. ePD training only. ePD devices are given to the patients at the baseline visit",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "42c598a8-8657-4d98-b868-298f4f2b0538",
                "text": "a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening Period is up to 8 weeks before Baseline. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results.",
                "instanceType": "Note"
              },
              {
                "id": "62a85b8a-01a1-47e0-bb18-b9d50641055a",
                "text": "jj. Please refer to Section 10.11.2 for Italy specific requirement",
                "instanceType": "Note"
              },
              {
                "id": "db122bcd-48f9-4f2a-81d1-6baf205b8c27",
                "text": "1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies.",
                "instanceType": "Note"
              },
              {
                "id": "640c9687-e210-4fce-88a5-9fc95e112205",
                "text": "2. NSAIDs at doses above the maximum dose specified in local prescribing information.",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "a76e0eb8-a933-4824-b6ec-350b1ba5e598",
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "2e7031ef-e0ed-44c5-ae6d-e87671cf3574",
                "name": "Severe Hemophilia A",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Previously treated patients ≥12 years of age with severe Hemophilia A"
              }
            ],
            "procedures": [
              {
                "id": "c30348b2-1c0f-4790-8bd7-6771facc9f61",
                "name": "Venipuncture",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "4be90d3e-df75-4d13-8616-75c59febf2a7",
                  "code": "36415",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Collection of venous blood by venipuncture",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Blood Draw",
                "description": "Collection of blood samples for FVIII activity, laboratory safety panels, and PK sampling"
              },
              {
                "id": "a1768e96-f62b-48f2-8029-16891bb48bd9",
                "name": "Intravenous Injection",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "c3419514-bd3e-41f0-80ac-2e1abd6ce609",
                  "code": "96374",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Therapeutic, prophylactic, or diagnostic injection; intravenous push",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Slow Push IV Injection",
                "description": "Administration of BIVV001 via slow push IV injection over 8 ±2 minutes"
              },
              {
                "id": "1a2e2dbf-db94-4b9b-b0dd-4254a8f586f9",
                "name": "Joint Health Assessment",
                "procedureType": "Assessment",
                "code": {
                  "id": "13dca10f-fa9a-40b3-baee-da318279e45b",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Assessment",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "HJHS",
                "description": "Examination of joints per the Hemophilia Joint Health Score"
              },
              {
                "id": "f4670981-67c5-40d3-98ea-bd54e4ac3f93",
                "name": "Ultrasound Imaging",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "803fb00c-3374-4d0f-ae04-51d98f857b14",
                  "code": "C17369",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Imaging Technique",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Joint Ultrasound",
                "description": "Anatomical structural joint-health assessment via JADE or HEAD-US protocols"
              },
              {
                "id": "6019b58e-9d7e-4cb7-82fe-14f711496a24",
                "name": "Electrocardiogram",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "57d08622-d51e-4b61-a931-b65fc891c3c9",
                  "code": "C25391",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Diagnostic Procedure",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "ECG",
                "description": "Diagnostic imaging of heart electrical activity"
              }
            ],
            "analysisPopulations": [
              {
                "id": "a6c02097-2779-415e-a9d4-f2a5564789da",
                "name": "Screened Set",
                "text": "The Screened Set includes all subjects who signed an informed consent form.",
                "populationType": "Other",
                "instanceType": "AnalysisPopulation",
                "label": "SCR",
                "populationDescription": "The Screened Set includes all subjects who signed an informed consent form.",
                "criteria": "Signed informed consent form"
              },
              {
                "id": "10384da6-10af-4266-b772-c516de5ca2df",
                "name": "Full Analysis Set",
                "text": "The Full Analysis Set includes all enrolled subjects who received at least one dose of study drug.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "FAS",
                "populationDescription": "The Full Analysis Set includes all enrolled subjects who received at least one dose of study drug.",
                "criteria": "Enrolled AND received >=1 dose of BIVV001"
              },
              {
                "id": "755b49ad-36a1-4b53-8cf3-8e5c57ab3539",
                "name": "Safety Analysis Set",
                "text": "The Safety Set consists of all subjects who received at least one dose of study medication.",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "SAF",
                "populationDescription": "The Safety Set consists of all subjects who received at least one dose of study medication.",
                "criteria": "Received >=1 dose of BIVV001"
              },
              {
                "id": "2cb9fc72-8ae2-4b89-b305-63f475d475d6",
                "name": "Pharmacokinetic Analysis Set",
                "text": "Subjects with evaluable PK samples; includes at least 16 participants in Arm A participating in the sequential PK subgroup undergoing extensive PK sampling at Baseline and Week 26, and other participants undergoing abbreviated PK sampling.",
                "populationType": "PK/PD",
                "instanceType": "AnalysisPopulation",
                "label": "PK Set",
                "populationDescription": "Subjects with evaluable PK samples; includes at least 16 participants in Arm A participating in the sequential PK subgroup undergoing extensive PK sampling at Baseline and Week 26, and other participants undergoing abbreviated PK sampling.",
                "criteria": "Received BIVV001 AND has evaluable PK samples"
              },
              {
                "id": "0d081878-8c05-497d-b023-ccd503126ae1",
                "name": "Surgery Subgroup",
                "text": "Participants from any arm who undergo major surgery during the study to assess control and prevention of bleeding with BIVV001 treatment in the surgical setting.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "Surgery",
                "populationDescription": "Participants from any arm who undergo major surgery during the study to assess control and prevention of bleeding with BIVV001 treatment in the surgical setting.",
                "criteria": "Enrolled AND undergo major surgery during study period"
              }
            ],
            "characteristics": [
              {
                "id": "3cb56d80-d1ec-4d18-9bec-9200174fa483",
                "code": "AGE",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Age",
                "instanceType": "Code"
              },
              {
                "id": "2610e3dc-c7cf-47fd-819a-7b6fe93c0049",
                "code": "ENDOGENOUS_FVIII_ACT",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Endogenous FVIII activity",
                "instanceType": "Code"
              },
              {
                "id": "93c933e0-9cb4-4163-9dfa-d7de352e0c93",
                "code": "ANNUALIZED_BLEEDING_",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Annualized Bleeding Rate",
                "instanceType": "Code"
              }
            ],
            "extensionAttributes": [
              {
                "id": "ext_conceptual_18905e22-0575-41cc-be6c-4b48169bddfa",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-conceptualAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"f6515aa4-2cdb-453c-9b5c-5e83978d3d78\", \"name\": \"Minor Dental Surgery Blood Draw\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}]"
              },
              {
                "id": "e281a4aa-8427-49f0-9337-06813190c663",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-promotionIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Screening Window' reference remapped: 6aded665-a100-439e-9831-471a6eb1ed9c \\u2192 anchor_inst_anchor_3\", \"affectedPath\": \"$.timings[?(@.id=='timing_1')]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Screening Inhibitor Test Washout' reference remapped: 30e47bd0-602a-4e6c-a411-464679f053cc \\u2192 anchor_inst_anchor_3\", \"affectedPath\": \"$.timings[?(@.id=='timing_2')]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Baseline Washout Conventional FVIII' reference remapped: 296e16e4-b721-4d6c-b3f3-6dcb0e5c429f \\u2192 anchor_inst_anchor_2\", \"affectedPath\": \"$.timings[?(@.id=='timing_3')]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Baseline Washout EHL FVIII' reference remapped: 266e9475-ed9c-41d5-9e58-4142e1a7bc56 \\u2192 anchor_inst_anchor_2\", \"affectedPath\": \"$.timings[?(@.id=='timing_4')]\"}, {\"severity\": \"info\", \"category\": \"visit_anchor_created\", \"message\": \"Created VISIT anchor instance: ef1ca940-6883-46e9-b2cd-0133c19b81e5 (encounter: enc_1)\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"visit_anchor_created\", \"message\": \"Created VISIT anchor instance: e6aa3d0b-1edb-4a23-9b3f-ef860bd6646a (encounter: enc_1)\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Minor Dental Surgery Blood Draw' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}]"
              },
              {
                "id": "d1fbd44a-943c-4510-9efa-218f45ae8dd2",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"455b357e-b139-4929-8642-00eb2cb10711\", \"definition\": \"First administration of investigational product\", \"anchorType\": \"FirstDose\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 60, \"sourceText\": \"Day 1 dosing\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"c0a20493-531e-48b0-9549-4febc041b137\", \"definition\": \"Baseline visit/assessment\", \"anchorType\": \"Baseline\", \"classification\": \"Visit\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 50, \"sourceText\": \"baseline visit\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"071ef9bc-f7d3-4fec-a217-4d53384acc5f\", \"definition\": \"Screening visit\", \"anchorType\": \"Screening\", \"classification\": \"Visit\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 20, \"sourceText\": \"Screening visit\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"54468220-ae26-4a8e-8e3f-68352c6ac3e7\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 10, \"sourceText\": \"Informed consent\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"150c8296-f994-4e50-a11f-0a9fe6ea63bc\", \"definition\": \"surgery\", \"anchorType\": \"Custom\", \"classification\": \"Conceptual\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 100, \"sourceText\": \"surgery\", \"encounterId\": null, \"activityId\": null}]"
              },
              {
                "id": "49ebe412-9b4c-45df-a844-ab8739bc8be4",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"6686d2db-adc1-4ebe-bedc-953a5a28d593\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"007d8037-5375-4faa-9392-42bcea2c13c3\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"OD\"}, {\"id\": \"e44c5353-6601-486c-967c-1d06d2969720\", \"type\": \"Interval\", \"sourceText\": \"PK sampling at \"}, {\"id\": \"9c49113a-95f8-4589-89c2-0253a10a933a\", \"type\": \"Continuous\", \"sourceText\": \"washout period\"}, {\"id\": \"1794aa19-fe07-4f10-ab24-b4f0a3192d4b\", \"type\": \"Continuous\", \"sourceText\": \"Screening Period\"}, {\"id\": \"9c20d18a-dc63-4b43-855f-130607eab224\", \"type\": \"Continuous\", \"sourceText\": \"treatment period\"}, {\"id\": \"14049c60-6535-4cdc-867d-cc448ae34777\", \"type\": \"Continuous\", \"sourceText\": \"1 day after\"}, {\"id\": \"d1a6ee36-4a41-4340-b506-86a4784d3e63\", \"type\": \"Continuous\", \"sourceText\": \"14 days post\"}, {\"id\": \"9a8fe153-1d67-4cf1-aa3e-5e1c41f904f0\", \"type\": \"Continuous\", \"startOffset\": \"P0D\", \"endOffset\": \"P0D\", \"interval\": \"P1D\", \"minObservations\": 1, \"exitCondition\": \"End of study\", \"sourceText\": \"Time period and frequency for collecting AE and SAE information\"}, {\"id\": \"72c23d01-bab8-430b-8e80-4fb4f9468602\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"endOffset\": \"P6D\", \"interval\": \"P1D\", \"minObservations\": 6, \"exitCondition\": \"Completion of 6 exposure days\", \"sourceText\": \"Participants should have at least 6 EDs to BIVV001 to be eligible for major surgery.\"}, {\"id\": \"d0df2abc-c486-42df-9cd9-9f95e4595f01\", \"type\": \"Continuous\", \"startOffset\": \"-P7D\", \"endOffset\": \"P0D\", \"interval\": \"P7D\", \"minObservations\": 1, \"exitCondition\": \"null\", \"sourceText\": \"the PROMIS-SF Physical Function - SF 6b instrument does not use a 7-day recall period\"}, {\"id\": \"3c6f0df8-a879-42ea-b2bb-5cd45351e51e\", \"type\": \"Continuous\", \"startOffset\": \"-P28D\", \"endOffset\": \"P0D\", \"interval\": \"P28D\", \"minObservations\": 1, \"exitCondition\": \"null\", \"sourceText\": \"negative inhibitor test within 4 weeks prior to surgery\"}]"
              },
              {
                "id": "0b503854-e4cb-4ddd-b7e3-f57196a56728",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"324c121a-34f1-4f9d-b40e-22f53769a870\", \"requiredSequence\": [\"epoch_1\", \"epoch_1\", \"epoch_1\"], \"allowEarlyExit\": true, \"exitEpochIds\": [], \"mandatoryVisits\": [\"enc_1\", \"enc_1\", \"enc_7\"], \"sourceText\": \"washout period\"}, {\"id\": \"02e0c762-2991-43d1-83fd-9b44a821db8d\", \"requiredSequence\": [\"epoch_1\", \"epoch_1\", \"epoch_1\", \"epoch_1\"], \"allowEarlyExit\": true, \"exitEpochIds\": [], \"mandatoryVisits\": [\"enc_7\", \"enc_1\", \"enc_1\", \"enc_2\"], \"sourceText\": \"[{'condition': 'If subject undergoes major surgery', 'path': ['SURGERY_SUBGROUP', '6_EXPOSURE_DAYS_MINIMUM', 'NEGATIVE_INHIBITOR_TEST']}, {'condition': 'Use of FVIII products other than BIVV001 (non-emergency)', 'path': ['DEFINITIVE_DISCONTINUATION']}, {'condition': 'Life-threatening emergency requiring other FVIII product', 'path': ['SPONSOR_REVIEW', 'CONTINUATION_OR_DISCONTINUATION']}]\"}]"
              },
              {
                "id": "ecd94711-ae0b-4d91-9147-3a33e4aeeedf",
                "url": "https://protocol2usdm.io/extensions/x-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"f06141f5-8b86-4dc1-9c12-2023033799e9\", \"conditionType\": \"timing_before\", \"text\": \"a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening Period is up to 8 weeks before Baseline. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results.\", \"footnoteId\": \"f12b0efe-4593-4990-894a-eff39a17d15c\", \"structuredCondition\": \"timing.before(Baseline, P8W) && timing.after(InhibitorTest, PT48H)\", \"appliesToActivityIds\": [\"Screening\", \"Inhibitor Test\"], \"timingConstraint\": \"PT48H\", \"sourceText\": \"a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening\"}, {\"id\": \"2918ff6d-efb8-41aa-bbbc-6daf277ffb9d\", \"conditionType\": \"timing_before\", \"text\": \"b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period before the Baseline Visit for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor.\", \"footnoteId\": \"30a4556b-837a-4723-8bf6-c822cf86d007\", \"structuredCondition\": \"if(product == 'conventional') timing.after(last_dose, PT96H) else if(product == 'EHL') timing.after(last_dose, PT120H)\", \"appliesToActivityIds\": [\"d7ecac8b-a972-4f88-8cba-08dc5281627a\", \"9aeca392-dd20-4cc8-a891-e8a78660dc62\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"be883257-ec2f-472b-b90a-5edd6de1e881\", \"5dbb1b6d-2881-45c5-947a-f5abbba99712\", \"2ec5a524-1a97-4ff0-81e7-ba65e0852c55\"], \"timingConstraint\": \"PT96H\", \"sourceText\": \"b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participa\"}, {\"id\": \"bc43fee9-5a9f-468a-a0ed-76d517e7dddd\", \"conditionType\": \"timing_after\", \"text\": \"c. Participants should schedule their study visits to be 7 \\u00b11 day after the previous prophylactic dose of BIVV001.\", \"footnoteId\": \"c540c134-003c-4a05-a64f-8cfbb3e212c5\", \"structuredCondition\": \"timing.after(previous_dose, P7D) +/- P1D\", \"appliesToActivityIds\": [\"be883257-ec2f-472b-b90a-5edd6de1e881\"], \"sourceText\": \"c. Participants should schedule their study visits to be 7 \\u00b11 day after the previous prophylactic do\"}, {\"id\": \"9c7e064c-e18c-44fd-bb85-59264acd79b7\", \"conditionType\": \"timing_after\", \"text\": \"d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in the Sequential PK arm should schedule their Week 26 study visit to be 7 (+2) days after the previous prophylactic dose of BIVV001.\", \"footnoteId\": \"f7158168-18c4-4509-b135-8427dfa00a32\", \"structuredCondition\": \"if(arm == 'Sequential PK') timing.after(previous_dose, P7D) + P2D\", \"appliesToActivityIds\": [\"58702b84-7ba4-4b73-99eb-72c9f9acc0af\", \"be883257-ec2f-472b-b90a-5edd6de1e881\", \"d7ecac8b-a972-4f88-8cba-08dc5281627a\"], \"sourceText\": \"d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in\"}, {\"id\": \"b13974d3-40fb-45e9-a31e-beee7a5737b0\", \"conditionType\": \"eligibility_conditional\", \"text\": \"e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or at the discretion of the Investigator. If a participant has an unscheduled visit, the Investigator will record data as appropriate based on the purpose of the visit.\", \"footnoteId\": \"cb767af1-60fb-4513-9f54-93c84664c491\", \"sourceText\": \"e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or\", \"appliesToActivityIds\": [\"5dbb1b6d-2881-45c5-947a-f5abbba99712\"]}, {\"id\": \"188a5651-b9b9-4124-8fd2-fe79b9441e79\", \"conditionType\": \"timing_after\", \"text\": \"f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant enrolls in the open-label extension study. For France specific pregnancy testing at the safety follow-up visit refer to Section 10.11.1.\", \"footnoteId\": \"858da27d-df64-44f7-abe8-32fa70524825\", \"structuredCondition\": \"timing.after(last_dose, P14D) + P7D\", \"appliesToActivityIds\": [\"b26ced41-f6d8-40e7-bf36-3d80ba3a019b\"], \"sourceText\": \"f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant\"}, {\"id\": \"ee210219-ce84-4784-a9b4-555e1047eb49\", \"conditionType\": \"timing_before\", \"text\": \"g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior to any study-related procedures, including washout of current FVIII therapy specifically for entry into the study, or the country's local regulations. Participant assent must also be obtained where applicable (according to the study site's geographic region).\", \"footnoteId\": \"5a6b8741-8f8d-434c-a416-11c778510885\", \"structuredCondition\": \"timing.before(any_procedure, PT0S)\", \"appliesToActivityIds\": [\"610f1bad-97a5-4257-bda6-d470c96c4344\"], \"sourceText\": \"g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior \"}, {\"id\": \"42099827-d796-4a54-b55a-856af78d1bd8\", \"conditionType\": \"general\", \"text\": \"h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted by local regulations. Race and ethnicity will be collected for reasons described in Section 10.1.4.\", \"footnoteId\": \"84fb275a-be0c-45cd-9fa7-3b2b5920aecf\", \"sourceText\": \"h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted b\", \"appliesToActivityIds\": [\"72466392-e800-419c-8311-b41b2c6f711c\"]}, {\"id\": \"91256dc5-127e-4359-9f7e-4721d90c9ce8\", \"conditionType\": \"general\", \"text\": \"i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not previously documented. For Repeat Screening Visit, update with any changes since original Screening Visit.\", \"footnoteId\": \"000e8219-f600-4a3d-9376-ac414ac7f389\", \"sourceText\": \"i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not prev\", \"appliesToActivityIds\": [\"0a754a18-a635-44d5-b363-eadf29293321\", \"d302fc6f-6360-48fc-badd-4e32c5d4c140\", \"cea776ef-376b-4390-abcc-b413758a6bdb\", \"32fa8fa9-ba0e-445c-92dd-0d9f5c124053\"]}, {\"id\": \"50fd90cb-e931-4307-8ecc-11dfbbb300a9\", \"conditionType\": \"general\", \"text\": \"j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committees) will be governed by a separate informed consent. HLA genotype will not be needed if previously documented.\", \"footnoteId\": \"13d8f47a-1c14-495c-8dc7-151b51e0296f\", \"sourceText\": \"j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committ\", \"appliesToActivityIds\": [\"5f7ce80e-4941-4b7f-a1ac-87252b1c9f28\", \"610f1bad-97a5-4257-bda6-d470c96c4344\", \"563785e3-c9ea-445a-8860-bb8b0d268c69\"]}, {\"id\": \"cedcfa7a-18ba-40c8-a58f-f107bcb42f17\", \"conditionType\": \"timing_before\", \"text\": \"k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period prior to BIVV001 Day 1 dose administration for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor. Washout prior to all other scheduled inhibitor tests must be at least 7\\u00b11 days. Inhibitor and ADA samples will be collected prior to BIVV001 dosing. Separate samples for anti-rFVIIIFc-VWF-XTEN antibody (ADA) testing will be collected at the same timepoint when any samples are collected for inhibitor testing (including samples for suspected inhibitor and confirmatory inhibitor tests). All inhibitor assays, including the assay for the Screening Visit and any confirmatory assays, will be performed by the central laboratory using the Nijmegen-modified Bethesda assay. If a Nijmegen-modified Bethesda assay result returns as \\u22650.6 BU/mL, a separate sample must be collected and tested for confirmation of inhibitor development within 2 to 4 weeks of the original sample. Testing for potential ADA formation will be performed at a central laboratory using a validated rFVIIIFc-VWF-XTEN-specific ADA assay. Confirmed positive samples will be further characterized for antibodies specific to FVIII, Fc, D'D3, or XTEN.\", \"footnoteId\": \"c0a8f2a0-8f91-4c65-9581-3962669038b8\", \"structuredCondition\": \"timing.after(original_sample, P2W) && timing.before(original_sample, P4W)\", \"appliesToActivityIds\": [\"012a558b-ef32-4cd4-8494-1edbe44163e8\", \"563785e3-c9ea-445a-8860-bb8b0d268c69\", \"d7ecac8b-a972-4f88-8cba-08dc5281627a\", \"9ecb19e2-4a31-4255-998e-a30389df2b4c\", \"9aeca392-dd20-4cc8-a891-e8a78660dc62\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"be883257-ec2f-472b-b90a-5edd6de1e881\", \"5dbb1b6d-2881-45c5-947a-f5abbba99712\", \"2ec5a524-1a97-4ff0-81e7-ba65e0852c55\", \"b473ec84-1bfe-44c6-983c-ccff73d621dc\"], \"timingConstraint\": \"PT48H\", \"sourceText\": \"k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test r\"}, {\"id\": \"05c91541-c180-4d16-a278-997778df750f\", \"conditionType\": \"general\", \"text\": \"l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participants in Arm B will have BIVV001 doses at visits Day 1, Weeks 26, 39, and 52. During the Scheduled study visits, BIVV001 will be delivered via a slow push IV injection of 8 \\u00b12 minutes, at a rate of administration determined by the participant's comfort level. For all BIVV001 injections performed at home BIVV001 will be delivered via a slow push IV injection at a rate of administration determined by the participant's comfort level according to the vial and injection rate recommendations (Table 7). Injection start and stop time will be recorded in the eCRF. Other doses may be self/caregiver administered at home (or in clinic) (Table 3)\", \"footnoteId\": \"86ab4945-2df5-452b-91fc-e708d317052c\", \"sourceText\": \"l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participa\", \"appliesToActivityIds\": [\"be883257-ec2f-472b-b90a-5edd6de1e881\"]}, {\"id\": \"cc1b6d31-33b7-4aef-8523-a8bc5d004002\", \"conditionType\": \"timing_after\", \"text\": \"m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (\\u00b0C). Vital signs should be taken after the participant has been resting supine for 5 minutes. Vital signs will be measured pre-injection and 30 (\\u00b115 minutes) from the start of injection at clinic visits. Vital signs should also be taken at any unscheduled visit.\", \"footnoteId\": \"32fdd306-c266-425c-9941-e4993684c6c4\", \"structuredCondition\": \"timing.after(rest, PT5M) && timing.before(injection, PT0S) && timing.after(injection_start, PT30M) +/- PT15M\", \"appliesToActivityIds\": [\"22364548-d56c-414b-a7c4-2af9e39fdc64\"], \"timingConstraint\": \"PT5M\", \"sourceText\": \"m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (\\u00b0C). Vital sig\"}, {\"id\": \"11b1ffdc-bf8a-49ff-bfa7-3140c99cc4aa\", \"conditionType\": \"general\", \"text\": \"n. Applicable to female participants only. A serum pregnancy test should be performed at screening. For all other time points, the choice of the pregnancy test (urine or serum) is at the discretion of the Investigator. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from further participation if the serum pregnancy result is positive.\", \"footnoteId\": \"4fce6950-7c6d-430c-bf7a-8c7e6783f00e\", \"structuredCondition\": \"if(sex == 'female') procedure.perform(Pregnancy Test)\", \"appliesToActivityIds\": [\"b473ec84-1bfe-44c6-983c-ccff73d621dc\"], \"sourceText\": \"n. Applicable to female participants only. A serum pregnancy test should be performed at screening. \"}, {\"id\": \"fde4360e-71e8-4406-9b11-19ca3c25d894\", \"conditionType\": \"general\", \"text\": \"o. For participants who have been historically negative, viral testing will be performed at a central laboratory. Human immunodeficiency virus (HIV) tests will include HIV-1 antibodies, HIV-2 antibodies and HIV-1 p24 antigen. Hepatitis B virus (HBV) tests will include HBV surface antigen, anti-HBV surface antibody and anti-HBV core antibody. Hepatitis C virus (HCV) tests will include anti-HCV antibodies.\", \"footnoteId\": \"9a9c9a9b-8859-4e05-acd4-74a84e6de23c\", \"sourceText\": \"o. For participants who have been historically negative, viral testing will be performed at a centra\", \"appliesToActivityIds\": [\"e62aaa1e-820e-421d-a2b4-cd1f723b120c\", \"012a558b-ef32-4cd4-8494-1edbe44163e8\", \"b473ec84-1bfe-44c6-983c-ccff73d621dc\"]}, {\"id\": \"3d028784-2466-4e65-89f3-ddaf6a1d5e6c\", \"conditionType\": \"timing_before\", \"text\": \"p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be performed at the central laboratory if results are not available from within 26 weeks prior to screening.\", \"footnoteId\": \"14d22ad5-0c38-4457-b02d-0e8a1ff627cc\", \"sourceText\": \"p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be perfor\", \"appliesToActivityIds\": [\"e62aaa1e-820e-421d-a2b4-cd1f723b120c\", \"012a558b-ef32-4cd4-8494-1edbe44163e8\"]}, {\"id\": \"97b5b1a4-8f82-414c-8cf1-340e46d3ed86\", \"conditionType\": \"timing_before\", \"text\": \"q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differential, platelet count, hemoglobin (Hgb), and hematocrit (Hct). Blood samples for hematology analysis will be collected prior to BIVV001 dosing.\", \"footnoteId\": \"74957102-8b92-4e81-b837-e2e0315f8573\", \"structuredCondition\": \"timing.before(BIVV001_dosing, PT0S)\", \"appliesToActivityIds\": [\"36a0e78e-4296-4387-8247-7aaebde9bd33\"], \"sourceText\": \"q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differ\"}, {\"id\": \"bd02d45f-578a-4a0a-8e17-227742da1095\", \"conditionType\": \"timing_before\", \"text\": \"r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin, blood urea nitrogen (BUN), creatinine, glucose, total protein, sodium, potassium, and chloride. Blood samples for clinical chemistry analysis will be collected prior to BIVV001 dosing.\", \"footnoteId\": \"27daf236-a7b4-480c-9064-9a3cdb4a3ef4\", \"structuredCondition\": \"timing.before(BIVV001_dosing, PT0S)\", \"appliesToActivityIds\": [\"2ec5a524-1a97-4ff0-81e7-ba65e0852c55\"], \"sourceText\": \"r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase \"}, {\"id\": \"dc6280a7-1f2d-4d5a-80e3-8fdbee34800b\", \"conditionType\": \"timing_before\", \"text\": \"s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] ristocetin cofactor activity and VWF antigen). Blood samples for analysis of Von Willebrand comprehensive panel will be collected prior to any BIVV001 dosing.\", \"footnoteId\": \"fcaf2460-21ed-4202-89ad-6d48f02becc2\", \"sourceText\": \"s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] risto\", \"appliesToActivityIds\": [\"cea776ef-376b-4390-abcc-b413758a6bdb\", \"563785e3-c9ea-445a-8860-bb8b0d268c69\", \"c5840ccd-ebc1-4016-ae91-ea38b952e412\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"be883257-ec2f-472b-b90a-5edd6de1e881\", \"1a97b24f-d9cd-49aa-893b-90d9db187982\"]}, {\"id\": \"48160995-136e-422e-bbc5-7892931eb63c\", \"conditionType\": \"timing_before\", \"text\": \"t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed consent form (ICF) through the Safety Follow-Up Call or Visit will be recorded on the case report form (CRF). Pain medication related to Hemophilia and administered within 2 weeks prior to the visit will be recorded on the CRF.\", \"footnoteId\": \"690a202d-0c4c-4a14-bd6e-efcd4c8ee007\", \"sourceText\": \"t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed co\", \"appliesToActivityIds\": [\"b26ced41-f6d8-40e7-bf36-3d80ba3a019b\", \"610f1bad-97a5-4257-bda6-d470c96c4344\", \"d302fc6f-6360-48fc-badd-4e32c5d4c140\"]}, {\"id\": \"9c69ad09-7820-4f40-8669-6eca8afadf5f\", \"conditionType\": \"timing_before\", \"text\": \"u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies and procedures from signing of ICF through the Safety Follow-Up Call or Visit will be recorded on the CRF.\", \"footnoteId\": \"2af6eb60-770f-479a-8203-9e476167e094\", \"sourceText\": \"u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies\", \"appliesToActivityIds\": [\"b26ced41-f6d8-40e7-bf36-3d80ba3a019b\"]}, {\"id\": \"26073f31-f11c-41c6-a624-cf0aa497a587\", \"conditionType\": \"general\", \"text\": \"v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month for the site staff to check on each participant's status. During the monthly telephone call, the participant's parent/caregiver will also be reminded about the requirement for timely ePD data entry, and assessments of \\\"spontaneous\\\" and \\\"traumatic\\\" bleeding episodes will be noted.\", \"footnoteId\": \"786466fe-ce0d-4236-a790-5009c9159d25\", \"sourceText\": \"v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month fo\", \"appliesToActivityIds\": [\"cea776ef-376b-4390-abcc-b413758a6bdb\", \"1bfbd19b-b16f-4a48-b148-b10eac1d4c64\", \"1a97b24f-d9cd-49aa-893b-90d9db187982\"]}, {\"id\": \"206a136c-c86b-4362-a02d-ed439e99e186\", \"conditionType\": \"general\", \"text\": \"w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS). At baseline, the Investigator will assess the presence of any target joints according to ISTH criteria.\", \"footnoteId\": \"34dbdeab-d679-4cb0-bd72-6e4e87e1fb25\", \"sourceText\": \"w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS)\", \"appliesToActivityIds\": [\"55b85ae5-79c2-49f8-b354-ead564f0b857\", \"6fe03ca8-9487-40eb-a53e-e6aeaa7946f3\", \"e10e5c6d-0d13-40c0-8c40-f2eeee70c95f\", \"44076f02-54fb-48cd-940f-243b01db52a5\"]}, {\"id\": \"751264da-e9d2-4604-b687-d26628b2e575\", \"conditionType\": \"general\", \"text\": \"x. For bleeding episodes treated at the study sites, the Investigator will contact the participant approximately 72 hours from the time the BIVV001 injection was administered to treat the bleeding episode and record the participant's assessment of response to BIVV001 treatment on the eCRF using a 4-point bleeding response scale. For bleeding episodes that are treated at home, participants will record response to bleeding episodes in the ePD.\", \"footnoteId\": \"cb15403e-d6b5-4249-bcf0-9cf36b57a5a4\", \"sourceText\": \"x. For bleeding episodes treated at the study sites, the Investigator will contact the participant a\", \"appliesToActivityIds\": [\"be883257-ec2f-472b-b90a-5edd6de1e881\", \"d7ecac8b-a972-4f88-8cba-08dc5281627a\", \"cea776ef-376b-4390-abcc-b413758a6bdb\"]}, {\"id\": \"0d66f242-fdfd-417d-af4b-8989825eed20\", \"conditionType\": \"timing_after\", \"text\": \"y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity and Damage Examination (JADE) protocol and/or Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) in a subpopulation of participants from Arm A at selected sites. The Ultrasound can be performed at the Baseline visit or up to 2 weeks after the Baseline Visit.\", \"footnoteId\": \"18c3cbd9-00e4-4453-a281-20201ae3e53e\", \"structuredCondition\": \"timing.at(Baseline) || timing.after(Baseline, P2W)\", \"appliesToActivityIds\": [\"e10e5c6d-0d13-40c0-8c40-f2eeee70c95f\", \"0a2f244e-2e64-415d-b599-46e7dfffd3ee\", \"d302fc6f-6360-48fc-badd-4e32c5d4c140\", \"cea776ef-376b-4390-abcc-b413758a6bdb\", \"44076f02-54fb-48cd-940f-243b01db52a5\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\"], \"sourceText\": \"y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity an\"}, {\"id\": \"ade38b12-4343-4833-aa91-dd9817d72837\", \"conditionType\": \"timing_before\", \"text\": \"z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laboratory (if required) for future research, eg., immunology assays, further coagulation assays, or clarification of clinical or laboratory AE, etc. This is optional and participants will sign an additional consent for this research.\", \"footnoteId\": \"c81b7fa4-83b1-49dc-aca7-69035b7feac4\", \"sourceText\": \"z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laborat\", \"appliesToActivityIds\": [\"610f1bad-97a5-4257-bda6-d470c96c4344\", \"563785e3-c9ea-445a-8860-bb8b0d268c69\", \"9ecb19e2-4a31-4255-998e-a30389df2b4c\", \"5327b400-a0cc-4e3a-b89c-a29a26a75167\", \"be883257-ec2f-472b-b90a-5edd6de1e881\", \"2ec5a524-1a97-4ff0-81e7-ba65e0852c55\"]}, {\"id\": \"5b804dab-e207-42dd-b8ed-51f8b3ca5d69\", \"conditionType\": \"general\", \"text\": \"aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of response to bleeding episodes using a 4-point bleeding response scale. The participant should record response approximately 72 hours from the time the first BIVV001 injection was administered to treat the bleeding episode, unless treatment of the bleed was administered in the clinic. In that case, the investigator will report the participant's response to treatment via the eCRF.\", \"footnoteId\": \"3612f458-11d8-44d6-aade-82e8a5d2ebb4\", \"sourceText\": \"aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of r\", \"appliesToActivityIds\": [\"be883257-ec2f-472b-b90a-5edd6de1e881\", \"d7ecac8b-a972-4f88-8cba-08dc5281627a\", \"cea776ef-376b-4390-abcc-b413758a6bdb\"]}, {\"id\": \"a58a3fd5-6690-4245-aaae-c2c152240a20\", \"conditionType\": \"timing_after\", \"text\": \"bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated PK sampling after the first dose of BIVV001 (Baseline). See abbreviated PK sampling details in Table 2.\", \"footnoteId\": \"09906cb6-b60f-4493-8d4c-d561770c8d88\", \"sourceText\": \"bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated \", \"appliesToActivityIds\": [\"58702b84-7ba4-4b73-99eb-72c9f9acc0af\", \"be883257-ec2f-472b-b90a-5edd6de1e881\", \"5dbb1b6d-2881-45c5-947a-f5abbba99712\"]}, {\"id\": \"320b2c79-5304-4da0-a38b-d20888691f3e\", \"conditionType\": \"timing_at\", \"text\": \"cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Baseline and again at Week 26. See sequential PK sampling details as described in Table 3.\", \"footnoteId\": \"65d82cd5-2287-4527-bfac-4f0d70680234\", \"sourceText\": \"cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Bas\", \"appliesToActivityIds\": [\"58702b84-7ba4-4b73-99eb-72c9f9acc0af\", \"5dbb1b6d-2881-45c5-947a-f5abbba99712\"]}, {\"id\": \"adb70ad2-1166-4746-8de9-499004acf665\", \"conditionType\": \"timing_before\", \"text\": \"dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 min \\u00b1 3 min post injection. This trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ADA) samples taken predose (Table 2).\", \"footnoteId\": \"3e70085b-f6f3-4b7a-ab2c-4c9ff0a8538c\", \"structuredCondition\": \"timing.before(rfviiifc-vwf-xten dosing and 15 min \\u00b1 3 min post injection. this trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ada) samples taken predose (table 2)., PT30M)\", \"appliesToActivityIds\": [\"012a558b-ef32-4cd4-8494-1edbe44163e8\", \"563785e3-c9ea-445a-8860-bb8b0d268c69\", \"6ecfdea3-c015-4f87-962e-3c0c3a3dae4f\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"be883257-ec2f-472b-b90a-5edd6de1e881\"], \"timingConstraint\": \"PT30M\", \"sourceText\": \"dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 mi\"}, {\"id\": \"869e7f84-de3b-49e4-b8af-ced595fb50ec\", \"conditionType\": \"general\", \"text\": \"ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference \\u226518 years old or PROMIS Pediatric-SF Pain Interference <18 years old), and Physical Function (PROMIS-SF Physical Function \\u226518 years old or PROMIS Pediatric-SF Physical Activity <18 years old). See Section 8.1.2.\", \"footnoteId\": \"03165ef2-e36f-4d97-98e9-5e5a3b52f6cf\", \"sourceText\": \"ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference \\u226518\", \"appliesToActivityIds\": [\"e10e5c6d-0d13-40c0-8c40-f2eeee70c95f\", \"cea776ef-376b-4390-abcc-b413758a6bdb\", \"6fe03ca8-9487-40eb-a53e-e6aeaa7946f3\", \"44658d7b-7486-402d-a992-56d8c8a672bc\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"1a97b24f-d9cd-49aa-893b-90d9db187982\"]}, {\"id\": \"12a03afa-9b5e-4fc2-a151-9b90fe0a970a\", \"conditionType\": \"general\", \"text\": \"ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patient perception of activity and a single question on patient perception of joint health. See Section 8.1.2.\", \"footnoteId\": \"c90d1e46-c603-4331-92f7-cff54ab193c3\", \"sourceText\": \"ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patien\", \"appliesToActivityIds\": [\"cea776ef-376b-4390-abcc-b413758a6bdb\", \"0a754a18-a635-44d5-b363-eadf29293321\", \"d7ecac8b-a972-4f88-8cba-08dc5281627a\", \"44076f02-54fb-48cd-940f-243b01db52a5\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"e45433b5-90e1-4471-8cc1-71a4ac578f37\"]}, {\"id\": \"b52cbd22-8c39-444f-8857-9b5bdcdda4f4\", \"conditionType\": \"general\", \"text\": \"gg. Treatment preference survey will consist of 2 questions on patient preference and a single question on Patient Global Impression of Change (PGIC). See Section 8.1.2.\", \"footnoteId\": \"48c5753c-025c-4618-a5bf-39dfd5c14472\", \"sourceText\": \"gg. Treatment preference survey will consist of 2 questions on patient preference and a single quest\", \"appliesToActivityIds\": [\"c18a6c0b-6c48-4750-a9fd-d6a78655fc81\", \"0a754a18-a635-44d5-b363-eadf29293321\", \"d7ecac8b-a972-4f88-8cba-08dc5281627a\", \"32fa8fa9-ba0e-445c-92dd-0d9f5c124053\", \"e45433b5-90e1-4471-8cc1-71a4ac578f37\"]}, {\"id\": \"68955c98-58aa-46ac-9a95-ad1856517704\", \"conditionType\": \"timing_before\", \"text\": \"hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical grade accelerometer (ActiGraph Activity Monitor) worn on the nondominant wrist. Device will be worn daily for 8 consecutive days after the scheduled visits at Screening, Baseline, Weeks 4, 13, 26, 39, and for 8 consecutive days before the Week 52 visit. Refer to Section 8.1.4\", \"footnoteId\": \"c937e14e-bd6f-4c5b-aca2-50b90bc64ba6\", \"structuredCondition\": \"duration(P8D)\", \"appliesToActivityIds\": [\"e10e5c6d-0d13-40c0-8c40-f2eeee70c95f\", \"cea776ef-376b-4390-abcc-b413758a6bdb\", \"9aeca392-dd20-4cc8-a891-e8a78660dc62\", \"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"1a97b24f-d9cd-49aa-893b-90d9db187982\"], \"sourceText\": \"hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical \"}, {\"id\": \"6775dd14-6ebe-4486-ae31-bc8da51e9298\", \"conditionType\": \"general\", \"text\": \"ii. Coagulation parameters include activated partial thromboplastin time (aPTT)\", \"footnoteId\": \"c20afdbc-57db-4197-9dec-b4cdcbf62d56\", \"sourceText\": \"ii. Coagulation parameters include activated partial thromboplastin time (aPTT)\", \"appliesToActivityIds\": [\"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"5327b400-a0cc-4e3a-b89c-a29a26a75167\"]}, {\"id\": \"14e03d82-7780-4647-90e7-bd06c75762a1\", \"conditionType\": \"general\", \"text\": \"jj. Please refer to Section 10.11.2 for Italy specific requirement\", \"footnoteId\": \"83c613bc-63c0-4900-8772-b2b085da79f9\", \"sourceText\": \"jj. Please refer to Section 10.11.2 for Italy specific requirement\"}, {\"id\": \"fd5d03e5-9da8-4898-8d2e-93adda7cdcf6\", \"conditionType\": \"timing_before\", \"text\": \"kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.\", \"footnoteId\": \"0ea76ff4-62f4-45bb-ad5f-33e2912a8690\", \"sourceText\": \"kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after \", \"appliesToActivityIds\": [\"44b0638b-c2f2-43db-86df-41de0df940fc\"]}, {\"id\": \"f1be6f67-2084-4a5d-acc7-ee0ad5db810d\", \"conditionType\": \"general\", \"text\": \"ll. ePD training only. ePD devices are given to the patients at the baseline visit\", \"footnoteId\": \"f3a4553c-a79e-4538-b02f-6784dd883b86\", \"sourceText\": \"ll. ePD training only. ePD devices are given to the patients at the baseline visit\", \"appliesToActivityIds\": [\"e45433b5-90e1-4471-8cc1-71a4ac578f37\"]}, {\"id\": \"b843b6e7-186d-4738-ba9e-c1cbef39cdc3\", \"conditionType\": \"general\", \"text\": \"1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies.\", \"footnoteId\": \"79b00d1f-8ddb-4b1c-9a86-8ff1024ac654\", \"sourceText\": \"1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies.\"}, {\"id\": \"9d84c493-c4b1-4439-9bcf-8cd61b231ee1\", \"conditionType\": \"general\", \"text\": \"2. NSAIDs at doses above the maximum dose specified in local prescribing information.\", \"footnoteId\": \"ac541c45-d88e-4343-90ce-bb99ccb950cb\", \"sourceText\": \"2. NSAIDs at doses above the maximum dose specified in local prescribing information.\"}, {\"id\": \"e997566a-26f4-4c38-892b-b82513f8b87b\", \"conditionType\": \"general\", \"text\": \"3. Systemic treatment with chemotherapy and/or other immunosuppressive drugs (except for the treatment of hepatitis C virus [HCV] or HIV). The use of systemic steroids for the treatment of acute respiratory illness (eg, asthma), acute allergic episodes, or otherwise life threatening episodes is allowed. Treatment in these circumstances should not exceed a 14 day duration. Local, topical, and/or inhaled steroid use is permitted.\", \"footnoteId\": \"61eb5ddd-d569-45e7-96ca-5745e0cbaefa\", \"sourceText\": \"3. Systemic treatment with chemotherapy and/or other immunosuppressive drugs (except for the treatme\", \"appliesToActivityIds\": [\"d7ecac8b-a972-4f88-8cba-08dc5281627a\"]}, {\"id\": \"7926e514-6049-4168-b01b-0f9a7b7a849a\", \"conditionType\": \"general\", \"text\": \"4. Any other FVIII product (with exceptions listed in Section 7.1.1).\", \"footnoteId\": \"80ffa601-02d1-4ad2-ae52-53366b1b69f0\", \"sourceText\": \"4. Any other FVIII product (with exceptions listed in Section 7.1.1).\", \"appliesToActivityIds\": [\"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\"]}, {\"id\": \"13d78585-2059-480f-9d1d-07b014be9a64\", \"conditionType\": \"timing_before\", \"text\": \"6. Anticoagulant agents, excluding the use of heparin for intermittent flushing for maintenance of patency of intravenous catheters, and short-term thromboembolic prophylaxis during immobilization and/or perioperatively. The Investigator must discuss the use of anticoagulant agents with the medical monitor. As stated in Section 5.3, participants who routinely administer an additional dose of FVIII prior to a sports activity or increased physical activity will not be allowed to do so in this study. However, the day of dosing BIVV001 in Arms A and B (prophylaxis period) could be chosen prior to a weekly recurring physical activity.\", \"footnoteId\": \"30ea8628-bd26-44f2-a6d7-eb5aa83867a4\", \"sourceText\": \"6. Anticoagulant agents, excluding the use of heparin for intermittent flushing for maintenance of p\", \"appliesToActivityIds\": [\"0249edfe-fb3a-4154-aa84-fdf09a49d9a2\", \"be883257-ec2f-472b-b90a-5edd6de1e881\", \"e10e5c6d-0d13-40c0-8c40-f2eeee70c95f\", \"9aeca392-dd20-4cc8-a891-e8a78660dc62\"]}]"
              },
              {
                "id": "3dd77a83-ab3e-4351-a035-9c89bfd1407e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"019f4561-6557-4439-8540-3efb2db37b0d\", \"name\": \"Key Secondary: Intra-patient comparison of ABR\", \"endpointType\": \"Secondary\", \"inputs\": [\"ABR_BIVV001_period\", \"ABR_historical_prophylaxis\", \"study_duration_current\", \"study_duration_observational\"], \"timeWindow\": {\"reference\": \"BIVV001 weekly prophylaxis treatment period\", \"duration\": \"P6M\"}, \"algorithm\": \"ABR_BIVV001_period - ABR_historical_prophylaxis\", \"successCriteria\": \"Participants in Arm A must have at least 6 months of study duration in both this study and in observational study 242HA201/OBS16221\", \"sourceText\": \"an intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR... participants in Arm A must have at least 6 months of study duration i\"}, {\"id\": \"170ab6c8-8297-47bc-bbd9-75fb2098ca0d\", \"name\": \"Patient Reported Outcome: TSQM-9\", \"endpointType\": \"Secondary\", \"inputs\": [\"TSQM-9_scores\"], \"timeWindow\": {\"reference\": \"Baseline and subsequent visits per SoA\", \"duration\": null}, \"algorithm\": \"Calculation of 9-item Treatment Satisfaction Questionnaire for Medication scores\", \"successCriteria\": \"Evaluation of treatment satisfaction\", \"sourceText\": \"the 9-item version of the Treatment Satisfaction Questionnaire for Medication (TSQM-9) is being used\"}, {\"id\": \"2534c9cc-5f27-43d1-8e23-de869740b7a3\", \"name\": \"Exploratory: Patient expectations and perception\", \"endpointType\": \"Exploratory\", \"inputs\": [\"exit_interview_data\"], \"timeWindow\": {\"reference\": \"Study Exit\", \"duration\": null}, \"algorithm\": \"Qualitative/Quantitative analysis of exit interview responses\", \"successCriteria\": \"Evaluation of participants\\u2019 expectations of treatment and perception of treatment impact\", \"sourceText\": \"An exit interview... related endpoint was added to the exploratory objective for patient reported outcome measures... To evaluate participants\\u2019 expectations of treatment and perception of treatment im\"}]"
              },
              {
                "id": "17205ab8-18ba-4b84-a684-0322601c9232",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"9d84bf40-b8f0-486d-a254-2628ff531a91\", \"name\": \"Patient Global Impression of Change\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"Patient Global Impression of Severity\"], \"derivationRule\": \"Assessment of change in condition compared to baseline status\", \"baselineDefinition\": \"Baseline assessment at Day 1\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"Week 26 and Week 52 \\u00b1 7 days\", \"imputationRule\": \"Not specified in text\", \"unit\": \"Scale\"}, {\"id\": \"34578dbe-9a55-4e65-b6e8-2f2a0bacde4e\", \"name\": \"FVIII Activity Half-life\", \"variableType\": \"Custom\", \"sourceVariables\": [\"FVIII activity\", \"one-stage aPTT assay\"], \"derivationRule\": \"Geometric mean of half-life calculated from sequential PK sampling\", \"baselineDefinition\": \"Predose PK sample on Day 1\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"Sequential sampling post-dose\", \"imputationRule\": \"Not specified in text\", \"unit\": \"Hours\"}, {\"id\": \"74bb33f2-ba71-4945-80e6-f729c656cf2f\", \"name\": \"Treatment Emergent Adverse Events (TEAE)\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Adverse Events\"], \"derivationRule\": \"Events occurring after the first dose of BIVV001 or Advate\", \"baselineDefinition\": \"First dose administration\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"From Day 1 through Safety follow-up\", \"imputationRule\": \"Not specified in text\", \"unit\": \"Count/Incidence\"}, {\"id\": \"4630897d-2e48-44d9-abb4-5cdd5edd2725\", \"name\": \"FVIII Activity Geometric Mean Ratio (GMR)\", \"variableType\": \"Custom\", \"sourceVariables\": [\"BIVV001 FVIII activity\", \"Advate FVIII activity\"], \"derivationRule\": \"Ratio of geometric mean half-life (BIVV001 / Advate)\", \"baselineDefinition\": \"Comparator dose (Advate) results\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"PK sampling period\", \"imputationRule\": \"Not specified in text\", \"unit\": \"Ratio\"}]"
              },
              {
                "id": "6221c7a7-23c5-4bd5-8eea-54355f4406bb",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"1bfd543b-e2cb-48b3-8d58-c3ffa7358194\", \"initialState\": \"Screening\", \"terminalStates\": [\"Early Termination\", \"Completed\"], \"states\": [\"Screening\", \"Baseline\", \"Treatment\", \"End Of Study\", \"Early Termination\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Baseline\", \"trigger\": \"Progress to Baseline\"}, {\"fromState\": \"Baseline\", \"toState\": \"Treatment\", \"trigger\": \"Progress to Treatment\"}, {\"fromState\": \"Treatment\", \"toState\": \"End Of Study\", \"trigger\": \"Progress to End Of Study\"}, {\"fromState\": \"Treatment\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}], \"epochIds\": {\"Screening\": \"SCREENING\", \"Baseline\": \"BASELINE\", \"Treatment\": \"TREATMENT\", \"End Of Study\": \"END_OF_STUDY\", \"Early Termination\": \"EARLY_TERMINATION\"}}"
              },
              {
                "id": "617fdd2f-7697-40d1-9036-a5079cfd28ea",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"c7b97271-8456-4c16-9c0f-50a917611c91\", \"treatmentName\": \"Following BIVV001\", \"frequency\": \"QW\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 50.0, \"unit\": \"iu\"}], \"sourceText\": \"with QW dosing, mean FVIII activities based on one-stage and chromogenic assays were 46.28% and 30.46% at 72 hours, 22.30% and 14.48% at 120 hours, and 9.83% and 6.74% at 168 hours, respectively. Foll\"}, {\"id\": \"6c4bc3a5-740d-4b75-9aed-de71e0bd75cf\", \"treatmentName\": \"BIVV001 (efanesoctocog alfa)\", \"frequency\": \"QW\", \"route\": \"IV\", \"startDay\": 1, \"durationDescription\": \"At least 6 months\", \"doseModifications\": [\"Major surgery only allowed after 6 exposure days (EDs)\", \"Negative inhibitor test required within 4 weeks prior to surgery\"]}]"
              },
              {
                "id": "6c329083-c43c-4b6b-ada0-b7683c944a89",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"0f56d235-8f12-4f82-a4f0-fefd97bc2096\", \"visitName\": \"Screening\", \"targetDay\": -14, \"windowBefore\": 7, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 1, \"epoch\": \"Screening\", \"sourceText\": \"electronic patient diary (ePD) is performed at the Screening visit. ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs\"}, {\"id\": \"8bf751af-98e4-4dec-80ca-560d94f769d6\", \"visitName\": \"Early Termination\", \"targetDay\": null, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"Determination The selection of participants to be included in the analysis for the key secondary efficacy endpoint (ie, an intra-patient comparison of\"}, {\"id\": \"78772cbf-2547-460d-a536-964cf2388e05\", \"visitName\": \"Visit 001\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR) was updated to clarify that participants in Arm A must have at least 6 months of study duration\"}, {\"id\": \"54f797a0-cdc6-445c-9015-da051d77cc7f\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 1, \"windowAfter\": 1, \"isRequired\": true, \"visitNumber\": 4, \"epoch\": \"Treatment\", \"sourceText\": \"ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs during the Screening period, before the baseline visit, it will be\"}, {\"id\": \"aedb3d2f-de0d-4bac-b65d-c38fb13d3374\", \"visitName\": \"EOS\", \"targetDay\": null, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": false, \"visitNumber\": 5, \"sourceText\": \"EOS/ETc \\u00b17 days Unscheduled\"}, {\"id\": \"eb572a71-b1cb-423e-a74f-a66d53632dc1\", \"visitName\": \"Visit 52\", \"targetDay\": null, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"(EOS) Visit 52 weeks (\\u00b17 days) post-Baseline, or earlier if EOS has been declared. 4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN\"}, {\"id\": \"96ad6490-2820-4dc3-a144-16b8c2b0cb92\", \"visitName\": \"Minor Dental Surgery\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 0, \"isRequired\": false, \"visitNumber\": 4, \"epoch\": \"Surgical\"}, {\"id\": \"152a455e-790a-4bd3-83c8-63e32344c49e\", \"visitName\": \"Major Surgery\", \"targetDay\": null, \"windowBefore\": null, \"windowAfter\": null, \"isRequired\": false, \"visitNumber\": 5, \"epoch\": \"Surgical\"}, {\"id\": \"e80e529c-84a1-430c-82ae-ae300d337225\", \"visitName\": \"Exit Interview\", \"targetDay\": null, \"windowBefore\": null, \"windowAfter\": null, \"isRequired\": true, \"visitNumber\": 7, \"epoch\": \"End of Study\"}, {\"id\": \"079cc1a0-5096-4375-aa0c-1469c1c2253b\", \"visitName\": \"Week 1\", \"targetDay\": 1, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 11, \"targetWeek\": 1, \"sourceText\": \"Table 3 - PK sampling schedule of activities first dose (Week 1) and Week 26 for sequential PK subgroup ................................................................................................\"}, {\"id\": \"be96efc0-b87e-40a9-9cb2-afaca1bafb4e\", \"visitName\": \"Day 2\", \"targetDay\": 2, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 12, \"sourceText\": \"Day 2 Day 4 Day 8d (study drug can be\"}, {\"id\": \"0b05c596-a272-4b1f-96b6-097a82e56a56\", \"visitName\": \"Day 4\", \"targetDay\": 4, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 13, \"sourceText\": \"Day 4 Day 8d (study drug can be taken after assessments on\"}, {\"id\": \"2a00f21e-37fd-4522-b00e-4ad6f191f51c\", \"visitName\": \"Week 2\", \"targetDay\": 8, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 14, \"targetWeek\": 2, \"sourceText\": \"Note: Participants in the sequential PK subgroup will not receive BIVV001 at Week 2 and Week 27 (or 1 week after the repeat PK). a\"}, {\"id\": \"fa0bbc6a-bffd-40e4-88a8-4d7d9a6c8f40\", \"visitName\": \"Day 11\", \"targetDay\": 11, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 15, \"sourceText\": \"Day 11 Day 15e 15 m\"}, {\"id\": \"97478594-6d9c-4dc5-aefd-7d2fc4dfab9e\", \"visitName\": \"Day 15\", \"targetDay\": 15, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 16, \"sourceText\": \"Day 15e 15 m (\\u00b13 m)\"}, {\"id\": \"e22e4e98-edf1-4fae-b55d-c9e628d75947\", \"visitName\": \"Week 4\", \"targetDay\": 22, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 17, \"targetWeek\": 4, \"sourceText\": \"Week 4c \\u00b17 days Week 13c\"}, {\"id\": \"faf7d706-9610-4d13-a816-588f43ff29bf\", \"visitName\": \"Week 13\", \"targetDay\": 85, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 18, \"targetWeek\": 13, \"sourceText\": \"Week 13c \\u00b17 days Week\"}, {\"id\": \"4d075f71-accd-423c-b09a-c432076d0ac3\", \"visitName\": \"Week 26\", \"targetDay\": 176, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 19, \"targetWeek\": 26, \"epoch\": \"Treatment\", \"sourceText\": \"undergo more extensive PK sampling at Baseline and again at Week 26. Participants from any arm who undergo major surgery during the study will be included in the surgery subset. A minimum of 10 major \"}, {\"id\": \"464d4738-bcb6-4515-9292-053c058edd88\", \"visitName\": \"Week 39\", \"targetDay\": 267, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 20, \"targetWeek\": 39, \"sourceText\": \"Week 39c \\u00b17 days Week 52/\"}, {\"id\": \"b311a77c-e31f-4f89-ab67-85a206906896\", \"visitName\": \"Week 52\", \"targetDay\": 358, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 21, \"targetWeek\": 52, \"sourceText\": \"3 endpoints from baseline to Week 52, along with its 95% CI, will be estimated by the MMRM model. Analysis of other secondary efficacy endpoints: All secondary efficacy endpoints will be\"}, {\"id\": \"b13cf606-ab14-42db-894b-16141b5d3e0a\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 22, \"sourceText\": \"Table 1 - Overall schedule of activities from screening to safety follow-up call or visit................................. 17 Table 2 - Abbreviated PK sampling schedule of activities .................\"}]"
              },
              {
                "id": "454671b2-944e-4be4-925e-ebb578d3eef9",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"5e424412-cfd0-4b1b-896b-a88e86db128c\", \"ratio\": \"357:535\", \"method\": \"Simple randomization\", \"centralRandomization\": true, \"sourceText\": \"Amended clinical Trial Protocol 05 \\nEFC16293 - efanesoctocog alfa       \\n20-Aug-2021 \\nVersion number: 1 \\n \\nProperty of the Sanofi group - strictly confidential \\nPage 27 \\nhemophilia A is estimated to b\"}"
              },
              {
                "id": "ext_execution_model_f03776a1-76de-4484-ac6f-f7fab6ad2113",
                "url": "https://protocol2usdm.io/extensions/x-executionModel",
                "instanceType": "ExtensionAttribute",
                "valueObject": {
                  "schemaVersion": "1.0.0",
                  "extractionTimestamp": "2026-01-23T04:46:34.717719",
                  "executionModel": {
                    "timeAnchors": [
                      {
                        "id": "455b357e-b139-4929-8642-00eb2cb10711",
                        "definition": "First administration of investigational product",
                        "anchorType": "FirstDose",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 60,
                        "sourceText": "Day 1 dosing",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "c0a20493-531e-48b0-9549-4febc041b137",
                        "definition": "Baseline visit/assessment",
                        "anchorType": "Baseline",
                        "classification": "Visit",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 50,
                        "sourceText": "baseline visit",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "071ef9bc-f7d3-4fec-a217-4d53384acc5f",
                        "definition": "Screening visit",
                        "anchorType": "Screening",
                        "classification": "Visit",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 20,
                        "sourceText": "Screening visit",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "54468220-ae26-4a8e-8e3f-68352c6ac3e7",
                        "definition": "Informed consent obtained",
                        "anchorType": "InformedConsent",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 10,
                        "sourceText": "Informed consent",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "150c8296-f994-4e50-a11f-0a9fe6ea63bc",
                        "definition": "surgery",
                        "anchorType": "Custom",
                        "classification": "Conceptual",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 100,
                        "sourceText": "surgery",
                        "encounterId": null,
                        "activityId": null
                      }
                    ],
                    "repetitions": [
                      {
                        "id": "6686d2db-adc1-4ebe-bedc-953a5a28d593",
                        "type": "Daily",
                        "interval": "P1D",
                        "sourceText": "od"
                      },
                      {
                        "id": "007d8037-5375-4faa-9392-42bcea2c13c3",
                        "type": "Daily",
                        "interval": "P1D",
                        "sourceText": "OD"
                      },
                      {
                        "id": "e44c5353-6601-486c-967c-1d06d2969720",
                        "type": "Interval",
                        "sourceText": "PK sampling at "
                      },
                      {
                        "id": "9c49113a-95f8-4589-89c2-0253a10a933a",
                        "type": "Continuous",
                        "sourceText": "washout period"
                      },
                      {
                        "id": "1794aa19-fe07-4f10-ab24-b4f0a3192d4b",
                        "type": "Continuous",
                        "sourceText": "Screening Period"
                      },
                      {
                        "id": "9c20d18a-dc63-4b43-855f-130607eab224",
                        "type": "Continuous",
                        "sourceText": "treatment period"
                      },
                      {
                        "id": "14049c60-6535-4cdc-867d-cc448ae34777",
                        "type": "Continuous",
                        "sourceText": "1 day after"
                      },
                      {
                        "id": "d1a6ee36-4a41-4340-b506-86a4784d3e63",
                        "type": "Continuous",
                        "sourceText": "14 days post"
                      },
                      {
                        "id": "9a8fe153-1d67-4cf1-aa3e-5e1c41f904f0",
                        "type": "Continuous",
                        "startOffset": "P0D",
                        "endOffset": "P0D",
                        "interval": "P1D",
                        "minObservations": 1,
                        "exitCondition": "End of study",
                        "sourceText": "Time period and frequency for collecting AE and SAE information"
                      },
                      {
                        "id": "72c23d01-bab8-430b-8e80-4fb4f9468602",
                        "type": "Cycle",
                        "startOffset": "P0D",
                        "endOffset": "P6D",
                        "interval": "P1D",
                        "minObservations": 6,
                        "exitCondition": "Completion of 6 exposure days",
                        "sourceText": "Participants should have at least 6 EDs to BIVV001 to be eligible for major surgery."
                      },
                      {
                        "id": "d0df2abc-c486-42df-9cd9-9f95e4595f01",
                        "type": "Continuous",
                        "startOffset": "-P7D",
                        "endOffset": "P0D",
                        "interval": "P7D",
                        "minObservations": 1,
                        "exitCondition": "null",
                        "sourceText": "the PROMIS-SF Physical Function - SF 6b instrument does not use a 7-day recall period"
                      },
                      {
                        "id": "3c6f0df8-a879-42ea-b2bb-5cd45351e51e",
                        "type": "Continuous",
                        "startOffset": "-P28D",
                        "endOffset": "P0D",
                        "interval": "P28D",
                        "minObservations": 1,
                        "exitCondition": "null",
                        "sourceText": "negative inhibitor test within 4 weeks prior to surgery"
                      }
                    ],
                    "samplingConstraints": [],
                    "traversalConstraints": [
                      {
                        "id": "324c121a-34f1-4f9d-b40e-22f53769a870",
                        "requiredSequence": [
                          "epoch_1",
                          "epoch_1",
                          "epoch_1"
                        ],
                        "allowEarlyExit": true,
                        "exitEpochIds": [
                          "e910cc5a-c653-4718-ae05-d6c24638c243"
                        ],
                        "mandatoryVisits": [
                          "Screening",
                          "Day 1",
                          "End of Study"
                        ],
                        "sourceText": "washout period"
                      },
                      {
                        "id": "02e0c762-2991-43d1-83fd-9b44a821db8d",
                        "requiredSequence": [
                          "epoch_1",
                          "epoch_1",
                          "epoch_1",
                          "epoch_1"
                        ],
                        "allowEarlyExit": true,
                        "exitEpochIds": [
                          "e910cc5a-c653-4718-ae05-d6c24638c243"
                        ],
                        "mandatoryVisits": [
                          "End of Study",
                          "Screening",
                          "Day 1",
                          "Baseline"
                        ],
                        "sourceText": "[{'condition': 'If subject undergoes major surgery', 'path': ['SURGERY_SUBGROUP', '6_EXPOSURE_DAYS_MINIMUM', 'NEGATIVE_INHIBITOR_TEST']}, {'condition': 'Use of FVIII products other than BIVV001 (non-emergency)', 'path': ['DEFINITIVE_DISCONTINUATION']}, {'condition': 'Life-threatening emergency requiring other FVIII product', 'path': ['SPONSOR_REVIEW', 'CONTINUATION_OR_DISCONTINUATION']}]"
                      }
                    ],
                    "executionTypes": [
                      {
                        "activityId": "Blood Sample",
                        "executionType": "Single",
                        "rationale": "EPISODE signals: 2; SINGLE signals: 8"
                      },
                      {
                        "activityId": "Vital Signs",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Pe",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Ae",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 6"
                      },
                      {
                        "activityId": "Concomitant Medications",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 11; RECURRING signals: 3"
                      },
                      {
                        "activityId": "Laboratory Assessments",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Pharmacokinetic",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Pharmacodynamic",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Dosing",
                        "executionType": "Single",
                        "rationale": "WINDOW signals: 2; SINGLE signals: 8"
                      },
                      {
                        "activityId": "Imaging",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 2"
                      },
                      {
                        "activityId": "Questionnaire",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "1420cb4f-ed3e-4483-8a41-d5a77e144205",
                        "executionType": "Single",
                        "rationale": "Secondary efficacy endpoint measures like PROs are typically scheduled repeats at specific study visits as per the Schedule of Activities."
                      },
                      {
                        "activityId": "PROMIS Pain Intensity 3a",
                        "executionType": "Single",
                        "rationale": "Patient Reported Outcome measures are scheduled for collection at multiple study visits to assess efficacy over time."
                      },
                      {
                        "activityId": "Hemophilia Joint Health Score (HJHS)",
                        "executionType": "Single",
                        "rationale": "Total score measures for joint health are assessed at scheduled intervals throughout the study duration."
                      },
                      {
                        "activityId": "Treatment Satisfaction Questionnaire for Medication (TSQM-9)",
                        "executionType": "Single",
                        "rationale": "Standardized questionnaires in Phase 3 trials are administered at recurring scheduled visits to track patient satisfaction."
                      },
                      {
                        "activityId": "Exit Interview",
                        "executionType": "Single",
                        "rationale": "The exit interview is a one-time assessment conducted at the end of the participant's involvement in the study."
                      },
                      {
                        "activityId": "ABR (Annualized Bleed Rate) Monitoring",
                        "executionType": "Single",
                        "rationale": "ABR requires continuous monitoring and recording of bleeding events over a 6-month period to calculate the rate."
                      }
                    ],
                    "footnoteConditions": [
                      {
                        "id": "f06141f5-8b86-4dc1-9c12-2023033799e9",
                        "conditionType": "timing_before",
                        "text": "a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening Period is up to 8 weeks before Baseline. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results.",
                        "footnoteId": "f12b0efe-4593-4990-894a-eff39a17d15c",
                        "structuredCondition": "timing.before(Baseline, P8W) && timing.after(InhibitorTest, PT48H)",
                        "appliesToActivityIds": [
                          "Screening",
                          "Inhibitor Test"
                        ],
                        "timingConstraint": "PT48H",
                        "sourceText": "a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening"
                      },
                      {
                        "id": "2918ff6d-efb8-41aa-bbbc-6daf277ffb9d",
                        "conditionType": "timing_before",
                        "text": "b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period before the Baseline Visit for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor.",
                        "footnoteId": "30a4556b-837a-4723-8bf6-c822cf86d007",
                        "structuredCondition": "if(product == 'conventional') timing.after(last_dose, PT96H) else if(product == 'EHL') timing.after(last_dose, PT120H)",
                        "appliesToActivityIds": [
                          "BIVV001 Day 1 Dose"
                        ],
                        "timingConstraint": "PT96H",
                        "sourceText": "b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participa"
                      },
                      {
                        "id": "bc43fee9-5a9f-468a-a0ed-76d517e7dddd",
                        "conditionType": "timing_after",
                        "text": "c. Participants should schedule their study visits to be 7 ±1 day after the previous prophylactic dose of BIVV001.",
                        "footnoteId": "c540c134-003c-4a05-a64f-8cfbb3e212c5",
                        "structuredCondition": "timing.after(previous_dose, P7D) +/- P1D",
                        "appliesToActivityIds": [
                          "Study Visits"
                        ],
                        "sourceText": "c. Participants should schedule their study visits to be 7 ±1 day after the previous prophylactic do"
                      },
                      {
                        "id": "9c7e064c-e18c-44fd-bb85-59264acd79b7",
                        "conditionType": "timing_after",
                        "text": "d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in the Sequential PK arm should schedule their Week 26 study visit to be 7 (+2) days after the previous prophylactic dose of BIVV001.",
                        "footnoteId": "f7158168-18c4-4509-b135-8427dfa00a32",
                        "structuredCondition": "if(arm == 'Sequential PK') timing.after(previous_dose, P7D) + P2D",
                        "appliesToActivityIds": [
                          "Week 26 Visit"
                        ],
                        "sourceText": "d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in"
                      },
                      {
                        "id": "b13974d3-40fb-45e9-a31e-beee7a5737b0",
                        "conditionType": "eligibility_conditional",
                        "text": "e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or at the discretion of the Investigator. If a participant has an unscheduled visit, the Investigator will record data as appropriate based on the purpose of the visit.",
                        "footnoteId": "cb767af1-60fb-4513-9f54-93c84664c491",
                        "sourceText": "e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or"
                      },
                      {
                        "id": "188a5651-b9b9-4124-8fd2-fe79b9441e79",
                        "conditionType": "timing_after",
                        "text": "f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant enrolls in the open-label extension study. For France specific pregnancy testing at the safety follow-up visit refer to Section 10.11.1.",
                        "footnoteId": "858da27d-df64-44f7-abe8-32fa70524825",
                        "structuredCondition": "timing.after(last_dose, P14D) + P7D",
                        "appliesToActivityIds": [
                          "32d1eeb9-fc54-4e2d-9bf1-32cdefaf7e47",
                          "750048a2-d8c2-4702-b490-47bd9f018c29"
                        ],
                        "sourceText": "f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant"
                      },
                      {
                        "id": "ee210219-ce84-4784-a9b4-555e1047eb49",
                        "conditionType": "timing_before",
                        "text": "g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior to any study-related procedures, including washout of current FVIII therapy specifically for entry into the study, or the country's local regulations. Participant assent must also be obtained where applicable (according to the study site's geographic region).",
                        "footnoteId": "5a6b8741-8f8d-434c-a416-11c778510885",
                        "structuredCondition": "timing.before(any_procedure, PT0S)",
                        "appliesToActivityIds": [
                          "Informed Consent"
                        ],
                        "sourceText": "g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior "
                      },
                      {
                        "id": "42099827-d796-4a54-b55a-856af78d1bd8",
                        "conditionType": "general",
                        "text": "h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted by local regulations. Race and ethnicity will be collected for reasons described in Section 10.1.4.",
                        "footnoteId": "84fb275a-be0c-45cd-9fa7-3b2b5920aecf",
                        "sourceText": "h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted b"
                      },
                      {
                        "id": "91256dc5-127e-4359-9f7e-4721d90c9ce8",
                        "conditionType": "general",
                        "text": "i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not previously documented. For Repeat Screening Visit, update with any changes since original Screening Visit.",
                        "footnoteId": "000e8219-f600-4a3d-9376-ac414ac7f389",
                        "sourceText": "i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not prev"
                      },
                      {
                        "id": "50fd90cb-e931-4307-8ecc-11dfbbb300a9",
                        "conditionType": "general",
                        "text": "j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committees) will be governed by a separate informed consent. HLA genotype will not be needed if previously documented.",
                        "footnoteId": "13d8f47a-1c14-495c-8dc7-151b51e0296f",
                        "sourceText": "j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committ"
                      },
                      {
                        "id": "cedcfa7a-18ba-40c8-a58f-f107bcb42f17",
                        "conditionType": "timing_before",
                        "text": "k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period prior to BIVV001 Day 1 dose administration for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor. Washout prior to all other scheduled inhibitor tests must be at least 7±1 days. Inhibitor and ADA samples will be collected prior to BIVV001 dosing. Separate samples for anti-rFVIIIFc-VWF-XTEN antibody (ADA) testing will be collected at the same timepoint when any samples are collected for inhibitor testing (including samples for suspected inhibitor and confirmatory inhibitor tests). All inhibitor assays, including the assay for the Screening Visit and any confirmatory assays, will be performed by the central laboratory using the Nijmegen-modified Bethesda assay. If a Nijmegen-modified Bethesda assay result returns as ≥0.6 BU/mL, a separate sample must be collected and tested for confirmation of inhibitor development within 2 to 4 weeks of the original sample. Testing for potential ADA formation will be performed at a central laboratory using a validated rFVIIIFc-VWF-XTEN-specific ADA assay. Confirmed positive samples will be further characterized for antibodies specific to FVIII, Fc, D'D3, or XTEN.",
                        "footnoteId": "c0a8f2a0-8f91-4c65-9581-3962669038b8",
                        "structuredCondition": "timing.after(original_sample, P2W) && timing.before(original_sample, P4W)",
                        "appliesToActivityIds": [
                          "Inhibitor Confirmation Test"
                        ],
                        "timingConstraint": "PT48H",
                        "sourceText": "k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test r"
                      },
                      {
                        "id": "05c91541-c180-4d16-a278-997778df750f",
                        "conditionType": "general",
                        "text": "l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participants in Arm B will have BIVV001 doses at visits Day 1, Weeks 26, 39, and 52. During the Scheduled study visits, BIVV001 will be delivered via a slow push IV injection of 8 ±2 minutes, at a rate of administration determined by the participant's comfort level. For all BIVV001 injections performed at home BIVV001 will be delivered via a slow push IV injection at a rate of administration determined by the participant's comfort level according to the vial and injection rate recommendations (Table 7). Injection start and stop time will be recorded in the eCRF. Other doses may be self/caregiver administered at home (or in clinic) (Table 3)",
                        "footnoteId": "86ab4945-2df5-452b-91fc-e708d317052c",
                        "sourceText": "l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participa"
                      },
                      {
                        "id": "cc1b6d31-33b7-4aef-8523-a8bc5d004002",
                        "conditionType": "timing_after",
                        "text": "m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (°C). Vital signs should be taken after the participant has been resting supine for 5 minutes. Vital signs will be measured pre-injection and 30 (±15 minutes) from the start of injection at clinic visits. Vital signs should also be taken at any unscheduled visit.",
                        "footnoteId": "32fdd306-c266-425c-9941-e4993684c6c4",
                        "structuredCondition": "timing.after(rest, PT5M) && timing.before(injection, PT0S) && timing.after(injection_start, PT30M) +/- PT15M",
                        "appliesToActivityIds": [
                          "Vital Signs"
                        ],
                        "timingConstraint": "PT5M",
                        "sourceText": "m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (°C). Vital sig"
                      },
                      {
                        "id": "11b1ffdc-bf8a-49ff-bfa7-3140c99cc4aa",
                        "conditionType": "general",
                        "text": "n. Applicable to female participants only. A serum pregnancy test should be performed at screening. For all other time points, the choice of the pregnancy test (urine or serum) is at the discretion of the Investigator. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from further participation if the serum pregnancy result is positive.",
                        "footnoteId": "4fce6950-7c6d-430c-bf7a-8c7e6783f00e",
                        "structuredCondition": "if(sex == 'female') procedure.perform(Pregnancy Test)",
                        "appliesToActivityIds": [
                          "Pregnancy Test"
                        ],
                        "sourceText": "n. Applicable to female participants only. A serum pregnancy test should be performed at screening. "
                      },
                      {
                        "id": "fde4360e-71e8-4406-9b11-19ca3c25d894",
                        "conditionType": "general",
                        "text": "o. For participants who have been historically negative, viral testing will be performed at a central laboratory. Human immunodeficiency virus (HIV) tests will include HIV-1 antibodies, HIV-2 antibodies and HIV-1 p24 antigen. Hepatitis B virus (HBV) tests will include HBV surface antigen, anti-HBV surface antibody and anti-HBV core antibody. Hepatitis C virus (HCV) tests will include anti-HCV antibodies.",
                        "footnoteId": "9a9c9a9b-8859-4e05-acd4-74a84e6de23c",
                        "sourceText": "o. For participants who have been historically negative, viral testing will be performed at a centra"
                      },
                      {
                        "id": "3d028784-2466-4e65-89f3-ddaf6a1d5e6c",
                        "conditionType": "timing_before",
                        "text": "p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be performed at the central laboratory if results are not available from within 26 weeks prior to screening.",
                        "footnoteId": "14d22ad5-0c38-4457-b02d-0e8a1ff627cc",
                        "sourceText": "p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be perfor"
                      },
                      {
                        "id": "97b5b1a4-8f82-414c-8cf1-340e46d3ed86",
                        "conditionType": "timing_before",
                        "text": "q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differential, platelet count, hemoglobin (Hgb), and hematocrit (Hct). Blood samples for hematology analysis will be collected prior to BIVV001 dosing.",
                        "footnoteId": "74957102-8b92-4e81-b837-e2e0315f8573",
                        "structuredCondition": "timing.before(BIVV001_dosing, PT0S)",
                        "appliesToActivityIds": [
                          "Hematology"
                        ],
                        "sourceText": "q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differ"
                      },
                      {
                        "id": "bd02d45f-578a-4a0a-8e17-227742da1095",
                        "conditionType": "timing_before",
                        "text": "r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin, blood urea nitrogen (BUN), creatinine, glucose, total protein, sodium, potassium, and chloride. Blood samples for clinical chemistry analysis will be collected prior to BIVV001 dosing.",
                        "footnoteId": "27daf236-a7b4-480c-9064-9a3cdb4a3ef4",
                        "structuredCondition": "timing.before(BIVV001_dosing, PT0S)",
                        "appliesToActivityIds": [
                          "Clinical Chemistry"
                        ],
                        "sourceText": "r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase "
                      },
                      {
                        "id": "dc6280a7-1f2d-4d5a-80e3-8fdbee34800b",
                        "conditionType": "timing_before",
                        "text": "s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] ristocetin cofactor activity and VWF antigen). Blood samples for analysis of Von Willebrand comprehensive panel will be collected prior to any BIVV001 dosing.",
                        "footnoteId": "fcaf2460-21ed-4202-89ad-6d48f02becc2",
                        "sourceText": "s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] risto"
                      },
                      {
                        "id": "48160995-136e-422e-bbc5-7892931eb63c",
                        "conditionType": "timing_before",
                        "text": "t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed consent form (ICF) through the Safety Follow-Up Call or Visit will be recorded on the case report form (CRF). Pain medication related to Hemophilia and administered within 2 weeks prior to the visit will be recorded on the CRF.",
                        "footnoteId": "690a202d-0c4c-4a14-bd6e-efcd4c8ee007",
                        "sourceText": "t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed co"
                      },
                      {
                        "id": "9c69ad09-7820-4f40-8669-6eca8afadf5f",
                        "conditionType": "timing_before",
                        "text": "u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies and procedures from signing of ICF through the Safety Follow-Up Call or Visit will be recorded on the CRF.",
                        "footnoteId": "2af6eb60-770f-479a-8203-9e476167e094",
                        "sourceText": "u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies"
                      },
                      {
                        "id": "26073f31-f11c-41c6-a624-cf0aa497a587",
                        "conditionType": "general",
                        "text": "v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month for the site staff to check on each participant's status. During the monthly telephone call, the participant's parent/caregiver will also be reminded about the requirement for timely ePD data entry, and assessments of \"spontaneous\" and \"traumatic\" bleeding episodes will be noted.",
                        "footnoteId": "786466fe-ce0d-4236-a790-5009c9159d25",
                        "sourceText": "v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month fo"
                      },
                      {
                        "id": "206a136c-c86b-4362-a02d-ed439e99e186",
                        "conditionType": "general",
                        "text": "w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS). At baseline, the Investigator will assess the presence of any target joints according to ISTH criteria.",
                        "footnoteId": "34dbdeab-d679-4cb0-bd72-6e4e87e1fb25",
                        "sourceText": "w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS)"
                      },
                      {
                        "id": "751264da-e9d2-4604-b687-d26628b2e575",
                        "conditionType": "general",
                        "text": "x. For bleeding episodes treated at the study sites, the Investigator will contact the participant approximately 72 hours from the time the BIVV001 injection was administered to treat the bleeding episode and record the participant's assessment of response to BIVV001 treatment on the eCRF using a 4-point bleeding response scale. For bleeding episodes that are treated at home, participants will record response to bleeding episodes in the ePD.",
                        "footnoteId": "cb15403e-d6b5-4249-bcf0-9cf36b57a5a4",
                        "sourceText": "x. For bleeding episodes treated at the study sites, the Investigator will contact the participant a"
                      },
                      {
                        "id": "0d66f242-fdfd-417d-af4b-8989825eed20",
                        "conditionType": "timing_after",
                        "text": "y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity and Damage Examination (JADE) protocol and/or Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) in a subpopulation of participants from Arm A at selected sites. The Ultrasound can be performed at the Baseline visit or up to 2 weeks after the Baseline Visit.",
                        "footnoteId": "18c3cbd9-00e4-4453-a281-20201ae3e53e",
                        "structuredCondition": "timing.at(Baseline) || timing.after(Baseline, P2W)",
                        "appliesToActivityIds": [
                          "Ultrasound Imaging"
                        ],
                        "sourceText": "y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity an"
                      },
                      {
                        "id": "ade38b12-4343-4833-aa91-dd9817d72837",
                        "conditionType": "timing_before",
                        "text": "z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laboratory (if required) for future research, eg., immunology assays, further coagulation assays, or clarification of clinical or laboratory AE, etc. This is optional and participants will sign an additional consent for this research.",
                        "footnoteId": "c81b7fa4-83b1-49dc-aca7-69035b7feac4",
                        "sourceText": "z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laborat"
                      },
                      {
                        "id": "5b804dab-e207-42dd-b8ed-51f8b3ca5d69",
                        "conditionType": "general",
                        "text": "aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of response to bleeding episodes using a 4-point bleeding response scale. The participant should record response approximately 72 hours from the time the first BIVV001 injection was administered to treat the bleeding episode, unless treatment of the bleed was administered in the clinic. In that case, the investigator will report the participant's response to treatment via the eCRF.",
                        "footnoteId": "3612f458-11d8-44d6-aade-82e8a5d2ebb4",
                        "sourceText": "aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of r"
                      },
                      {
                        "id": "a58a3fd5-6690-4245-aaae-c2c152240a20",
                        "conditionType": "timing_after",
                        "text": "bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated PK sampling after the first dose of BIVV001 (Baseline). See abbreviated PK sampling details in Table 2.",
                        "footnoteId": "09906cb6-b60f-4493-8d4c-d561770c8d88",
                        "sourceText": "bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated "
                      },
                      {
                        "id": "320b2c79-5304-4da0-a38b-d20888691f3e",
                        "conditionType": "timing_at",
                        "text": "cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Baseline and again at Week 26. See sequential PK sampling details as described in Table 3.",
                        "footnoteId": "65d82cd5-2287-4527-bfac-4f0d70680234",
                        "sourceText": "cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Bas"
                      },
                      {
                        "id": "adb70ad2-1166-4746-8de9-499004acf665",
                        "conditionType": "timing_before",
                        "text": "dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 min ± 3 min post injection. This trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ADA) samples taken predose (Table 2).",
                        "footnoteId": "3e70085b-f6f3-4b7a-ab2c-4c9ff0a8538c",
                        "structuredCondition": "timing.before(rfviiifc-vwf-xten dosing and 15 min ± 3 min post injection. this trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ada) samples taken predose (table 2)., PT30M)",
                        "appliesToActivityIds": [
                          "PK Peak Sample",
                          "PK Trough Sample"
                        ],
                        "timingConstraint": "PT30M",
                        "sourceText": "dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 mi"
                      },
                      {
                        "id": "869e7f84-de3b-49e4-b8af-ced595fb50ec",
                        "conditionType": "general",
                        "text": "ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference ≥18 years old or PROMIS Pediatric-SF Pain Interference <18 years old), and Physical Function (PROMIS-SF Physical Function ≥18 years old or PROMIS Pediatric-SF Physical Activity <18 years old). See Section 8.1.2.",
                        "footnoteId": "03165ef2-e36f-4d97-98e9-5e5a3b52f6cf",
                        "sourceText": "ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference ≥18"
                      },
                      {
                        "id": "12a03afa-9b5e-4fc2-a151-9b90fe0a970a",
                        "conditionType": "general",
                        "text": "ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patient perception of activity and a single question on patient perception of joint health. See Section 8.1.2.",
                        "footnoteId": "c90d1e46-c603-4331-92f7-cff54ab193c3",
                        "sourceText": "ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patien"
                      },
                      {
                        "id": "b52cbd22-8c39-444f-8857-9b5bdcdda4f4",
                        "conditionType": "general",
                        "text": "gg. Treatment preference survey will consist of 2 questions on patient preference and a single question on Patient Global Impression of Change (PGIC). See Section 8.1.2.",
                        "footnoteId": "48c5753c-025c-4618-a5bf-39dfd5c14472",
                        "sourceText": "gg. Treatment preference survey will consist of 2 questions on patient preference and a single quest"
                      },
                      {
                        "id": "68955c98-58aa-46ac-9a95-ad1856517704",
                        "conditionType": "timing_before",
                        "text": "hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical grade accelerometer (ActiGraph Activity Monitor) worn on the nondominant wrist. Device will be worn daily for 8 consecutive days after the scheduled visits at Screening, Baseline, Weeks 4, 13, 26, 39, and for 8 consecutive days before the Week 52 visit. Refer to Section 8.1.4",
                        "footnoteId": "c937e14e-bd6f-4c5b-aca2-50b90bc64ba6",
                        "structuredCondition": "duration(P8D)",
                        "appliesToActivityIds": [
                          "Physical Activity Assessment"
                        ],
                        "sourceText": "hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical "
                      },
                      {
                        "id": "6775dd14-6ebe-4486-ae31-bc8da51e9298",
                        "conditionType": "general",
                        "text": "ii. Coagulation parameters include activated partial thromboplastin time (aPTT)",
                        "footnoteId": "c20afdbc-57db-4197-9dec-b4cdcbf62d56",
                        "sourceText": "ii. Coagulation parameters include activated partial thromboplastin time (aPTT)"
                      },
                      {
                        "id": "14e03d82-7780-4647-90e7-bd06c75762a1",
                        "conditionType": "general",
                        "text": "jj. Please refer to Section 10.11.2 for Italy specific requirement",
                        "footnoteId": "83c613bc-63c0-4900-8772-b2b085da79f9",
                        "sourceText": "jj. Please refer to Section 10.11.2 for Italy specific requirement"
                      },
                      {
                        "id": "fd5d03e5-9da8-4898-8d2e-93adda7cdcf6",
                        "conditionType": "timing_before",
                        "text": "kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.",
                        "footnoteId": "0ea76ff4-62f4-45bb-ad5f-33e2912a8690",
                        "sourceText": "kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after "
                      },
                      {
                        "id": "f1be6f67-2084-4a5d-acc7-ee0ad5db810d",
                        "conditionType": "general",
                        "text": "ll. ePD training only. ePD devices are given to the patients at the baseline visit",
                        "footnoteId": "f3a4553c-a79e-4538-b02f-6784dd883b86",
                        "sourceText": "ll. ePD training only. ePD devices are given to the patients at the baseline visit"
                      },
                      {
                        "id": "b843b6e7-186d-4738-ba9e-c1cbef39cdc3",
                        "conditionType": "general",
                        "text": "1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies.",
                        "footnoteId": "79b00d1f-8ddb-4b1c-9a86-8ff1024ac654",
                        "sourceText": "1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies."
                      },
                      {
                        "id": "9d84c493-c4b1-4439-9bcf-8cd61b231ee1",
                        "conditionType": "general",
                        "text": "2. NSAIDs at doses above the maximum dose specified in local prescribing information.",
                        "footnoteId": "ac541c45-d88e-4343-90ce-bb99ccb950cb",
                        "sourceText": "2. NSAIDs at doses above the maximum dose specified in local prescribing information."
                      },
                      {
                        "id": "e997566a-26f4-4c38-892b-b82513f8b87b",
                        "conditionType": "general",
                        "text": "3. Systemic treatment with chemotherapy and/or other immunosuppressive drugs (except for the treatment of hepatitis C virus [HCV] or HIV). The use of systemic steroids for the treatment of acute respiratory illness (eg, asthma), acute allergic episodes, or otherwise life threatening episodes is allowed. Treatment in these circumstances should not exceed a 14 day duration. Local, topical, and/or inhaled steroid use is permitted.",
                        "footnoteId": "61eb5ddd-d569-45e7-96ca-5745e0cbaefa",
                        "sourceText": "3. Systemic treatment with chemotherapy and/or other immunosuppressive drugs (except for the treatme"
                      },
                      {
                        "id": "7926e514-6049-4168-b01b-0f9a7b7a849a",
                        "conditionType": "general",
                        "text": "4. Any other FVIII product (with exceptions listed in Section 7.1.1).",
                        "footnoteId": "80ffa601-02d1-4ad2-ae52-53366b1b69f0",
                        "sourceText": "4. Any other FVIII product (with exceptions listed in Section 7.1.1)."
                      },
                      {
                        "id": "13d78585-2059-480f-9d1d-07b014be9a64",
                        "conditionType": "timing_before",
                        "text": "6. Anticoagulant agents, excluding the use of heparin for intermittent flushing for maintenance of patency of intravenous catheters, and short-term thromboembolic prophylaxis during immobilization and/or perioperatively. The Investigator must discuss the use of anticoagulant agents with the medical monitor. As stated in Section 5.3, participants who routinely administer an additional dose of FVIII prior to a sports activity or increased physical activity will not be allowed to do so in this study. However, the day of dosing BIVV001 in Arms A and B (prophylaxis period) could be chosen prior to a weekly recurring physical activity.",
                        "footnoteId": "30ea8628-bd26-44f2-a6d7-eb5aa83867a4",
                        "sourceText": "6. Anticoagulant agents, excluding the use of heparin for intermittent flushing for maintenance of p"
                      }
                    ],
                    "endpointAlgorithms": [
                      {
                        "id": "019f4561-6557-4439-8540-3efb2db37b0d",
                        "name": "Key Secondary: Intra-patient comparison of ABR",
                        "endpointType": "Secondary",
                        "inputs": [
                          "ABR_BIVV001_period",
                          "ABR_historical_prophylaxis",
                          "study_duration_current",
                          "study_duration_observational"
                        ],
                        "timeWindow": {
                          "reference": "BIVV001 weekly prophylaxis treatment period",
                          "duration": "P6M"
                        },
                        "algorithm": "ABR_BIVV001_period - ABR_historical_prophylaxis",
                        "successCriteria": "Participants in Arm A must have at least 6 months of study duration in both this study and in observational study 242HA201/OBS16221",
                        "sourceText": "an intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR... participants in Arm A must have at least 6 months of study duration i"
                      },
                      {
                        "id": "170ab6c8-8297-47bc-bbd9-75fb2098ca0d",
                        "name": "Patient Reported Outcome: TSQM-9",
                        "endpointType": "Secondary",
                        "inputs": [
                          "TSQM-9_scores"
                        ],
                        "timeWindow": {
                          "reference": "Baseline and subsequent visits per SoA",
                          "duration": null
                        },
                        "algorithm": "Calculation of 9-item Treatment Satisfaction Questionnaire for Medication scores",
                        "successCriteria": "Evaluation of treatment satisfaction",
                        "sourceText": "the 9-item version of the Treatment Satisfaction Questionnaire for Medication (TSQM-9) is being used"
                      },
                      {
                        "id": "2534c9cc-5f27-43d1-8e23-de869740b7a3",
                        "name": "Exploratory: Patient expectations and perception",
                        "endpointType": "Exploratory",
                        "inputs": [
                          "exit_interview_data"
                        ],
                        "timeWindow": {
                          "reference": "Study Exit",
                          "duration": null
                        },
                        "algorithm": "Qualitative/Quantitative analysis of exit interview responses",
                        "successCriteria": "Evaluation of participants’ expectations of treatment and perception of treatment impact",
                        "sourceText": "An exit interview... related endpoint was added to the exploratory objective for patient reported outcome measures... To evaluate participants’ expectations of treatment and perception of treatment im"
                      }
                    ],
                    "derivedVariables": [
                      {
                        "id": "9d84bf40-b8f0-486d-a254-2628ff531a91",
                        "name": "Patient Global Impression of Change",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "Patient Global Impression of Severity"
                        ],
                        "derivationRule": "Assessment of change in condition compared to baseline status",
                        "baselineDefinition": "Baseline assessment at Day 1",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "Week 26 and Week 52 ± 7 days",
                        "imputationRule": "Not specified in text",
                        "unit": "Scale"
                      },
                      {
                        "id": "34578dbe-9a55-4e65-b6e8-2f2a0bacde4e",
                        "name": "FVIII Activity Half-life",
                        "variableType": "Custom",
                        "sourceVariables": [
                          "FVIII activity",
                          "one-stage aPTT assay"
                        ],
                        "derivationRule": "Geometric mean of half-life calculated from sequential PK sampling",
                        "baselineDefinition": "Predose PK sample on Day 1",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "Sequential sampling post-dose",
                        "imputationRule": "Not specified in text",
                        "unit": "Hours"
                      },
                      {
                        "id": "74bb33f2-ba71-4945-80e6-f729c656cf2f",
                        "name": "Treatment Emergent Adverse Events (TEAE)",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "Adverse Events"
                        ],
                        "derivationRule": "Events occurring after the first dose of BIVV001 or Advate",
                        "baselineDefinition": "First dose administration",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "From Day 1 through Safety follow-up",
                        "imputationRule": "Not specified in text",
                        "unit": "Count/Incidence"
                      },
                      {
                        "id": "4630897d-2e48-44d9-abb4-5cdd5edd2725",
                        "name": "FVIII Activity Geometric Mean Ratio (GMR)",
                        "variableType": "Custom",
                        "sourceVariables": [
                          "BIVV001 FVIII activity",
                          "Advate FVIII activity"
                        ],
                        "derivationRule": "Ratio of geometric mean half-life (BIVV001 / Advate)",
                        "baselineDefinition": "Comparator dose (Advate) results",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "PK sampling period",
                        "imputationRule": "Not specified in text",
                        "unit": "Ratio"
                      }
                    ],
                    "stateMachine": {
                      "id": "1bfd543b-e2cb-48b3-8d58-c3ffa7358194",
                      "initialState": "Screening",
                      "terminalStates": [
                        "Early Termination",
                        "Completed"
                      ],
                      "states": [
                        "Screening",
                        "Baseline",
                        "Treatment",
                        "End Of Study",
                        "Early Termination"
                      ],
                      "transitions": [
                        {
                          "fromState": "Screening",
                          "toState": "Baseline",
                          "trigger": "Progress to Baseline"
                        },
                        {
                          "fromState": "Baseline",
                          "toState": "Treatment",
                          "trigger": "Progress to Treatment"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "End Of Study",
                          "trigger": "Progress to End Of Study"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Early Termination",
                          "trigger": "Subject exits to Early Termination"
                        }
                      ],
                      "epochIds": {
                        "Screening": "SCREENING",
                        "Baseline": "BASELINE",
                        "Treatment": "TREATMENT",
                        "End Of Study": "END_OF_STUDY",
                        "Early Termination": "EARLY_TERMINATION"
                      }
                    },
                    "dosingRegimens": [
                      {
                        "id": "c7b97271-8456-4c16-9c0f-50a917611c91",
                        "treatmentName": "Following BIVV001",
                        "frequency": "QW",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 50.0,
                            "unit": "iu"
                          }
                        ],
                        "sourceText": "with QW dosing, mean FVIII activities based on one-stage and chromogenic assays were 46.28% and 30.46% at 72 hours, 22.30% and 14.48% at 120 hours, and 9.83% and 6.74% at 168 hours, respectively. Foll"
                      },
                      {
                        "id": "6c4bc3a5-740d-4b75-9aed-de71e0bd75cf",
                        "treatmentName": "BIVV001 (efanesoctocog alfa)",
                        "frequency": "QW",
                        "route": "IV",
                        "startDay": 1,
                        "durationDescription": "At least 6 months",
                        "doseModifications": [
                          "Major surgery only allowed after 6 exposure days (EDs)",
                          "Negative inhibitor test required within 4 weeks prior to surgery"
                        ]
                      }
                    ],
                    "visitWindows": [
                      {
                        "id": "0f56d235-8f12-4f82-a4f0-fefd97bc2096",
                        "visitName": "Screening",
                        "targetDay": -14,
                        "windowBefore": 7,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 1,
                        "epoch": "Screening",
                        "sourceText": "electronic patient diary (ePD) is performed at the Screening visit. ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs"
                      },
                      {
                        "id": "8bf751af-98e4-4dec-80ca-560d94f769d6",
                        "visitName": "Early Termination",
                        "targetDay": null,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 2,
                        "sourceText": "Determination The selection of participants to be included in the analysis for the key secondary efficacy endpoint (ie, an intra-patient comparison of"
                      },
                      {
                        "id": "78772cbf-2547-460d-a536-964cf2388e05",
                        "visitName": "Visit 001",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 3,
                        "sourceText": "ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR) was updated to clarify that participants in Arm A must have at least 6 months of study duration"
                      },
                      {
                        "id": "54f797a0-cdc6-445c-9015-da051d77cc7f",
                        "visitName": "baseline",
                        "targetDay": 0,
                        "windowBefore": 1,
                        "windowAfter": 1,
                        "isRequired": true,
                        "visitNumber": 4,
                        "epoch": "Treatment",
                        "sourceText": "ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs during the Screening period, before the baseline visit, it will be"
                      },
                      {
                        "id": "aedb3d2f-de0d-4bac-b65d-c38fb13d3374",
                        "visitName": "EOS",
                        "targetDay": null,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": false,
                        "visitNumber": 5,
                        "sourceText": "EOS/ETc ±7 days Unscheduled"
                      },
                      {
                        "id": "eb572a71-b1cb-423e-a74f-a66d53632dc1",
                        "visitName": "Visit 52",
                        "targetDay": null,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 6,
                        "sourceText": "(EOS) Visit 52 weeks (±7 days) post-Baseline, or earlier if EOS has been declared. 4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN"
                      },
                      {
                        "id": "96ad6490-2820-4dc3-a144-16b8c2b0cb92",
                        "visitName": "Minor Dental Surgery",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 0,
                        "isRequired": false,
                        "visitNumber": 4,
                        "epoch": "Surgical"
                      },
                      {
                        "id": "152a455e-790a-4bd3-83c8-63e32344c49e",
                        "visitName": "Major Surgery",
                        "targetDay": null,
                        "windowBefore": null,
                        "windowAfter": null,
                        "isRequired": false,
                        "visitNumber": 5,
                        "epoch": "Surgical"
                      },
                      {
                        "id": "1666c34a-1366-4c58-ac3e-2c8781a37cdb",
                        "visitName": "Safety Follow-up",
                        "targetDay": null,
                        "windowBefore": null,
                        "windowAfter": null,
                        "isRequired": true,
                        "visitNumber": 6,
                        "epoch": "Follow-up"
                      },
                      {
                        "id": "e80e529c-84a1-430c-82ae-ae300d337225",
                        "visitName": "Exit Interview",
                        "targetDay": null,
                        "windowBefore": null,
                        "windowAfter": null,
                        "isRequired": true,
                        "visitNumber": 7,
                        "epoch": "End of Study"
                      },
                      {
                        "id": "079cc1a0-5096-4375-aa0c-1469c1c2253b",
                        "visitName": "Week 1",
                        "targetDay": 1,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 11,
                        "targetWeek": 1,
                        "sourceText": "Table 3 - PK sampling schedule of activities first dose (Week 1) and Week 26 for sequential PK subgroup ................................................................................................"
                      },
                      {
                        "id": "be96efc0-b87e-40a9-9cb2-afaca1bafb4e",
                        "visitName": "Day 2",
                        "targetDay": 2,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 12,
                        "sourceText": "Day 2 Day 4 Day 8d (study drug can be"
                      },
                      {
                        "id": "0b05c596-a272-4b1f-96b6-097a82e56a56",
                        "visitName": "Day 4",
                        "targetDay": 4,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 13,
                        "sourceText": "Day 4 Day 8d (study drug can be taken after assessments on"
                      },
                      {
                        "id": "2a00f21e-37fd-4522-b00e-4ad6f191f51c",
                        "visitName": "Week 2",
                        "targetDay": 8,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 14,
                        "targetWeek": 2,
                        "sourceText": "Note: Participants in the sequential PK subgroup will not receive BIVV001 at Week 2 and Week 27 (or 1 week after the repeat PK). a"
                      },
                      {
                        "id": "fa0bbc6a-bffd-40e4-88a8-4d7d9a6c8f40",
                        "visitName": "Day 11",
                        "targetDay": 11,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 15,
                        "sourceText": "Day 11 Day 15e 15 m"
                      },
                      {
                        "id": "97478594-6d9c-4dc5-aefd-7d2fc4dfab9e",
                        "visitName": "Day 15",
                        "targetDay": 15,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 16,
                        "sourceText": "Day 15e 15 m (±3 m)"
                      },
                      {
                        "id": "e22e4e98-edf1-4fae-b55d-c9e628d75947",
                        "visitName": "Week 4",
                        "targetDay": 22,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 17,
                        "targetWeek": 4,
                        "sourceText": "Week 4c ±7 days Week 13c"
                      },
                      {
                        "id": "faf7d706-9610-4d13-a816-588f43ff29bf",
                        "visitName": "Week 13",
                        "targetDay": 85,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 18,
                        "targetWeek": 13,
                        "sourceText": "Week 13c ±7 days Week"
                      },
                      {
                        "id": "4d075f71-accd-423c-b09a-c432076d0ac3",
                        "visitName": "Week 26",
                        "targetDay": 176,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 19,
                        "targetWeek": 26,
                        "epoch": "Treatment",
                        "sourceText": "undergo more extensive PK sampling at Baseline and again at Week 26. Participants from any arm who undergo major surgery during the study will be included in the surgery subset. A minimum of 10 major "
                      },
                      {
                        "id": "464d4738-bcb6-4515-9292-053c058edd88",
                        "visitName": "Week 39",
                        "targetDay": 267,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 20,
                        "targetWeek": 39,
                        "sourceText": "Week 39c ±7 days Week 52/"
                      },
                      {
                        "id": "b311a77c-e31f-4f89-ab67-85a206906896",
                        "visitName": "Week 52",
                        "targetDay": 358,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 21,
                        "targetWeek": 52,
                        "sourceText": "3 endpoints from baseline to Week 52, along with its 95% CI, will be estimated by the MMRM model. Analysis of other secondary efficacy endpoints: All secondary efficacy endpoints will be"
                      },
                      {
                        "id": "b13cf606-ab14-42db-894b-16141b5d3e0a",
                        "visitName": "Follow-up",
                        "targetDay": 365,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 22,
                        "sourceText": "Table 1 - Overall schedule of activities from screening to safety follow-up call or visit................................. 17 Table 2 - Abbreviated PK sampling schedule of activities ................."
                      }
                    ],
                    "randomizationScheme": {
                      "id": "5e424412-cfd0-4b1b-896b-a88e86db128c",
                      "ratio": "357:535",
                      "method": "Simple randomization",
                      "centralRandomization": true,
                      "sourceText": "Amended clinical Trial Protocol 05 \nEFC16293 - efanesoctocog alfa       \n20-Aug-2021 \nVersion number: 1 \n \nProperty of the Sanofi group - strictly confidential \nPage 27 \nhemophilia A is estimated to b"
                    }
                  }
                }
              },
              {
                "id": "7a473c19-1e67-4470-9f00-9d9b140fcaaf",
                "url": "https://protocol2usdm.io/extensions/x-soaFootnotes",
                "valueString": "[\"a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening Period is up to 8 weeks before Baseline. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results.\", \"b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period before the Baseline Visit for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor.\", \"c. Participants should schedule their study visits to be 7 \\u00b11 day after the previous prophylactic dose of BIVV001.\", \"d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in the Sequential PK arm should schedule their Week 26 study visit to be 7 (+2) days after the previous prophylactic dose of BIVV001.\", \"e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or at the discretion of the Investigator. If a participant has an unscheduled visit, the Investigator will record data as appropriate based on the purpose of the visit.\", \"f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant enrolls in the open-label extension study. For France specific pregnancy testing at the safety follow-up visit refer to Section 10.11.1.\", \"g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior to any study-related procedures, including washout of current FVIII therapy specifically for entry into the study, or the country's local regulations. Participant assent must also be obtained where applicable (according to the study site's geographic region).\", \"h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted by local regulations. Race and ethnicity will be collected for reasons described in Section 10.1.4.\", \"i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not previously documented. For Repeat Screening Visit, update with any changes since original Screening Visit.\", \"j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committees) will be governed by a separate informed consent. HLA genotype will not be needed if previously documented.\", \"k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period prior to BIVV001 Day 1 dose administration for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor. Washout prior to all other scheduled inhibitor tests must be at least 7\\u00b11 days. Inhibitor and ADA samples will be collected prior to BIVV001 dosing. Separate samples for anti-rFVIIIFc-VWF-XTEN antibody (ADA) testing will be collected at the same timepoint when any samples are collected for inhibitor testing (including samples for suspected inhibitor and confirmatory inhibitor tests). All inhibitor assays, including the assay for the Screening Visit and any confirmatory assays, will be performed by the central laboratory using the Nijmegen-modified Bethesda assay. If a Nijmegen-modified Bethesda assay result returns as \\u22650.6 BU/mL, a separate sample must be collected and tested for confirmation of inhibitor development within 2 to 4 weeks of the original sample. Testing for potential ADA formation will be performed at a central laboratory using a validated rFVIIIFc-VWF-XTEN-specific ADA assay. Confirmed positive samples will be further characterized for antibodies specific to FVIII, Fc, D'D3, or XTEN.\", \"l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participants in Arm B will have BIVV001 doses at visits Day 1, Weeks 26, 39, and 52. During the Scheduled study visits, BIVV001 will be delivered via a slow push IV injection of 8 \\u00b12 minutes, at a rate of administration determined by the participant's comfort level. For all BIVV001 injections performed at home BIVV001 will be delivered via a slow push IV injection at a rate of administration determined by the participant's comfort level according to the vial and injection rate recommendations (Table 7). Injection start and stop time will be recorded in the eCRF. Other doses may be self/caregiver administered at home (or in clinic) (Table 3)\", \"m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (\\u00b0C). Vital signs should be taken after the participant has been resting supine for 5 minutes. Vital signs will be measured pre-injection and 30 (\\u00b115 minutes) from the start of injection at clinic visits. Vital signs should also be taken at any unscheduled visit.\", \"n. Applicable to female participants only. A serum pregnancy test should be performed at screening. For all other time points, the choice of the pregnancy test (urine or serum) is at the discretion of the Investigator. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from further participation if the serum pregnancy result is positive.\", \"o. For participants who have been historically negative, viral testing will be performed at a central laboratory. Human immunodeficiency virus (HIV) tests will include HIV-1 antibodies, HIV-2 antibodies and HIV-1 p24 antigen. Hepatitis B virus (HBV) tests will include HBV surface antigen, anti-HBV surface antibody and anti-HBV core antibody. Hepatitis C virus (HCV) tests will include anti-HCV antibodies.\", \"p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be performed at the central laboratory if results are not available from within 26 weeks prior to screening.\", \"q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differential, platelet count, hemoglobin (Hgb), and hematocrit (Hct). Blood samples for hematology analysis will be collected prior to BIVV001 dosing.\", \"r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin, blood urea nitrogen (BUN), creatinine, glucose, total protein, sodium, potassium, and chloride. Blood samples for clinical chemistry analysis will be collected prior to BIVV001 dosing.\", \"s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] ristocetin cofactor activity and VWF antigen). Blood samples for analysis of Von Willebrand comprehensive panel will be collected prior to any BIVV001 dosing.\", \"t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed consent form (ICF) through the Safety Follow-Up Call or Visit will be recorded on the case report form (CRF). Pain medication related to Hemophilia and administered within 2 weeks prior to the visit will be recorded on the CRF.\", \"u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies and procedures from signing of ICF through the Safety Follow-Up Call or Visit will be recorded on the CRF.\", \"v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month for the site staff to check on each participant's status. During the monthly telephone call, the participant's parent/caregiver will also be reminded about the requirement for timely ePD data entry, and assessments of \\\"spontaneous\\\" and \\\"traumatic\\\" bleeding episodes will be noted.\", \"w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS). At baseline, the Investigator will assess the presence of any target joints according to ISTH criteria.\", \"x. For bleeding episodes treated at the study sites, the Investigator will contact the participant approximately 72 hours from the time the BIVV001 injection was administered to treat the bleeding episode and record the participant's assessment of response to BIVV001 treatment on the eCRF using a 4-point bleeding response scale. For bleeding episodes that are treated at home, participants will record response to bleeding episodes in the ePD.\", \"y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity and Damage Examination (JADE) protocol and/or Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) in a subpopulation of participants from Arm A at selected sites. The Ultrasound can be performed at the Baseline visit or up to 2 weeks after the Baseline Visit.\", \"z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laboratory (if required) for future research, eg., immunology assays, further coagulation assays, or clarification of clinical or laboratory AE, etc. This is optional and participants will sign an additional consent for this research.\", \"aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of response to bleeding episodes using a 4-point bleeding response scale. The participant should record response approximately 72 hours from the time the first BIVV001 injection was administered to treat the bleeding episode, unless treatment of the bleed was administered in the clinic. In that case, the investigator will report the participant's response to treatment via the eCRF.\", \"bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated PK sampling after the first dose of BIVV001 (Baseline). See abbreviated PK sampling details in Table 2.\", \"cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Baseline and again at Week 26. See sequential PK sampling details as described in Table 3.\", \"dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 min \\u00b1 3 min post injection. This trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ADA) samples taken predose (Table 2).\", \"ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference \\u226518 years old or PROMIS Pediatric-SF Pain Interference <18 years old), and Physical Function (PROMIS-SF Physical Function \\u226518 years old or PROMIS Pediatric-SF Physical Activity <18 years old). See Section 8.1.2.\", \"ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patient perception of activity and a single question on patient perception of joint health. See Section 8.1.2.\", \"gg. Treatment preference survey will consist of 2 questions on patient preference and a single question on Patient Global Impression of Change (PGIC). See Section 8.1.2.\", \"hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical grade accelerometer (ActiGraph Activity Monitor) worn on the nondominant wrist. Device will be worn daily for 8 consecutive days after the scheduled visits at Screening, Baseline, Weeks 4, 13, 26, 39, and for 8 consecutive days before the Week 52 visit. Refer to Section 8.1.4\", \"ii. Coagulation parameters include activated partial thromboplastin time (aPTT)\", \"jj. Please refer to Section 10.11.2 for Italy specific requirement\", \"kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.\", \"ll. ePD training only. ePD devices are given to the patients at the baseline visit\", \"1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies.\", \"2. NSAIDs at doses above the maximum dose specified in local prescribing information.\", \"3. Systemic treatment with chemotherapy and/or other immunosuppressive drugs (except for the treatment of hepatitis C virus [HCV] or HIV). The use of systemic steroids for the treatment of acute respiratory illness (eg, asthma), acute allergic episodes, or otherwise life threatening episodes is allowed. Treatment in these circumstances should not exceed a 14 day duration. Local, topical, and/or inhaled steroid use is permitted.\", \"4. Any other FVIII product (with exceptions listed in Section 7.1.1).\", \"5. Emicizumab. VV-CLIN-0548164 7.0\", \"6. Anticoagulant agents, excluding the use of heparin for intermittent flushing for maintenance of patency of intravenous catheters, and short-term thromboembolic prophylaxis during immobilization and/or perioperatively. The Investigator must discuss the use of anticoagulant agents with the medical monitor. As stated in Section 5.3, participants who routinely administer an additional dose of FVIII prior to a sports activity or increased physical activity will not be allowed to do so in this study. However, the day of dosing BIVV001 in Arms A and B (prophylaxis period) could be chosen prior to a weekly recurring physical activity.\"]",
                "instanceType": "ExtensionAttribute"
              }
            ],
            "administrations": [
              {
                "id": "c5736ead-ebda-4667-b6e5-2b75ec37dafa",
                "name": "Following BIVV001 Administration",
                "instanceType": "Administration",
                "dose": "50.0 iu",
                "doseFrequency": "QW",
                "route": {
                  "id": "8c81c9e6-6451-41b1-ae82-2fbfe620b841",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "with QW dosing, mean FVIII activities based on one-stage and chromogenic assays were 46.28% and 30.46% at 72 hours, 22.30% and 14.48% at 120 hours, and 9.83% and 6.74% at 168 hours, respectively. Foll"
              },
              {
                "id": "8122c1a2-2f7a-4bb9-ad60-47a8c5b73164",
                "name": "BIVV001 (efanesoctocog alfa) Administration",
                "instanceType": "Administration",
                "doseFrequency": "QW",
                "route": {
                  "id": "f62a56e4-a470-42be-b6f8-933293792cb6",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "At least 6 months"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "b439030f-b6d1-4d88-891a-814a12369c43",
            "text": "A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients ≥12 Years of Age With Severe Hemophilia A",
            "type": {
              "id": "064faff9-1b47-4e48-97f4-dc50f6629dd5",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "9730458d-f189-4a30-b60d-2501de82c0a0",
            "text": "XTEND-1",
            "type": {
              "id": "2ae72a80-f163-428b-a688-595e3fb18680",
              "code": "Study Acronym",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Acronym",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "0c713932-63e8-444a-8b03-4fa92ee2f797",
            "text": "NCT04161495",
            "instanceType": "StudyIdentifier",
            "scopeId": "4afdfdf3-bbbe-4640-b749-497529e29844",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "a62879db-b16b-4901-b489-67dfe6e0660e",
            "text": "EFC16293",
            "instanceType": "StudyIdentifier",
            "scopeId": "2d2bdea4-6ca8-4040-8c07-e8d6d2c4db1d",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "40b0597a-4165-466a-a4cf-a08529ea00a0",
            "text": "2019-002023-15",
            "instanceType": "StudyIdentifier",
            "scopeId": "b4a218ab-b8dd-49bd-bc5f-57e6f02dd956",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "460aa9fc-aaf5-410a-b68c-b539dfa08b24",
            "text": "17464",
            "instanceType": "StudyIdentifier",
            "scopeId": "3df09d4b-04a2-42a4-a3e9-c17ffee320da",
            "type": {
              "code": "C218685",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "US FDA Investigational New Drug Application Number",
              "instanceType": "Code"
            }
          },
          {
            "id": "8112bf29-1aaa-4169-90af-15f8fb04ade1",
            "text": "U1111-1223-4867",
            "instanceType": "StudyIdentifier",
            "scopeId": "3df09d4b-04a2-42a4-a3e9-c17ffee320da",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "71acc076-28fa-4e44-8e69-e18eab8c03bc",
            "text": "VV-CLIN-0548164 7.0",
            "instanceType": "StudyIdentifier",
            "scopeId": "2d2bdea4-6ca8-4040-8c07-e8d6d2c4db1d",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "2d2bdea4-6ca8-4040-8c07-e8d6d2c4db1d",
            "name": "Bioverativ Therapeutics Inc. (a Sanofi Company)",
            "type": {
              "id": "f22d59a4-ea8f-4d15-897c-f66023ca10ab",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Bioverativ Therapeutics Inc. (a Sanofi Company)",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "36fc44ee-01e7-45cd-a522-1bb59307c52b",
            "name": "Sanofi",
            "type": {
              "id": "db08a06e-91e6-4659-b2c1-b45cb83613b7",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Sanofi",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "4afdfdf3-bbbe-4640-b749-497529e29844",
            "name": "ClinicalTrials.gov",
            "type": {
              "id": "3c62472e-7cda-43a9-93c2-4d272c3f9aba",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "ClinicalTrials.gov",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "2d2bdea4-6ca8-4040-8c07-e8d6d2c4db1d",
            "name": "Investigational Site Number 920",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "1",
            "type": {
              "id": "1fa262f0-7092-4e1e-903d-fa230d559c7b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "36fc44ee-01e7-45cd-a522-1bb59307c52b",
            "name": "Investigational Site Number 921",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "2",
            "type": {
              "id": "70bad490-a54f-458f-9ad7-d58d02ba9b7a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4afdfdf3-bbbe-4640-b749-497529e29844",
            "name": "Investigational Site Number 911",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "3",
            "type": {
              "id": "a5147a9a-76cd-40a3-9a1a-bc7d7b9807b4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "08865b04-6e1d-4d32-841c-025cef995560",
            "name": "Investigational Site Number 917",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "4",
            "type": {
              "id": "cd1a1fa9-4ccf-4bf9-8151-8fb6246554a8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "69fed8ce-97e2-40b7-88e9-d7a58ba40eba",
            "name": "Investigational Site Number 919",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "5",
            "type": {
              "id": "0afaf135-35a5-41bd-94d5-5ab4110c195d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fb4895c9-77ad-4b7a-b034-2f0884cc9c10",
            "name": "Investigational Site Number 908",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "6",
            "type": {
              "id": "3f7bd462-ffbc-4fdb-8974-3278698ea14a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "adb55fd3-cad4-40e2-b86b-d0a279044fc4",
            "name": "Investigational Site Number 906",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "7",
            "type": {
              "id": "38ef046b-8dfe-42fa-9ebe-cb6430ef0bd6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "38fbdcc6-5fc9-4f06-a0c9-98730b38544c",
            "name": "Investigational Site Number 902",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "8",
            "type": {
              "id": "201da70f-c851-4017-8499-fdb20caf8c86",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "060a3849-ef6a-4fd8-a05f-4e51fc86fbae",
            "name": "Investigational Site Number 136",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "9",
            "type": {
              "id": "907d5ca0-ce40-4a6e-8fb7-9f6c989a63ae",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "47b7f961-3656-4488-90be-40128c8a4d5a",
            "name": "Investigational Site Number 137",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "10",
            "type": {
              "id": "fcb8aa85-3cee-487c-bc78-63ed5befc8e8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4d8187bf-99bf-45df-8a48-992e41f22fe6",
            "name": "Investigational Site Number 139",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "11",
            "type": {
              "id": "def3ffd4-0431-4518-9cb6-a45ea203f324",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b8eab9a7-a4b3-4182-872e-aff08ba6f133",
            "name": "Investigational Site Number 121",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "12",
            "type": {
              "id": "218d54d6-1c20-4a1c-9e64-84d4efda05f8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9e77933b-f890-4110-8221-2f1d28e61860",
            "name": "Investigational Site Number 122",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "13",
            "type": {
              "id": "2449ad91-2259-4f4e-aebc-b523f14ecc49",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ab8a88a4-b052-4304-a2ef-ac717769278b",
            "name": "Investigational Site Number 161",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "14",
            "type": {
              "id": "e41405cb-d09f-40f4-8908-37df8ec46f35",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8d576b9d-9e7e-4156-b47c-5212b9443a90",
            "name": "Investigational Site Number 181",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "15",
            "type": {
              "id": "3290075d-e892-4a96-b03b-8baaf93a18fa",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c0e20025-6d3b-478a-a2f0-99174076a432",
            "name": "Investigational Site Number 171",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "16",
            "type": {
              "id": "d6e081b4-240b-409a-9580-2aedde73b503",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "71d498e8-3ded-4c90-9c9a-95c789a9fe85",
            "name": "Investigational Site Number 172",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "17",
            "type": {
              "id": "1be3df54-b64d-4861-aa18-a09209ce5e9b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0981e1f8-51de-4de5-b289-32c2ed49db37",
            "name": "Investigational Site Number 202",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "18",
            "type": {
              "id": "844b0b28-f4f3-4ecd-a46a-8c7b5a33420f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "844a31cc-16bc-434d-927e-f42f2fab3799",
            "name": "Investigational Site Number 205",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "19",
            "type": {
              "id": "b34203c6-8010-478c-9d96-e4426bd3a237",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "459bbc1c-a7aa-4721-b883-18467b0ba1d7",
            "name": "Investigational Site Number 281",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "20",
            "type": {
              "id": "3f5c6057-85e3-4148-9fd2-43c68d1c7c94",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4d015655-7a7f-4796-97b7-617ee7fc69f7",
            "name": "Investigational Site Number 283",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "21",
            "type": {
              "id": "7cdc231a-07c8-416e-8297-9e9aecd4c50d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1e5a41cf-44dd-4517-96c2-e9e0b0d8ca59",
            "name": "Investigational Site Number 282",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "22",
            "type": {
              "id": "87a4abc5-443c-4791-bab5-486dd95a4985",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fd4a431a-db7b-4f85-82f1-1fea4a7aeb1d",
            "name": "Investigational Site Number 284",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "23",
            "type": {
              "id": "f8362900-14c8-4876-a007-e1bba0d25302",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "23b5d454-a6e4-40c1-961a-8a6695b755fb",
            "name": "Investigational Site Number 304",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "24",
            "type": {
              "id": "c2c8f45e-38b0-4f45-bfa1-c6c937e36b36",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e5db31df-61ad-4d51-9fbc-ae8dec66384f",
            "name": "Investigational Site Number 302",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "25",
            "type": {
              "id": "92424f5a-4e08-4669-94c2-704e35a281ea",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2d909702-c0f9-4784-9e76-fdd99a0a0d29",
            "name": "Investigational Site Number 303",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "26",
            "type": {
              "id": "a7f56277-d90d-4552-a405-2976a32930d9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4f0be6be-bfaa-4f96-8dac-6a66b6235235",
            "name": "Investigational Site Number 321",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "27",
            "type": {
              "id": "bf813209-4413-47bd-978f-d687bb2a78f9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "42082ea7-4609-4dc8-9ed5-7a50c89dac04",
            "name": "Investigational Site Number 312",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "28",
            "type": {
              "id": "bd76deb3-fea6-456c-a065-2bc8454d8b19",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1ec875b5-be26-43c7-9755-dd4d91e98049",
            "name": "Investigational Site Number 314",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "29",
            "type": {
              "id": "b28107e5-159d-4b09-b7a7-ed6e0b87e8b9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "35e30735-f03f-4d80-996b-fd639ca88264",
            "name": "Investigational Site Number 402",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "30",
            "type": {
              "id": "ea6921ed-a998-4e06-a655-77764a6717bc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b42510bb-81fd-4e76-80ea-67165a8b1de0",
            "name": "Investigational Site Number 401",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "31",
            "type": {
              "id": "39209682-efbc-4f24-b243-8cd32353e82b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8553fcb7-1cb2-45b1-81d7-3e30ddd132e8",
            "name": "Investigational Site Number 426",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "32",
            "type": {
              "id": "b2d0f814-469c-4ee6-9155-47f9522e28f0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "489c21f2-aa1b-43b9-a028-c8b036e5a36f",
            "name": "Investigational Site Number 423",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "33",
            "type": {
              "id": "89ac7995-deaf-4f3f-8b6a-5b40a944325b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ee631238-2a8c-4989-9777-201a0d1a3b31",
            "name": "Investigational Site Number 425",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "34",
            "type": {
              "id": "5f922ce3-0af3-440f-9aca-bd4f5010ce38",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2d6c5339-c6a8-426d-8d20-2827513e9562",
            "name": "Investigational Site Number 422",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "35",
            "type": {
              "id": "6787e45a-317c-4eb1-a47a-0f22c459925a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "80c059ac-c388-4eeb-93f2-7dda49c2adb1",
            "name": "Investigational Site Number 421",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "36",
            "type": {
              "id": "cd13c2e0-acab-4cfd-ac27-61d540dffcc5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8cb4c819-455f-4e5e-8119-de6b5f6c2559",
            "name": "Investigational Site Number 424",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "37",
            "type": {
              "id": "f7a0b724-b1f8-4f3d-94b1-9e80c4104f7c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4d7e4e13-8eb7-4ffb-b10b-e3717656d555",
            "name": "Investigational Site Number 435",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "38",
            "type": {
              "id": "537b4a48-5cb0-479e-8fbc-6baa7e719b41",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0a507543-eecd-46a0-8981-45152420174e",
            "name": "Investigational Site Number 641",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "39",
            "type": {
              "id": "220c7efb-0c0c-4a79-a6df-cf4654fa4665",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e3f3b07a-5130-4d48-8c27-280c040b5d25",
            "name": "Investigational Site Number 603",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "40",
            "type": {
              "id": "1c5934d5-f15a-4e59-aa69-485435f4e716",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e63e3635-0d4a-4e4c-a8d9-2db06a594d6d",
            "name": "Investigational Site Number 600",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "41",
            "type": {
              "id": "cbec47e5-3ec0-45a4-bc0c-ac0a35796c8b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9fca6efa-1003-430d-b7e0-fee43ce3b8d3",
            "name": "Investigational Site Number 601",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "42",
            "type": {
              "id": "68a3ff4b-5a50-4b6b-9096-42649e930144",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3214a26a-4adf-4a2f-86c5-5261154648c3",
            "name": "Investigational Site Number 521",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "43",
            "type": {
              "id": "069c6e1b-5e81-4f5f-97b6-3cac7f3401f8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c8ebfa90-1aa8-4775-8018-d50ac150d7b5",
            "name": "Investigational Site Number 531",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "44",
            "type": {
              "id": "2c5232e7-6a42-4a62-93dc-980b1b4bcaad",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "623b8c37-6d90-4fda-9363-23409c3efee4",
            "name": "Investigational Site Number 532",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "45",
            "type": {
              "id": "4a97d154-ef71-4282-aff8-25b5cd293a05",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c98486bd-a1b6-4b04-8108-efd7d787b5ec",
            "name": "Investigational Site Number 581",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "46",
            "type": {
              "id": "977a582d-c628-4373-8cf9-875c919bf4dc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "24f32070-0b01-41a6-a93d-b63edeb4fbd4",
            "name": "Investigational Site Number 581",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "47",
            "type": {
              "id": "83a52c7e-3471-4500-8554-4d42070f0777",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "d5d52c12-bbc1-4fb1-a353-9ce2de4ed055",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "ae040abb-f723-4df3-b63c-a52328e016dc",
            "name": "Age requirement",
            "text": "Participant must be equal to or greater than 12 years of age inclusive, at the time of signing the informed consent.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "7ab41c21-431e-409d-ac58-04d5745ede79",
            "name": "Severe hemophilia A diagnosis",
            "text": "Severe hemophilia A, defined as <1 IU/dL (<1%) endogenous FVIII activity as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating <1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "385e0c6c-a841-49cd-9dd1-25cfd67249ed",
            "name": "Previous treatment history",
            "text": "Previous treatment for hemophilia A (prophylaxis or on demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 EDs.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "95e96023-be13-4c16-b6b1-f7e686694d2f",
            "name": "Current treatment regimen",
            "text": "Current regimen includes one of the following: Prophylactic treatment regimen with a FVIII product or prophylactic emicizumab therapy for at least 6 months during the previous 12 months. Appropriate washout time needs to be taken into account. OR On-demand regimen with a FVIII product with a history of at least 12 bleeding episodes in the previous 12 months or at least 6 bleeding episodes in the previous 6 months prior to study enrollment. On-demand participant is accepting to move to a prophylaxis treatment regimen after 26-week on-demand period.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "01a54295-587a-4933-9dc1-f7e01b08bab2",
            "name": "Platelet count",
            "text": "Platelet count ≥100,000 cells/μL at Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ea140f0a-d3fa-41cd-8d2f-ef5408c4b808",
            "name": "HIV status requirements",
            "text": "A participant known to be human immunodeficiency virus (HIV) antibody positive, either previously documented or identified from screening assessments, must have the following results prior to enrollment: a. CD4 lymphocyte count >200 cells/mm³ b. Viral load of <400 copies/mL. Documented results of CD4 lymphocyte count and viral load will be accepted if samples were collected within 26 weeks prior to Screening or if samples were collected during Screening and evaluated by the central laboratory. Participants who have previously tested negative for HIV must have a repeat test by the central laboratory during Screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "24c0f3dc-f1c4-4462-acad-fd1f3014729d",
            "name": "ePD training and use",
            "text": "Willingness and ability of the participant or surrogate (a caregiver or a family member ≥18 years of age) to complete training in the use of the study electronic Patient Diary (ePD) and to use the ePD throughout the study.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "38bbc066-24a5-4b6d-bdff-0558bc34e187",
            "name": "Sex and contraception",
            "text": "Male or Female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. a) Male participants: No contraceptive measures required for this study. b) Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP), as defined in Section 10.4 or Is a WOCBP and using an acceptable contraceptive method as described Section 10.4 during the intervention period (at a minimum until Safety Follow-up Call or Visit). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. and A WOCBP must have a negative highly sensitive pregnancy test before the first dose of study intervention as described in Section 10.2. A serum pregnancy test should be performed at screening. For all other time points, the choice of the pregnancy test (urine or serum) is at the discretion of the Investigator.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "17789054-b13c-4145-af0f-dfcbd8ae5c7e",
            "name": "Informed consent",
            "text": "Capable of giving signed informed consent as described in Appendix 1 (Section 10.1) which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. [In countries where legal age of majority is above 18 years, a specific ICF must also be signed by the participant’s legally authorized representative].",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a9cea678-7979-4e7d-80ef-7dd3c9079a99",
            "name": "Legal authorization",
            "text": "Ability of the participant or his or her legally authorized representative (eg., parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent or assent (as applicable) and authorization to use protected health information in accordance with national and local participant privacy regulations.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "bbeb4179-a5ef-4bbe-a7a9-ed7f03eaec68",
            "name": "Liver disease exclusion",
            "text": "Any concurrent clinically significant liver disease that, in the opinion of the Investigator, would make the participant unsuitable for enrollment. This may include, but is not limited to cirrhosis, portal hypertension, and acute hepatitis.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "381e171b-4005-4be0-a5ad-cf1ea38dee43",
            "name": "Active infection exclusion",
            "text": "Serious active bacterial or viral infection (other than chronic hepatitis or HIV) present within 30 days of Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "303bcccb-a043-433b-9f7a-1b4c7b45529b",
            "name": "Other coagulation disorders",
            "text": "Other known coagulation disorder(s) in addition to hemophilia A.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2749e41d-faea-459e-8242-28a3a3e3f84b",
            "name": "Hypersensitivity history",
            "text": "History of hypersensitivity or anaphylaxis associated with any FVIII product",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "33d920ad-5041-4e11-9e49-7e0c211a978f",
            "name": "Historical inhibitor test",
            "text": "History of a positive inhibitor test defined as ≥0.6 BU/mL, or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of decreased response to FVIII administrations. Family history of inhibitors will not exclude the participant.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "84696e18-2503-4863-828d-66c1be05cbd6",
            "name": "Screening inhibitor result",
            "text": "Positive inhibitor result, defined as ≥0.6 BU/mL at Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6e59124c-34d2-466e-a874-bf2bbd77bc3b",
            "name": "Renal function",
            "text": "Abnormal renal function, defined as serum creatinine >2.0 mg/dL taken at Screening. For Italy-specific E07 requirements refer to Section 10.11.2.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2af382af-aed7-42b0-8950-29c93164505b",
            "name": "Liver enzymes",
            "text": "Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 x upper limit of normal (ULN) taken at Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "497a56c8-53d3-4c15-8533-56963768e2ae",
            "name": "Bilirubin levels",
            "text": "Serum total bilirubin >3 x ULN, taken at Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "69a4425d-b027-405b-ae5a-c5fac0070909",
            "name": "Recent vaccination",
            "text": "Vaccination within 30 days of Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a3311dbf-0b70-4136-8f2d-009061e403e9",
            "name": "Anti-platelet therapy",
            "text": "Treatment with acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies within 2 weeks prior to screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "059ccc70-ef6b-4762-8f48-f0786221c41f",
            "name": "NSAID use",
            "text": "Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) above the maximum dose specified in the regional prescribing information within 2 weeks prior to Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "96115527-73ce-4152-aa92-1528f269c795",
            "name": "Immunosuppressive drugs",
            "text": "Systemic treatment within 12 weeks prior to Screening with chemotherapy and/or other immunosuppressive drugs (except for the treatment of hepatitis C virus [HCV] or HIV). Use of corticosteroids is allowed, except for systemic corticosteroid treatment given daily or on alternate days for >14 days. Local, topical, and/or inhaled steroid use is permitted.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "32751b56-7ad1-4bd9-99af-7a597ac07e18",
            "name": "Recent emicizumab use",
            "text": "Emicizumab use within the 20 weeks prior to Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "5f86b516-cb9c-4195-8c3c-f467aadb71b8",
            "name": "Previous enrollment",
            "text": "Previous enrolment in this study; participants who fail Screening may re-screen.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f87dd868-c552-47e4-b2df-cb44e38280d3",
            "name": "Investigational product use",
            "text": "Treatment with an investigational product within 30 days or 5.5 half-lives prior to Screening, whichever is longer. For investigational products with a pharmacodynamic effect that persists longer than the half-life, the maximal pharmacodynamic effect must return to baseline prior to Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fa6caa5a-bf81-4e7d-afa2-33b09b790ee8",
            "name": "Recent major surgery",
            "text": "Major surgery within 8 weeks prior to Screening. Major surgery is defined as any surgical procedure (elective or emergent) that usually, but not always, involves general anesthesia and/or respiratory assistance, in which a major body cavity is penetrated and exposed, or a substantial impairment of physical or physiological functions is produced (eg, laparotomy, thoracotomy, craniotomy, joint replacement, or limb amputation).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9c089551-721c-4e8a-8e86-ad144120d7fe",
            "name": "Institutionalization",
            "text": "Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "89654928-f13c-4c9a-a4a5-bfb4ac957a4f",
            "name": "Country-specific regulations",
            "text": "Any country-related specific regulation that would prevent the participant from entering the study – see Appendix 10 (Section 10.11) (country specific requirements).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2328606c-4dff-456e-8f58-ee8edb69de6a",
            "name": "Investigator judgment",
            "text": "Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "8b48dede-38f5-4622-b399-53dc4a1d64fb",
            "name": "Sponsor/Investigator dependency",
            "text": "Participants are dependent on the Sponsor or Investigator (in conjunction with Section 1.61 of the ICH-GCP Ordinance E6).",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "976d7bee-3074-42db-b568-e6ae0acac276",
            "name": "efanesoctocog alfa",
            "type": {
              "id": "27f5ccae-6921-483e-bb18-6d4b82a62e5e",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "d735a175-3d37-4de7-b8dc-e89674939aa3",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Recombinant coagulation factor VIII Fc-von Willebrand Factor XTEN Fusion Protein (BIVV001) for the treatment of severe hemophilia A.",
            "productIds": [
              "84434c65-72c4-4042-8074-7bc22c831122"
            ],
            "administrationIds": [
              "101a8d16-9b33-419d-b34a-45f9b8f66e12",
              "2e17f74e-5c3f-4aef-b86e-b0ded8e02615"
            ]
          },
          {
            "id": "e3cb388a-98ea-4bb0-baac-983285f358a0",
            "name": "FVIII product",
            "type": {
              "id": "99db2c86-2e5d-4164-b7de-8e14d1e9e963",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "687c99a4-3241-419f-a0ed-fa7e44bfb4c3",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Previous treatment for hemophilia A with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days.",
            "administrationIds": [
              "5929e658-2595-437b-a6e1-dc89cd316b5b"
            ]
          },
          {
            "id": "fe20fc27-130d-4d64-8645-c61cd1269e5f",
            "name": "Emicizumab",
            "type": {
              "id": "0eec70c1-2824-49ab-8168-fdd907fa26a5",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "ffc5a4a3-8762-4b2f-999a-a67fdc3bcdf4",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prophylactic emicizumab therapy; must be washed out for 20 weeks prior to screening.",
            "administrationIds": [
              "f73d9b11-ada4-45bc-83a7-234e5ff3ba55"
            ]
          },
          {
            "id": "1166a10a-01d2-49ba-b8cb-97d27ec6c046",
            "name": "Acetylsalicylic acid (ASA)",
            "type": {
              "id": "70a97526-fb28-4c88-bf28-620e984c3402",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "12dd7cb4-e1c6-4c4e-9eaf-043c1a73fa8e",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited within 2 weeks prior to screening.",
            "administrationIds": [
              "fac7b49b-6849-45f3-90f2-0a5496f2294d"
            ]
          },
          {
            "id": "a863fc8a-c36f-44cd-8a7c-89f300b6650b",
            "name": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
            "type": {
              "id": "7d91ed28-70a6-467f-b665-7f3dea5c54b3",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "b873ab30-d3d8-4f85-8441-492157a20e3d",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited above maximum dose specified in regional prescribing information within 2 weeks prior to screening.",
            "administrationIds": [
              "abe3252a-e1ee-4a7f-9e17-264b7e974c04"
            ]
          },
          {
            "id": "bb7c3276-80e0-4cbf-9c8e-c5d9412c7cf7",
            "name": "Immunosuppressive drugs",
            "type": {
              "id": "7eaed513-395a-4fae-be28-d543196d95ae",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "1566574c-9235-44a0-9b6a-e72b920c0127",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Systemic treatment prohibited within 12 weeks prior to screening (except for HCV or HIV treatment)."
          }
        ],
        "administrableProducts": [
          {
            "id": "84434c65-72c4-4042-8074-7bc22c831122",
            "name": "BIVV001",
            "administrableDoseForm": {
              "id": "6b3deab5-eb3d-4dd7-86eb-211e066cf48c",
              "code": "C42970",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Powder",
              "instanceType": "Code",
              "standardCode": {
                "id": "2852d6bf-d42b-40d2-9ce2-23157378b03b",
                "code": "C42970",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Powder",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "04295161-6a56-4593-bda0-ca9fe4c5d72a",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "250, 500, 1000, 2000, 3000, and 4000 IU per vial",
            "substanceIds": [
              "d5b03eb4-80d1-4bce-a59a-6192516f0f68"
            ],
            "manufacturer": "Sanofi"
          }
        ],
        "narrativeContents": [
          {
            "id": "ef766ba5-1655-4d38-af38-6188efe38509",
            "name": "PROTOCOL SUMMARY",
            "text": "PROTOCOL SUMMARY",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1",
            "sectionTitle": "PROTOCOL SUMMARY",
            "sectionType": {
              "id": "fdfcba5b-bb15-462b-ae80-22a069a8bc10",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            },
            "childIds": [
              "b3643190-a5f0-46b2-9aec-2e2dc16171d5",
              "35016546-1c3b-47cb-9dfa-027aa9ba4667",
              "51e16773-fe94-40f1-b324-080148118c1a"
            ]
          },
          {
            "id": "ae06c430-bd40-45b4-8613-142c6e860ccb",
            "name": "INTRODUCTION",
            "text": "INTRODUCTION",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "INTRODUCTION",
            "sectionType": {
              "id": "48129f5d-c09d-4eac-b01d-225738bfe3ee",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "27f3aba1-24e2-462a-809b-8ddf3b138940",
              "601f67cd-0f39-48db-97f8-13af020dca98",
              "d53a39cc-92ad-46d1-b31c-01e9d0db8035"
            ]
          },
          {
            "id": "7b74397f-58d4-4857-b071-4af8e4979d9e",
            "name": "OBJECTIVES AND ENDPOINTS",
            "text": "OBJECTIVES AND ENDPOINTS",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3",
            "sectionTitle": "OBJECTIVES AND ENDPOINTS",
            "sectionType": {
              "id": "740b40a7-3505-4a93-a94f-532f65080e34",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            },
            "childIds": [
              "de7eca53-edf7-4bb5-a21c-8f19288b8429"
            ]
          },
          {
            "id": "fae3e1a6-d233-446a-ac33-4841f2ea9744",
            "name": "STUDY DESIGN",
            "text": "STUDY DESIGN",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "4",
            "sectionTitle": "STUDY DESIGN",
            "sectionType": {
              "id": "de0c0227-6fc0-4352-ba73-994374e4d477",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            },
            "childIds": [
              "67befbc9-99fe-4c3f-8453-170cb4783be1",
              "a89020d2-549d-47a9-8998-310c40db75b3",
              "c93509d4-ad03-454b-9324-c6ef15a76a8e",
              "340cde7f-69fa-4a43-800a-775bb98f04e0",
              "7313a325-7cdf-4381-8a4e-ca027c45b20c"
            ]
          },
          {
            "id": "c620121e-14b3-4016-9891-e73e10173f17",
            "name": "STUDY POPULATION",
            "text": "STUDY POPULATION",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "5",
            "sectionTitle": "STUDY POPULATION",
            "sectionType": {
              "id": "225571b2-af1b-45b5-bc1b-9d59d2f6579e",
              "code": "Study Population",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Population",
              "instanceType": "Code"
            },
            "childIds": [
              "e5fbdafa-5d5d-48d6-b09a-c0dbd12e1b87"
            ]
          }
        ],
        "narrativeContentItems": [
          {
            "id": "b3643190-a5f0-46b2-9aec-2e2dc16171d5",
            "name": "SYNOPSIS",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1",
            "sectionTitle": "SYNOPSIS"
          },
          {
            "id": "35016546-1c3b-47cb-9dfa-027aa9ba4667",
            "name": "SCHEMA",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2",
            "sectionTitle": "SCHEMA"
          },
          {
            "id": "51e16773-fe94-40f1-b324-080148118c1a",
            "name": "SCHEDULE OF ACTIVITIES (SOA)",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.3",
            "sectionTitle": "SCHEDULE OF ACTIVITIES (SOA)"
          },
          {
            "id": "27f3aba1-24e2-462a-809b-8ddf3b138940",
            "name": "STUDY RATIONALE",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.1",
            "sectionTitle": "STUDY RATIONALE"
          },
          {
            "id": "601f67cd-0f39-48db-97f8-13af020dca98",
            "name": "BACKGROUND",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.2",
            "sectionTitle": "BACKGROUND"
          },
          {
            "id": "d53a39cc-92ad-46d1-b31c-01e9d0db8035",
            "name": "BENEFIT/RISK ASSESSMENT",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.3",
            "sectionTitle": "BENEFIT/RISK ASSESSMENT"
          },
          {
            "id": "de7eca53-edf7-4bb5-a21c-8f19288b8429",
            "name": "APPROPRIATENESS OF MEASUREMENTS",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1",
            "sectionTitle": "APPROPRIATENESS OF MEASUREMENTS"
          },
          {
            "id": "67befbc9-99fe-4c3f-8453-170cb4783be1",
            "name": "OVERALL DESIGN",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.1",
            "sectionTitle": "OVERALL DESIGN"
          },
          {
            "id": "a89020d2-549d-47a9-8998-310c40db75b3",
            "name": "SCIENTIFIC RATIONALE FOR STUDY DESIGN",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.2",
            "sectionTitle": "SCIENTIFIC RATIONALE FOR STUDY DESIGN"
          },
          {
            "id": "c93509d4-ad03-454b-9324-c6ef15a76a8e",
            "name": "JUSTIFICATION FOR DOSE",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.3",
            "sectionTitle": "JUSTIFICATION FOR DOSE"
          },
          {
            "id": "340cde7f-69fa-4a43-800a-775bb98f04e0",
            "name": "END OF STUDY DEFINITION",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.4",
            "sectionTitle": "END OF STUDY DEFINITION"
          },
          {
            "id": "7313a325-7cdf-4381-8a4e-ca027c45b20c",
            "name": "STUDY STOPPING RULES",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.5",
            "sectionTitle": "STUDY STOPPING RULES"
          },
          {
            "id": "e5fbdafa-5d5d-48d6-b09a-c0dbd12e1b87",
            "name": "INCLUSION CRITERIA",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.1",
            "sectionTitle": "INCLUSION CRITERIA"
          }
        ],
        "abbreviations": [
          {
            "id": "6ab7d2dd-5d08-45e0-be5c-b585610caea3",
            "abbreviatedText": "ABR",
            "expandedText": "annualized bleed rate",
            "instanceType": "Abbreviation"
          },
          {
            "id": "278c5333-64d9-44c8-9162-8df45a8876a2",
            "abbreviatedText": "ADA",
            "expandedText": "Anti-rFVIIIFc-VWF-XTEN Antibody",
            "instanceType": "Abbreviation"
          },
          {
            "id": "c5a2c9ea-dfea-42e3-8d58-1260cf8edeae",
            "abbreviatedText": "AE",
            "expandedText": "Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "e89bfa98-f215-475b-aaa8-823a9dbb9ea6",
            "abbreviatedText": "aPTT",
            "expandedText": "activated partial thromboplastin time",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3b1bf41e-c2b2-4152-a49f-9709459a404a",
            "abbreviatedText": "EHL",
            "expandedText": "extended half-life",
            "instanceType": "Abbreviation"
          },
          {
            "id": "fa4c22d5-e16c-46f5-8018-a8a89d21d5c9",
            "abbreviatedText": "EOS",
            "expandedText": "End of Study",
            "instanceType": "Abbreviation"
          },
          {
            "id": "24d5f5b7-c7af-4d85-82ca-a291be85919c",
            "abbreviatedText": "ePD",
            "expandedText": "electronic patient diary",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9fc1882a-2129-43e5-a3ce-a0a22899ab91",
            "abbreviatedText": "ET",
            "expandedText": "Early Termination",
            "instanceType": "Abbreviation"
          },
          {
            "id": "94bc37e1-122d-4139-9e5e-03666c8fd19e",
            "abbreviatedText": "FVIII",
            "expandedText": "Factor VIII",
            "instanceType": "Abbreviation"
          },
          {
            "id": "c7d9884e-f3c0-44b1-aaa2-7659b01c5f3c",
            "abbreviatedText": "HBV",
            "expandedText": "Hepatitis B Virus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "60fc3555-1520-4fa0-9a5c-a63e1694d4be",
            "abbreviatedText": "HCV",
            "expandedText": "Hepatitis C Virus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "af06657b-c008-4a7a-945a-1b61590e3e76",
            "abbreviatedText": "HIV",
            "expandedText": "Human Immunodeficiency Virus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "21210f86-a5d5-4d08-9b60-d43ae917030f",
            "abbreviatedText": "HJHS",
            "expandedText": "Hemophilia Joint Health Score",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b9bbb466-6e5b-4687-ac9f-1d6d9d9c4b57",
            "abbreviatedText": "INN",
            "expandedText": "international nonproprietary name",
            "instanceType": "Abbreviation"
          },
          {
            "id": "83f59a16-871b-493e-9e61-dad175c38e89",
            "abbreviatedText": "ISTH",
            "expandedText": "International Society on Thrombosis and Haemostasis",
            "instanceType": "Abbreviation"
          },
          {
            "id": "43a1fbd4-37ee-4453-8451-f50c749d87cd",
            "abbreviatedText": "PK",
            "expandedText": "Pharmacokinetics",
            "instanceType": "Abbreviation"
          },
          {
            "id": "98eaff06-d5af-4a68-9dbc-0409ad960c42",
            "abbreviatedText": "PROMIS",
            "expandedText": "Patient-Reported Outcomes Measurement Information System",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ff2b46c4-31ef-4f28-bf1e-7ca41c66949d",
            "abbreviatedText": "SAE",
            "expandedText": "Serious Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b1647a8e-0f2c-4c61-9784-cb641e4fdb2a",
            "abbreviatedText": "SAP",
            "expandedText": "statistical analytical plan",
            "instanceType": "Abbreviation"
          },
          {
            "id": "644c5ad0-ccb1-4353-b7ae-5e342ea8308e",
            "abbreviatedText": "SoA",
            "expandedText": "Schedule of Activities",
            "instanceType": "Abbreviation"
          },
          {
            "id": "36bca098-89ad-4560-af41-d1b2b3419134",
            "abbreviatedText": "TSQM-9",
            "expandedText": "9-item version of the Treatment Satisfaction Questionnaire for Medication",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "b96e2810-4f2c-4c20-8552-30772d8305a6",
            "number": "5",
            "name": "Amendment 5",
            "scope": {
              "id": "3f1f2180-4160-4a5b-a329-c09f899d43ac",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "1da19dd7-2cfd-44e3-926b-fafe5c753726",
              "code": {
                "id": "c0724fad-1569-49a3-9730-1101328d218e",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "478c253a-f703-4dd7-bef8-a673f6b9409b",
                "type": {
                  "id": "e5807648-96a9-4c5a-8e36-5c0dc6dc4204",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The protocol is amended with the following main changes: Addition of statistical testing for some secondary efficacy endpoints; Addition of an exit interview for participants from selected countries.",
            "effectiveDate": "2021-08-20",
            "reasonIds": [
              "9e11ab8a-2b7e-4e74-bcd4-c515965e0325",
              "68796072-9313-435e-91cd-fcd6749c0098",
              "ea23facb-9709-41f3-aa86-ea5bd4b41ad7"
            ],
            "previousVersion": "Amended Clinical Trial Protocol 04",
            "newVersion": "1 (electronic 7.0)"
          },
          {
            "id": "b5a2827c-b030-4f94-91f8-e003687dae2a",
            "number": "4",
            "name": "Amendment 4",
            "scope": {
              "id": "7ffc9b1b-e4fa-4e15-a1e3-430ff19ed68e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "23c76dd1-df79-4786-bc20-306c59c965c7",
              "code": {
                "id": "e4cdcf16-29f4-49c5-ab4a-1f1056007968",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "5b5c5058-a97c-4f7f-98f9-018d1e6edf3f",
                "type": {
                  "id": "249acd32-6a3b-4f02-8247-cfb0534766f3",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main reasons for this amendment are the following: to modify the requirements for the washout of FVIII products before screening and allow inclusion of patients based on historical FVIII results or documented genotype known to produce severe hemophilia A; to allow for flexibility in the washout of FVIII products before the Baseline visit in patients participating in the abbreviated PK group; to allow for faster infusion rate for the BIVV001 injection performed at home; to clarify that in case of minor surgery the FVIII activity and the BIVV001 dosing at the 24h follow up will be performed only if clinically warranted; to clarify the reporting of overdoses; to clarify that during study visits, for reliable PK assessment, PK sampling should not be done via the same intravenous access route as used for the BIVV001 administration.",
            "effectiveDate": "2020-05-13",
            "reasonIds": [
              "148beef4-ac06-48de-8ea8-66284a52a5aa",
              "6b4de2d1-24b0-4326-88b3-a988952efdba",
              "8bd377b7-4cb7-47e3-b7b0-6a8c2ab62a4f"
            ],
            "previousVersion": "Amended Clinical Trial Protocol 03",
            "newVersion": "1 (electronic 5.0)"
          },
          {
            "id": "77d56daf-5945-4bb0-92bb-4b546de86029",
            "number": "3",
            "name": "Amendment 3",
            "scope": {
              "id": "dbf8f568-b91f-44f4-8907-d6267513f103",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "f830cbc1-48d8-424c-b8a1-d46a10a40c91",
              "code": {
                "id": "43baa17c-02c9-4f2d-83be-9841addd0c53",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "f581e2d9-c23a-4a73-b465-1085e23f255f",
                "type": {
                  "id": "6418ec21-fdaf-4e40-9435-343c5a12ddf5",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Based on the request from Italy Competent Authority (AIFA) the protocol is amended to update an exclusion criterion related to renal function, as well as to add additional assessments for height and physical examination.",
            "effectiveDate": "2020-04-06",
            "reasonIds": [
              "ee51a531-3534-4f98-807d-b97038371f2a"
            ],
            "previousVersion": "Amended Clinical Trial Protocol 02",
            "newVersion": "1 (electronic 4.0)"
          },
          {
            "id": "527e02d4-1b36-40bf-a0ef-5c339194e15f",
            "number": "2",
            "name": "Amendment 2",
            "scope": {
              "id": "5cd85176-7cb4-44bd-9405-b3d0b256f75b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "57f8ebc9-1181-4626-b3bf-8ec4541aebd7",
              "code": {
                "id": "73138546-9ee9-464b-8884-81cdb62d8ec4",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "e2afbd39-39e7-485d-84d2-52e1a40ef432",
                "type": {
                  "id": "cd91e97f-ad24-4e92-a1b1-cedcda253cc0",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Based on the scientific advice from French Health Authority (ANSM), the protocol is amended to add a new exclusion criterion, add a pregnancy testing control at the safety follow-up visit, and provide clarity that the patient has the option at the end of the study to join a planned long-term study. Based on comments from the French Ethics Committee exclusion criterion E23 has been removed.",
            "effectiveDate": "2020-02-06",
            "reasonIds": [
              "7925f7be-1a45-4d49-a3f9-3658f329db22",
              "717611d7-2231-4de1-a74b-95bf0769ad4e",
              "2d8281d7-4030-4f0b-92de-44f9d1bb43c7"
            ],
            "previousVersion": "Amended Clinical Trial Protocol 01",
            "newVersion": "1 (electronic 2.0)"
          },
          {
            "id": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
            "number": "1",
            "name": "Amendment 1",
            "scope": {
              "id": "f9c27915-1236-4260-a0fd-033468d57a7a",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "1ab0ac93-861c-4934-bd73-92ed0ed6712e",
              "code": {
                "id": "44ef3a5c-bd1a-49f8-8459-a7a82c65b824",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "745475ee-f3de-4cbd-b8f3-f1a09efbfe22",
                "type": {
                  "id": "30e6bf08-8f5e-402a-8294-1d18147f3553",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Based on the final results of the repeat dose study and in alignment with scientific advice from Health Authorities, the protocol is amended to modify the dose regimen, efficacy endpoint analysis pertaining to an intra-patient comparison, and the safety endpoint of 'the occurrence of vascular thrombotic events'.",
            "effectiveDate": "2019-08-28",
            "reasonIds": [
              "508fa7bc-4bff-4a75-8577-b2fb3ce563ed",
              "c0358ffe-4ebc-4f8a-ad4e-1cf3bd86edcd",
              "ef4579a8-b363-4d47-93dd-0de21bb1aab8"
            ],
            "previousVersion": "Original Protocol",
            "newVersion": "1 (electronic 1.0)"
          }
        ],
        "medicalDevices": [
          {
            "id": "4ebbb8c4-ae33-446b-b87a-c4137a4271b4",
            "name": "Electronic Patient Diary",
            "instanceType": "MedicalDevice",
            "label": "ePD",
            "description": "Electronic device used by patients to record bleeding episodes and treatment response",
            "deviceType": {
              "id": "772b058c-1147-432b-baa0-41d038357aec",
              "code": "Monitoring Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Monitoring Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "e0cb36fb-f398-4394-8ff3-f0fe5e3eded2",
            "name": "Triaxial Medical Grade Accelerometer",
            "instanceType": "MedicalDevice",
            "label": "ActiGraph Activity Monitor",
            "description": "Wearable device worn on the nondominant wrist to monitor physical activity",
            "deviceType": {
              "id": "e2173667-ba56-4022-a7a8-072e305c6c1a",
              "code": "Wearable Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Wearable Device",
              "instanceType": "Code"
            },
            "manufacturer": "ActiGraph"
          },
          {
            "id": "6464e3b1-b01e-483b-9a79-19c20e302700",
            "name": "Intravenous Cannula",
            "instanceType": "MedicalDevice",
            "label": "IV Line",
            "description": "Venous access device for drug administration",
            "deviceType": {
              "id": "1510430d-1708-458e-b6ac-01edfbee149f",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "0c95d05c-d0eb-4931-95cb-c2f6a06ed6d1",
            "name": "Ultrasound Scanner",
            "instanceType": "MedicalDevice",
            "label": "Ultrasound",
            "description": "Imaging equipment used for JADE/HEAD-US assessments",
            "deviceType": {
              "id": "e5614021-1854-4251-8375-7aeb96d596ae",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          }
        ],
        "conditions": [
          {
            "id": "1e12b090-475e-4ed2-8049-507d406dc5ef",
            "name": "Severe Hemophilia A Definition",
            "instanceType": "Condition",
            "description": "Baseline FVIII activity level requirement",
            "text": "Endogenous FVIII < 1 IU/dL (<1%)"
          },
          {
            "id": "2578c20a-e9f4-428d-85a0-45233afdb358",
            "name": "Major Surgery Eligibility",
            "instanceType": "Condition",
            "description": "Minimum exposure and safety requirements for surgery",
            "text": "At least 6 Exposure Days (EDs) to BIVV001 and negative inhibitor test within 4 weeks prior to surgery"
          },
          {
            "id": "f8ee1b44-a108-430f-bcdd-93910f2a7e9f",
            "name": "Inhibitor Confirmation",
            "instanceType": "Condition",
            "description": "Threshold for repeating inhibitor test",
            "text": "Nijmegen-modified Bethesda assay result >= 0.6 BU/mL"
          }
        ],
        "studySites": [
          {
            "id": "364704b6-02a5-4e00-b4ff-32ff62d4b212",
            "name": "Investigational Site Number 920",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "1",
            "organizationId": "2d2bdea4-6ca8-4040-8c07-e8d6d2c4db1d",
            "country": "United States"
          },
          {
            "id": "218fc021-1d27-4036-a1be-5b2560dbebcd",
            "name": "Investigational Site Number 921",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "2",
            "organizationId": "36fc44ee-01e7-45cd-a522-1bb59307c52b",
            "country": "United States"
          },
          {
            "id": "42705b1a-843a-4346-97d3-9fc5c476c5e3",
            "name": "Investigational Site Number 911",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "3",
            "organizationId": "4afdfdf3-bbbe-4640-b749-497529e29844",
            "country": "United States"
          },
          {
            "id": "a4f9ad8b-5fda-47a9-8f14-435edb2cd0e7",
            "name": "Investigational Site Number 917",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "4",
            "organizationId": "08865b04-6e1d-4d32-841c-025cef995560",
            "country": "United States"
          },
          {
            "id": "5542653d-b000-4f1c-8299-c5b7e9edef8a",
            "name": "Investigational Site Number 919",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "5",
            "organizationId": "69fed8ce-97e2-40b7-88e9-d7a58ba40eba",
            "country": "United States"
          },
          {
            "id": "66830ecc-0ec4-408b-89f6-7d08327d45d7",
            "name": "Investigational Site Number 908",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "6",
            "organizationId": "fb4895c9-77ad-4b7a-b034-2f0884cc9c10",
            "country": "United States"
          },
          {
            "id": "0bd53eca-0658-40d6-a69b-b8cab7a98da3",
            "name": "Investigational Site Number 906",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "7",
            "organizationId": "adb55fd3-cad4-40e2-b86b-d0a279044fc4",
            "country": "United States"
          },
          {
            "id": "726085dd-ca1c-4533-97cd-2ba3e0affc17",
            "name": "Investigational Site Number 902",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "8",
            "organizationId": "38fbdcc6-5fc9-4f06-a0c9-98730b38544c",
            "country": "United States"
          },
          {
            "id": "e55e6ee5-1cc2-4ec5-aa84-22124b311efe",
            "name": "Investigational Site Number 136",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "9",
            "organizationId": "060a3849-ef6a-4fd8-a05f-4e51fc86fbae",
            "country": "Argentina"
          },
          {
            "id": "ae618c4d-adce-4183-afc7-fb08d3488750",
            "name": "Investigational Site Number 137",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "10",
            "organizationId": "47b7f961-3656-4488-90be-40128c8a4d5a",
            "country": "Argentina"
          },
          {
            "id": "720c5e63-e642-4d7d-9201-19b926227732",
            "name": "Investigational Site Number 139",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "11",
            "organizationId": "4d8187bf-99bf-45df-8a48-992e41f22fe6",
            "country": "Argentina"
          },
          {
            "id": "8bf0926b-9595-4aba-bf21-93cc06d31eff",
            "name": "Investigational Site Number 121",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "12",
            "organizationId": "b8eab9a7-a4b3-4182-872e-aff08ba6f133",
            "country": "Australia"
          },
          {
            "id": "ebedb186-2595-4e2e-8a1c-e91fbc052f87",
            "name": "Investigational Site Number 122",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "13",
            "organizationId": "9e77933b-f890-4110-8221-2f1d28e61860",
            "country": "Australia"
          },
          {
            "id": "ea5fa5ed-0fad-4264-b364-22bf3db7c2e6",
            "name": "Investigational Site Number 161",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "14",
            "organizationId": "ab8a88a4-b052-4304-a2ef-ac717769278b",
            "country": "Belgium"
          },
          {
            "id": "29c6a759-9b59-426f-b3c9-b6a6184a9105",
            "name": "Investigational Site Number 181",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "15",
            "organizationId": "8d576b9d-9e7e-4156-b47c-5212b9443a90",
            "country": "Brazil"
          },
          {
            "id": "ccd82707-5556-42da-b503-a1ecafd2e0e8",
            "name": "Investigational Site Number 171",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "16",
            "organizationId": "c0e20025-6d3b-478a-a2f0-99174076a432",
            "country": "Bulgaria"
          },
          {
            "id": "5a48371c-89a0-425c-81e9-a20eb17a2c7d",
            "name": "Investigational Site Number 172",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "17",
            "organizationId": "71d498e8-3ded-4c90-9c9a-95c789a9fe85",
            "country": "Bulgaria"
          },
          {
            "id": "1bd28cd7-3567-4b7a-8786-b06ad0547d8a",
            "name": "Investigational Site Number 202",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "18",
            "organizationId": "0981e1f8-51de-4de5-b289-32c2ed49db37",
            "country": "Canada"
          },
          {
            "id": "84dfb70a-68dc-4b01-ab31-7a023e98d4ab",
            "name": "Investigational Site Number 205",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "19",
            "organizationId": "844a31cc-16bc-434d-927e-f42f2fab3799",
            "country": "Canada"
          },
          {
            "id": "a0ab0451-d4fb-409f-9a26-06b4976d6e04",
            "name": "Investigational Site Number 281",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "20",
            "organizationId": "459bbc1c-a7aa-4721-b883-18467b0ba1d7",
            "country": "France"
          },
          {
            "id": "6349ee06-c05f-429d-a31f-80bfaa3ff0c7",
            "name": "Investigational Site Number 283",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "21",
            "organizationId": "4d015655-7a7f-4796-97b7-617ee7fc69f7",
            "country": "France"
          },
          {
            "id": "cd01b954-e5aa-4125-8149-11180339b36d",
            "name": "Investigational Site Number 282",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "22",
            "organizationId": "1e5a41cf-44dd-4517-96c2-e9e0b0d8ca59",
            "country": "France"
          },
          {
            "id": "00385ffd-7eaf-4511-a48f-94cd54920137",
            "name": "Investigational Site Number 284",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "23",
            "organizationId": "fd4a431a-db7b-4f85-82f1-1fea4a7aeb1d",
            "country": "France"
          },
          {
            "id": "bfe835a1-ce03-4449-b343-035f9d5835bf",
            "name": "Investigational Site Number 304",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "24",
            "organizationId": "23b5d454-a6e4-40c1-961a-8a6695b755fb",
            "country": "Germany"
          },
          {
            "id": "3d1b1130-ac11-49f6-a8a8-1ef5999563c6",
            "name": "Investigational Site Number 302",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "25",
            "organizationId": "e5db31df-61ad-4d51-9fbc-ae8dec66384f",
            "country": "Germany"
          },
          {
            "id": "7a17bcb4-c2ee-4d2a-8d59-3926d15510c4",
            "name": "Investigational Site Number 303",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "26",
            "organizationId": "2d909702-c0f9-4784-9e76-fdd99a0a0d29",
            "country": "Germany"
          },
          {
            "id": "35ad74c4-6a93-4f1b-99f2-07aff057252a",
            "name": "Investigational Site Number 321",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "27",
            "organizationId": "4f0be6be-bfaa-4f96-8dac-6a66b6235235",
            "country": "Greece"
          },
          {
            "id": "dcda4238-08d7-4fe3-87f5-2c4c0d97072b",
            "name": "Investigational Site Number 312",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "28",
            "organizationId": "42082ea7-4609-4dc8-9ed5-7a50c89dac04",
            "country": "Hungary"
          },
          {
            "id": "61050b2b-5154-4994-9fb7-4854d82ec37a",
            "name": "Investigational Site Number 314",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "29",
            "organizationId": "1ec875b5-be26-43c7-9755-dd4d91e98049",
            "country": "Hungary"
          },
          {
            "id": "801153be-a1cd-4b79-b3ff-2bbdd698726c",
            "name": "Investigational Site Number 402",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "30",
            "organizationId": "35e30735-f03f-4d80-996b-fd639ca88264",
            "country": "Italy"
          },
          {
            "id": "8b8dcd5b-6c4f-4ef6-955d-c0b20153480b",
            "name": "Investigational Site Number 401",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "31",
            "organizationId": "b42510bb-81fd-4e76-80ea-67165a8b1de0",
            "country": "Italy"
          },
          {
            "id": "e6127e6c-222b-4faa-9323-1896a3ce6c06",
            "name": "Investigational Site Number 426",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "32",
            "organizationId": "8553fcb7-1cb2-45b1-81d7-3e30ddd132e8",
            "country": "Japan"
          },
          {
            "id": "e3d11458-7031-4aa3-8e45-997e161c1bed",
            "name": "Investigational Site Number 423",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "33",
            "organizationId": "489c21f2-aa1b-43b9-a028-c8b036e5a36f",
            "country": "Japan"
          },
          {
            "id": "c2a70b9c-6a18-4ea8-853d-8da2c978c1a6",
            "name": "Investigational Site Number 425",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "34",
            "organizationId": "ee631238-2a8c-4989-9777-201a0d1a3b31",
            "country": "Japan"
          },
          {
            "id": "cf82c988-2016-46f5-8818-b97c720c6f78",
            "name": "Investigational Site Number 422",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "35",
            "organizationId": "2d6c5339-c6a8-426d-8d20-2827513e9562",
            "country": "Japan"
          },
          {
            "id": "d2b9167e-d802-43d6-92aa-17014b9c7df4",
            "name": "Investigational Site Number 421",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "36",
            "organizationId": "80c059ac-c388-4eeb-93f2-7dda49c2adb1",
            "country": "Japan"
          },
          {
            "id": "f952272c-cfba-4f4a-9ff9-fdb864e1697e",
            "name": "Investigational Site Number 424",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "37",
            "organizationId": "8cb4c819-455f-4e5e-8119-de6b5f6c2559",
            "country": "Japan"
          },
          {
            "id": "51688eee-ffa6-4379-9f19-fb5e83cdf5e7",
            "name": "Investigational Site Number 435",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "38",
            "organizationId": "4d7e4e13-8eb7-4ffb-b10b-e3717656d555",
            "country": "Mexico"
          },
          {
            "id": "f467f45e-ac69-4079-823e-8a05cd19a284",
            "name": "Investigational Site Number 641",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "39",
            "organizationId": "0a507543-eecd-46a0-8981-45152420174e",
            "country": "Netherlands"
          },
          {
            "id": "a25f2a7e-72e7-4327-94b1-22e2447e014f",
            "name": "Investigational Site Number 603",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "40",
            "organizationId": "e3f3b07a-5130-4d48-8c27-280c040b5d25",
            "country": "South Korea"
          },
          {
            "id": "2cbb5164-3984-46d0-bbf8-8de9c81a640b",
            "name": "Investigational Site Number 600",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "41",
            "organizationId": "e63e3635-0d4a-4e4c-a8d9-2db06a594d6d",
            "country": "South Korea"
          },
          {
            "id": "f6e98c23-e7d9-4340-a5ed-e5feaa19094f",
            "name": "Investigational Site Number 601",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "42",
            "organizationId": "9fca6efa-1003-430d-b7e0-fee43ce3b8d3",
            "country": "South Korea"
          },
          {
            "id": "16eaac47-de44-4b15-95c1-fe17cecd7d96",
            "name": "Investigational Site Number 521",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "43",
            "organizationId": "3214a26a-4adf-4a2f-86c5-5261154648c3",
            "country": "Spain"
          },
          {
            "id": "208453f2-1711-42c1-866b-4ecc670d3984",
            "name": "Investigational Site Number 531",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "44",
            "organizationId": "c8ebfa90-1aa8-4775-8018-d50ac150d7b5",
            "country": "Taiwan"
          },
          {
            "id": "88d01189-54bb-45ea-a907-5c7d236e44f0",
            "name": "Investigational Site Number 532",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "45",
            "organizationId": "623b8c37-6d90-4fda-9363-23409c3efee4",
            "country": "Taiwan"
          },
          {
            "id": "491417e5-45b3-48c4-9b03-cec247763012",
            "name": "Investigational Site Number 581",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "46",
            "organizationId": "c98486bd-a1b6-4b04-8108-efd7d787b5ec",
            "country": "United Kingdom"
          },
          {
            "id": "bc395294-9993-4c91-a463-6159a779f354",
            "name": "Investigational Site Number 581",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "47",
            "organizationId": "24f32070-0b01-41a6-a93d-b63edeb4fbd4",
            "country": "United Kingdom"
          }
        ],
        "administrations": [
          {
            "id": "df1affba-4538-4f1d-881e-7ddacc508450",
            "name": "Administration of Following BIVV001",
            "description": "RouteOfAdministration.ORAL DosingFrequency.WEEKLY",
            "instanceType": "Administration",
            "route": {
              "id": "0663e8be-a5fe-4058-ad4f-8d48105e0929",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "2e17f74e-5c3f-4aef-b86e-b0ded8e02615",
            "name": "Administration of BIVV001 (efanesoctocog alfa)",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.WEEKLY",
            "instanceType": "Administration",
            "route": {
              "id": "50010876-3f8f-414a-9147-9a0210354c8e",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients ≥12 Years of Age With Severe Hemophilia A"
  },
  "administrations": [
    {
      "id": "101a8d16-9b33-419d-b34a-45f9b8f66e12",
      "name": "Arm A Prophylaxis",
      "instanceType": "Administration",
      "dose": "50 IU/kg",
      "doseFrequency": "once weekly",
      "route": {
        "id": "8fcdfa6b-41bc-46fa-8a5e-950713296f9d",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "52 weeks"
    },
    {
      "id": "5929e658-2595-437b-a6e1-dc89cd316b5b",
      "name": "Arm B On-Demand",
      "instanceType": "Administration",
      "dose": "50 IU/kg",
      "doseFrequency": "as needed for bleeding episodes",
      "route": {
        "id": "836faf2c-a9ae-4fd1-8e92-f1d0da814639",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "26 weeks"
    },
    {
      "id": "f73d9b11-ada4-45bc-83a7-234e5ff3ba55",
      "name": "Arm B Prophylaxis (Switch)",
      "instanceType": "Administration",
      "dose": "50 IU/kg",
      "doseFrequency": "once weekly",
      "route": {
        "id": "1b985154-7c10-449a-9a8e-0d9c3e2d3226",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "26 weeks"
    },
    {
      "id": "fac7b49b-6849-45f3-90f2-0a5496f2294d",
      "name": "Bleeding Episode Treatment",
      "instanceType": "Administration",
      "dose": "50 IU/kg (initial), 30 or 50 IU/kg (follow-up)",
      "doseFrequency": "every 2 to 3 days if needed",
      "route": {
        "id": "4632098d-7582-4ab3-961b-c056aed6e5a8",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until bleeding is controlled"
    },
    {
      "id": "abe3252a-e1ee-4a7f-9e17-264b7e974c04",
      "name": "Surgical Dosing (Minor/Major)",
      "instanceType": "Administration",
      "dose": "50 IU/kg (loading dose)",
      "doseFrequency": "Repeated doses of 30 or 50 IU/kg as needed",
      "route": {
        "id": "b844d342-2160-4d83-b587-bd85828d5d8c",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Perioperative period"
    }
  ],
  "substances": [
    {
      "id": "d5b03eb4-80d1-4bce-a59a-6192516f0f68",
      "name": "efanesoctocog alfa",
      "instanceType": "Substance",
      "description": "Recombinant coagulation factor VIII Fc-von Willebrand Factor XTEN Fusion Protein"
    }
  ],
  "studyDefinitionDocument": {
    "id": "4a7edf39-5d42-4720-b2f9-d0b6978a3bb3",
    "name": "Amended clinical Trial Protocol 05 EFC16293 - efanesoctocog alfa",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "1",
    "versionDate": "20-Aug-2021",
    "contentIds": [
      "ef766ba5-1655-4d38-af38-6188efe38509",
      "ae06c430-bd40-45b4-8613-142c6e860ccb",
      "7b74397f-58d4-4857-b071-4af8e4979d9e",
      "fae3e1a6-d233-446a-ac33-4841f2ea9744",
      "c620121e-14b3-4016-9891-e73e10173f17"
    ]
  },
  "geographicScope": {
    "id": "b287cf3e-7d7e-49da-bc60-44d7fb329d0a",
    "name": "Study Geographic Scope",
    "scopeType": "Global",
    "instanceType": "GeographicScope",
    "countryIds": [
      "845c9fa5-0ba5-4660-9d4d-1d25c388d01a",
      "a1d4666c-a0b4-4ecf-8fa8-c1656358f237",
      "2c74d490-38b3-4ea7-ad07-4cd24ea378a6"
    ],
    "regions": [
      "North America",
      "Europe"
    ]
  },
  "countries": [
    {
      "id": "845c9fa5-0ba5-4660-9d4d-1d25c388d01a",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    },
    {
      "id": "a1d4666c-a0b4-4ecf-8fa8-c1656358f237",
      "name": "France",
      "instanceType": "Country",
      "code": "FR"
    },
    {
      "id": "2c74d490-38b3-4ea7-ad07-4cd24ea378a6",
      "name": "Italy",
      "instanceType": "Country",
      "code": "IT"
    }
  ],
  "ingredients": [
    {
      "id": "930cd2a6-21bf-48c7-810a-fd6310c3e3f2",
      "name": "efanesoctocog alfa",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "BIVV001"
    },
    {
      "id": "10b7ab5d-405b-4292-9cd5-30d7481f13b7",
      "name": "recombinant coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "d56ab8f9-6bf5-468f-a45b-660f95a58f99"
    }
  ],
  "strengths": [
    {
      "id": "8cc8f4f7-abfa-4b94-8f5d-a523b65f742f",
      "instanceType": "Strength",
      "value": 1,
      "unit": "IU/dL",
      "numerator": {
        "value": 1,
        "unit": "IU"
      },
      "denominator": {
        "value": 1,
        "unit": "dL"
      }
    }
  ],
  "transitionRules": [
    {
      "id": "36c7769d-8bf0-41af-818e-f1f6b02f4fa9",
      "name": "Arm B Transition",
      "instanceType": "TransitionRule",
      "transitionType": "Epoch Transition",
      "fromElementId": "2a087837-994c-4c49-bac1-498690c86f47",
      "toElementId": "95002988-fedd-48b2-b560-0142b38fafcf",
      "text": "Switch from on-demand to prophylaxis after 26 weeks"
    },
    {
      "id": "bdb60351-e12d-467c-a7f3-d314800d2eb0",
      "name": "Safety Discontinuation - Inhibitor",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Permanent discontinuation if participant develops an inhibitor"
    },
    {
      "id": "95fe5b61-ac3f-4b3f-a82b-f6142cd9d0fc",
      "name": "Safety Discontinuation - Allergic Reaction",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Permanent discontinuation for Grade 3 or greater allergic reaction or anaphylaxis"
    },
    {
      "id": "55d6d9f4-1fc2-41fb-8e53-6d8bcbf34103",
      "name": "Prohibited Product Discontinuation",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Use of FVIII products other than BIVV001 unless life-threatening emergency"
    }
  ],
  "documentContentReferences": [
    {
      "id": "aea8bce1-1d8f-4360-8e9f-f047cd565f58",
      "name": "Study Schema",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.2",
      "sectionTitle": "SCHEMA",
      "description": "Reference to the graphical study design"
    },
    {
      "id": "81ea799f-ab1a-4859-8ed6-9c313f3c8f41",
      "name": "Schedule of Activities",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "SCHEDULE OF ACTIVITIES (SOA)",
      "description": "Reference to the study visit and procedure tables"
    },
    {
      "id": "44e4ff34-9490-4a8f-9eea-b37e17094306",
      "name": "Inhibitor Definition",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.3.1.1",
      "sectionTitle": "Inhibitor development",
      "description": "Reference for the definition of inhibitor development in relation to stopping rules"
    },
    {
      "id": "7f94bdbe-8a8f-46ca-a913-ecb35f12aa59",
      "name": "Regulatory Oversight",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.1",
      "sectionTitle": "APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS",
      "description": "Reference for informed consent process"
    },
    {
      "id": "3f210096-2e96-4220-af69-c75982ba9ecc",
      "name": "Country Specific Requirements - Italy",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.11.2",
      "sectionTitle": "Italy",
      "description": "Reference for Italy-specific renal function exclusion criteria"
    },
    {
      "id": "6b761a3b-5e0f-4362-8e12-45e0d771eeab",
      "name": "Country Specific Requirements - France",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.11.1",
      "sectionTitle": "France",
      "description": "Reference for France-specific end of study requirements"
    },
    {
      "id": "ce1d6c5a-a69a-4d90-bd7d-f309f91b5692",
      "name": "PRO Assessments",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.1.2",
      "sectionTitle": "Patient reported outcomes",
      "description": "Reference for details on PROMIS and PGIS assessments"
    }
  ],
  "commentAnnotations": [
    {
      "id": "fab2b2e3-2d70-471f-8a40-8ebd5428fb8e",
      "text": "Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 21
    },
    {
      "id": "499cbcd4-7a68-492c-ab27-19eddca77de5",
      "text": "ePD training only. ePD devices are given to the patients at the baseline visit",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 21
    },
    {
      "id": "00b40fc6-f443-4189-80da-ee9d21dbccce",
      "text": "In the case of minor dental surgery, blood samples can be drawn within 3 days prior to the day of surgery.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities - Table 4",
      "pageNumber": 3
    },
    {
      "id": "06991e43-f487-4a60-80e6-4fd9f5d60932",
      "text": "Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Cover Page",
      "pageNumber": 1
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "df74b0ab-fcfa-46d0-9c72-35915b55bca7",
      "versionNumber": "1 (electronic 7.0)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-08-20",
      "description": "Amended Clinical Trial Protocol 05 incorporating statistical testing for secondary endpoints and exit interviews.",
      "amendmentNumber": "5"
    },
    {
      "id": "5c7a194d-2136-48d1-a778-1c571da78c38",
      "versionNumber": "1 (electronic 5.0)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-05-13",
      "description": "Amended Clinical Trial Protocol 04",
      "amendmentNumber": "4"
    },
    {
      "id": "d4051b6c-6cf9-4442-9480-487774f95bb5",
      "versionNumber": "1 (electronic 1.0)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2019-06-17",
      "description": "Original Protocol",
      "amendmentNumber": "Original"
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "6d79066d-0591-4f70-98da-67256693d61f",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "affectedSection": "Section 9 - Statistical Considerations",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Revised secondary efficacy endpoint analysis to allow formal statistical testing and updated multiplicity adjustments."
    },
    {
      "id": "97316353-1129-405a-a9ef-6e2649f98503",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "affectedSection": "Section 1.3 - Schedule of Activities",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Added exit interviews and clarified electronic patient diary (ePD) training and device distribution."
    },
    {
      "id": "3fdf6f00-7315-4886-aad8-1367b943c2ee",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "affectedSection": "Cover page and Section 2",
      "impactLevel": "Administrative",
      "instanceType": "StudyAmendmentImpact",
      "description": "Introduction of the International Nonproprietary Name (INN) efanesoctocog alfa."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "3651a53e-a078-4427-bf86-85920fc011e8",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "reasonText": "To include analysis of Patient Reported Outcomes within the overall statistical testing",
      "category": "Scientific",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "a601c93d-5e9e-4520-aedd-c9b35b203d86",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "reasonText": "To evaluate participants’ expectations of treatment and perception of treatment impact",
      "category": "Scientific",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "05331712-e2da-4340-8818-5f1c95fcac3a",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "reasonText": "Update to align with the statistical analytical plan (SAP)",
      "category": "Regulatory",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "90d887a1-a6bb-4fd8-b273-cf1d15187a87",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "reasonText": "To give greater flexibility to participants who undergo minor dental surgery outside of the hospital",
      "category": "Operational",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "5491d529-930e-4d75-b272-beffc388068f",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "Cover page",
      "beforeText": "BIVV001",
      "afterText": "BIVV001 (efanesoctocog alfa)",
      "summary": "The international nonproprietary name (INN), efanesoctocog alfa, was added."
    },
    {
      "id": "88019736-ea6b-40b4-ac4e-a737378d91c4",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "9.1",
      "beforeText": "null",
      "afterText": "Participants in Arm A must have at least 6 months of study duration in both this study and in observational study 242HA201/OBS16221.",
      "summary": "Updated selection criteria for participants included in the intra-patient comparison of ABR."
    },
    {
      "id": "4502e630-54cf-442e-9171-b456245a7c8e",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "changeType": "Clarification",
      "instanceType": "StudyChange",
      "sectionNumber": "8.1.2",
      "beforeText": "Treatment Satisfaction Questionnaire for Medication",
      "afterText": "9-item version of the Treatment Satisfaction Questionnaire for Medication (TSQM-9)",
      "summary": "Clarified the specific version of the TSQM being used and updated the appendix."
    },
    {
      "id": "8b771a66-f127-4e1d-9eb7-dc5688478d56",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "8.1.3",
      "beforeText": "null",
      "afterText": "Exit interview and footnote kk",
      "summary": "Added exit interview assessment, related endpoint, and description section."
    },
    {
      "id": "94fdf0a7-9bac-40f0-baa1-6d2e379cc5d8",
      "amendmentId": "ebab6bc7-00ac-4110-a2da-95d74cd7d129",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "1.3",
      "beforeText": "null",
      "afterText": "In the case of minor dental surgery, blood samples can be drawn within 3 days prior to the day of surgery.",
      "summary": "Added flexibility for blood draw timing for minor dental surgery."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "complete"
  }
}